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GENERAL INTRODUCTION AND AIMS OF THE THESIS
Introduction
In the Netherlands, ovarian cancer is diagnosed each year in about 1200 cases. Ovarian cancer 
is known for its poor prognosis with a 5-year survival rate of 30-40%, and even lower (5­
10%) if only advanced tumor stages IIIc and IV are considered [Nguyen 1993]. In Western 
Europe 11 per 100,000 women die of ovarian cancer each year and of all gynecologic 
malignancies it has the highest mortality rate [Koper 1996; Bray 2002]. The absense of 
clinical symptoms for a longer period often results in a delay of the diagnosis of an ovarian 
tumor. Once an ovarian mass is detected, it may be crucial to determine without further delay 
the nature of the tumor. This is essential for optimal treatment planning in case of suspected 
ovarian malignancy. In ovarian cancer optimal cytoreductive surgery by specialised surgeons 
positively influences progression free and overall survival [Eisenkop 1992; Kehoe 1994; 
Junor 1994; Junor 1999; Olaitan 2001].
Differentiation between benign and malignant ovarian tumors
Several tools for pre-operative differentiation between benign and malignant ovarian tumors 
have been studied in the past. These discriminating aids include physical examination, 
imaging techniques (abdominal- transvaginal ultrasound, color Doppler ultrasonography, CT- 
scan, MRI, PET-scan), and measurement of serum tumor markers (CA-125, CA15-3, CA 19­
9, CA 72-4, OVX1). A number of studies describe the discriminating accuracy for these 
various tools. It can be concluded that no single examination modality or even a combination 
of these discriminatory tests is able to confirm or exclude malignant disease in all patients 
with absolute certainty due to insufficient sensitivity and specificity [Jacobs 1994; Buist 
1994; Schutter 1994; Roman 1997; Schutter 1998, Thomas 2001].
Furthermore, the significance of various prognostic factors is a matter of debate in ovarian 
cancer. Prognostic factors are important in providing information that may predict the 
outcome of disease and thus may influence treatment planning. These prognostic factors can 
be related to histology, immunology, serum markers, molecular biology, genetics, and 
treatment modalities, such as surgery and type of chemotherapy. These factors are subject of a 
report of the European Society of Gynaecological Oncology (ESGO) in which a number of 
consensus statements are discussed [Bosze 2000]. For several factors there is little consensus 
on their role as an independent prognostic factor. Also the impact of (a number of) factors 
useful in identifying low and high risk patients for recurrent disease is as yet not clear.
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Furthermore, the report concluded that for most of these factors the methods of assessment I 
are too subjective, not standardised, or need to be studied in more detail.
Aim of the study
The majority of studies that focussed on the differentiation between benign and malignant 
ovarian tumors, or evaluation of prognostic factors were performed on tissue samples. 
However, the selection of the most representative tissue samples may be difficult due to 
heterogeneity of the tumor tissue. Ovarian tumors, benign as well as malignant, mostly 
present as cystic masses and in more than 85% are of epithelial origin. Furthermore, these 
cysts contain variable amounts of fluid [Clement 1987; Nicosia 1988; Dietl 1993]. It is 
reasonable to assume that the biochemical composition of ovarian cyst fluid may provide a 
fairly good insight into the biological processes taking place in the surrounding benign or 
malignant ovarian surface epithelium, and that these compounds are homogeneously 
distributed in the cyst fluid compartment. In the past the analytic composition of ovarian cyst 
fluid has been studied mainly focussing on the determination of tumor markers [de Bruijn 
1993, Gaetje 1994; Reimer 1997].
For the purpose of this thesis we selected a number of analytes of interest to be determined 
in ovarian cyst fluid. Besides hormonal components (gonadotropins and steroids) we 
concentrated on markers that have been described as important factors in angiogenesis and/or 
invasion. The following components that are involved in these processes were determined: 
vascular endothelial growth factor (VEGF); components of the plasminogen activation system 
(uPA, tPA, PAI-1, PAI-2), and angiostatin. Correlations between these markers were studied 
for better insight in tumor related angiogenesis and invasion.
Furthermore, we determined Glutathione S-transferases GSTP1-1 and GSTA1-1. These 
factors have been linked to chemoresistance and may as such be of clinical value.
Finally, we evaluated the ovarian cyst fluid composition using proton Nuclear Magnetic 
Resonance Spectroscopy in order to find analytes that can discriminate benign from malignant 
ovarian tumors. Based on these results we tested the feasibility of in vivo proton Magnetic 
Resonance Spectroscopy in patients with an ovarian tumor.
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Thus, the aim of this study was to explore in more detail all these analytes present in ovarian 
cyst fluid. This lead to the following questions:
1. Are there significant differences in ovarian cyst fluid composition between histopathologic 
subgroups?
2. Are there ovarian cyst fluid analytes that have a prognostic value?
3. Can we provide an overall inventory of the biochemical composition of ovarian cyst fluid 
by using in vitro proton Nuclear Magnetic Resonance Spectroscopy (1H-NMRS) and explore 
differences between benign and malignant ovarian tumors?
4. Can we develop a non-invasive technique to discriminate benign from malignant ovarian 
cysts by using in vivo proton Magnetic Resonance Spectroscopy (1H-MRS)?
To reach these goals we prospectively collected a large series of fluid samples that were 
aspirated from ovarian cysts. In small pilot studies the detection of several markers was 
tested, subsequently followed by larger series. Clinicopathologic parameters were included 
and correlated with the concentrations of several components in the cyst fluid samples.
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INTRODUCTION
The first elaborate studies on ovarian cyst fluid are from the gynecologist Henry Jacques 
Garrigues in 1882. In his “Diagnosis o f  ovarian cysts by means o f  the examination o f  their 
contents“ he described the results of careful evaluation of fluids tapped from cystic 
abdominal tumors [Garrigues 1882]. It was noticed in those years that macroscopic 
differences may provide information that can be helpful in exploring the origin of an 
abdominal cyst. Garrigues described differences in smell, color, viscosity after boiling, and 
coagulation capacity between cysts of different origin. Garrigues ends with the conclusion 
that “Examination of the fluid from abdominal tumors affords a valuable aid to diagnosis.” 
His conclusions can be classified as remarkably specific for those days.
The scientific interest in the contents of ovarian cyst fluid was limited during the 
decades thereafter, but in recent years an increasing number of studies has been published, 
describing one or several analytes in cyst fluid from ovarian tumors. The current review aims 
to describe and categorize studies on the biochemical composition of cyst fluid from ovarian 
tumors and discusses its clinical value. The majority of these studies could be categorized in 
one of the following topics:
1. cytologic examination
2. hormonal components
3. tumor markers
4. components involved in angiogenesis
5. components involved in tumor invasion
Table 1 provides a list of the studies of topic number 2-5 with specification of the determined 
analytes in ovarian cyst fluid and the corresponding sample sizes. Other studies that could not 
be directly related to one of these subgroups are listed in Table 2, and are not discussed 
separately.
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Table 1: Summary o f  studies that determined ovarian cyst flu id  components categorized in: 
hormonal components, tumor markers, components involved in angiogenesis and invasion.
SAMPLE SAMPLE
AUTHOR YEAR SIZE SPECIFICATION AUTHOR YEAR SIZE SPECIFICATION
HORMONAL ANGIOGENESIS
Geier 1981 32 17ß-estradiol Seppala 1987 37 IGFBP
Heinonen 1988 21 17ß-estradiol, progesterone Punnonen 1991 14 IL-1, TNF-alpha
Koninckx 1992 52 17ß-estradiol, progesterone Karasik 1994 36 IGF-1, IGFBP-2,
IGFBP-3
Gaetje 1994 71 17ß-estradiol, progesterone, Abu-Jawdeh 1996 11 VEGF
testosterone
Reimer 1997 138 LH,FSH, 17 ß-estradiol Yamamoto 1997 17 VEGF
Kraemer 1998 65 LH,FSH Ivarsson 1998 28 IL-8
Reimer 1999 42 LH,FSH, 17 ß-estradiol Sowter 1999 21 HGF
Kraemer 2001 92 hCG, 17ß-estradiol Hazelton 1999 49 VEGF, bFGF
Fasciani 2001 100 VEGF, IL-8
TUMOR
MARKERS INVASION
van Nagell 1975 27 CEA Saito 1990 19 TPA
Yamashita 1979 2 CEA Zhu 1993 57 PIIINP, PICP
Hill 1981 2 CEA Zhu 1994 8 PINP, PIIINP, PICP
Khoo 1982 6 CEA Casslen 1994 109 tPA,uPA, PAI-1,
PAI-2
Knight 1986 22 CEA Santala 1998 68 PINP, PIIINP, ICTP
Tohya 1986 15 CEA Darai 1998 78 sE-cadherin,
sICAM-1, sCD44std
Halila 1987 21 CA-125, CEA, TATI Furuya 2000 33 MMP, TIMMP
Fleuren 1987 57 CA-125 Sundfeldt 2001 33 sE-cadherin
Pinto 1990 136 CA-125, CEA, a-FP
Harlozinska 1991 50 CA-125, CEA
Koninckx 1992 52 CA-125
Menczer 1993 47 CA-125
de Bruijn 1993 25 CA-125, CEA,
TATI, CA 195
Gaetje 1994 55 CA-125, CEA, CA 15-3
Vercellini 1995 57 CA-125, CEA, CA19.9
Reimer 1997 138 CA-125, CEA, CASA,
CA 72-4
Harlozinska 1997 50 CA-125, TPS
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Table 2: Summary o f  remaining studies that determined various components in ovarian cyst 
flu id  samples
AUTHOR YEAR ANALYTE SAMPLE CONCLUSIONS
SIZE
van Kley 1981 amylase 21
Kutteh 1984 immunoglobulines IgG, IgM, IgA 31
Doellgast 1984 placental type alkaline phosphatase not specified 
Gocze 1991 placental protein 4 21
Riitinen 1992 endometrial placental protein 14 37
Haeger 1996 neopterin 29
Parker 1999 glucose 58
protein
lactate dehydrogenase
OVARIAN CYST (FLUID) PATHOGENESIS
The mechanism of the development of cystic malformation and cyst fluid production of the 
ovarian surface epithelium is only partially understood. The ovarian epithelium, which 
develops from the celomic epithelium, is composed of a single layer of modified mesothelial 
cells that covers the ovarian surface and changes continuously throughout the entire course of 
life [Nicosia 1983; Ozols 1992; Dietl 1993]. The concept that ovarian cancer arises from the 
surface epithelium was optioned by Sir Spencer Wells in 1872 [Ozols 1992; Dietl 1993]. On 
histopathologic examination ovarian carcinomas show characteristics of classical endocrine
higher in serous than in other types 
of ovarian neoplasms
no significant differences between 
histopathologic subgroups
more than 50 times higher in malignant 
cyst fluids than in benign cysts
significantly higher in serous than in 
mucinous cysts
in benign tumors significantly higher in 
mucinous than in serous cyst fluids
no significant differences between benign, 
borderline and malignant tumors
significantly higher in cyst fluids from 
malignant compared with benign cysts
LDH >451U/L discriminated malignancy 
best (sensitivity 90%, specificity 70%)
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responsive tissue [Godwin 1992]. For instance, serous tumors are similar in appearance to the 
epithelium of the Fallopian tube, mucinous tumors to that of the endocervix, and 
endometrioid tumors to that of the endometrium [Godwin 1992]. Thus, in its malignant form 
the ovarian surface epithelium undergoes metaplasia into one of the Mullerian duct 
derivatives. It has been postulated that ovarian cystadenomas and cystadenocarcinomas 
originate most frequently from surface epithelial cells that have invaded the ovarian cortex 
and formed epithelial inclusion cysts. These inclusion cysts form an actively proliferating cell 
compartment and are capable of neoplastic change under certain exogenous and endogenous 
conditions [Godwin 1992; Ozols 1992; Dietl 1993]. On histopathological examination the 
epithelial lining in benign cystadenomas consists of a single cell layer with uniform and 
regular structure of the epithelial cells [Janovski 1973; Nicosia 1988]. In malignant 
transformation multilayering of the epithelial cells, increased mitotic activity, and other 
features indicative for malignancy are noticed [Janovski 1973; Nicosia 1988]. On the origin of 
cyst fluid itself it can be said that most likely the differentiation of the ovarian surface 
epithelium into one of the celomic epithelium derivatives determines the specific 
characteristics of the fluid. The tall or cuboidal epithelium of serous cysts secretes fluid that is 
more clear and colorless (serous). In mucinous cysts the wall of the tumor consist of columnar 
epithelium with goblet cells secreting more mucinous fluid which is characteristic for this 
tumor type. In malignant tumors due to areas of necrosis and hemorrhage the cyst fluid might 
be more turbid and sero- or muco-sanguinous [Janovski 1973; Nicosia 1988; Nicosia 1991]
1. CYTOLOGIC EXAMINATION OF OVARIAN CYST FLUID
Several studies describe the results of cytologic examination of cyst fluid obtained from 
ovarian tumors. For this review we describe studies that appeared the last 20 years [Geier 
1981; Ganjei 1984; Granberg 1991; Patel 1992; Moran 1993; Greenebaum 1994; Gaetje 1994; 
Vercellini 1995; Kreuzer 1995; Mulvany 1996; Dietrich 1999; Higgins 1999]. Most of these 
studies included cyst fluids from benign, and in a minority of cases malignant ovarian tumors. 
Rarely, tumors of low malignant potential were included [Moran 1993; Gaetje 1994].
Reported problems of routine cytologic examination of ovarian cyst fluid are that many 
aspirates are devoid of diagnostic cells and/or contain inadequate and degenerated cell 
material [Gaetje 1994; Vercellini 1995; Kreuzer 1995; Mulvany 1996]. This phenomenon, 
noticed in 56% of the aspirates [Mulvany 1996], results in a diagnostic sensitivity with a 
range of 36%-85% between histologic subtypes. Only one study reports high accuracy rates of
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cytologic examination of intra operative cyst puncture of 91% (no false positive) for benign, 
and 84% (12% false negative) for malignant cysts, respectively. The authors describe a 
complication rate of 1.6% of severe pelvic inflammation and suggest that there are only a few 
indications for the use of aspiration cytology in ovarian tumors [Geier 1981]. Most authors 
conclude that cytologic examination of cyst fluid from ovarian tumors adds little reliable 
information for distinction between benign and malignant ovarian tumors [Granberg 1991; 
Moran 1993; Vercellini 1995; Kreuzer 1995; Mulvany 1996; Higgins 1999; Dietrich 1999].
A few case reports describe the results of cytological examination of cyst fluid that was 
suspicious of malignancy with a primary tumor location not in the ovary but in breast [Ramzy 
1979; Patel 1992] or lung [Ramzy 1979].
To improve the low diagnostic accuracy DNA ploidy was evaluated as a possible adjunctive 
criterion [Greenebaum 1994]. It was suggested that non diploidy may indicate, but is not 
conclusive of a malignant diagnosis [Greenebaum 1994].
In conclusion, cytologic examination of ovarian cyst fluid provides little reliable 
information, due to the lack of diagnostic cells in many aspirates and therefore should not be 
performed routinely.
2. HORMONAL COMPONENTS IN OVARIAN CYST FLUID
It has been suggested that hormonal factors may play a role in the differentiation, proliferation 
and malignant transformation of ovarian tumors [Biskind and Biskind 1944; Cramer 1983]. A 
number of studies describe different hormonal components in ovarian cyst fluid, the majority 
of which aim to improve the discrimination between functional (non-neoplastic) and 
neoplastic cysts [Geier 1981; Heinonen 1988; Gaetje 1994; Reimer 1997; Krämer 1998; 
Reimer 1999; Krämer 2001]. In some of these studies differences between benign and 
malignant cysts were determined in more detail [Gaetje 1994; Krämer 1998; Reimer 1999; 
Krämer 2001].
To differentiate between functional and neoplastic cysts, LH, FSH, 17ß-estradiol and 
progesterone cyst fluid concentrations were measured [Geier 1981; Gaetje 1984; Reimer 
1997; Reimer 1999]. Low FSH and LH concentrations seem to be indicative of functional 
cysts in peri- and postmenopausal age compared with benign neoplastic cysts [Reimer 1997; 
Reimer 1999]. Furthermore, higher cyst fluid 17ß-estradiol concentrations were found in 
functional cysts compared with neoplastic cysts [Geier 1981; Gaetje 1994; Reimer 1997;
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Reimer 1999]. One study found higher progesterone cyst fluid concentrations in functional 
cysts, but this finding was never confirmed [Gaetje 1994].
Studies with the purpose to differentiate between benign and malignant tumors based on cyst 
fluid gonadotropins or steroids show contradicting results. Significantly higher FSH 
concentrations were found in malignant compared with non-malignant cysts [Reimer 
1997;1999]. This finding was supported by the higher FSH levels found in serous malignant 
cyst fluid by Krämer et al. [Krämer 1998]. Furthermore, in this study significantly higher LH 
concentrations were also found in malignant serous cyst fluids [Krämer 1998]. Data about the 
concentration of 17ß-estradiol, progesterone, and testosterone are conflicting. Gaetje et al. 
found no differences in concentrations of 17ß-estradiol, progesterone, and testosterone 
between malignant and benign tumors. However, Reimer et al. (1999) found lower 17ß- 
estradiol levels in malignant cyst fluid. In contrast, Krämer et al. found higher 17ß-estradiol 
concentrations in malignant cyst fluid [Krämer 2001]. These authors also found a strong 
positive correlation between hCG and 17ß-estradiol cyst fluid levels in serous malignant 
tumors [Krämer 2001]. Within the benign subgroup higher 17ß-estradiol, and progesterone 
was found in mucinous- compared with serous tumors [Heinonen 1988]. According to these 
authors this reflects the hormonally inactive nature of benign serous tumors [Heinonen 1988]. 
In conclusion the determination of hormonal parameters in ovarian cyst fluid was mainly 
performed with the aim to discriminate functional from neoplastic cysts. The results of the 
studies on ovarian cyst fluid hormonal parameters that were aimed to differentiate between 
benign and malignant tumors conflict.
3. TUMOR MARKERS IN OVARIAN CYST FLUID
The majority of ovarian cyst fluid studies focused on the determination of tumormarkers [van 
Nagell 1975; Yamashita 1979; Hill 1981; Khoo 1982; Knight 1986; Tohya 1986; Halila 1987; 
Fleuren 1987; Pinto 1990; Harlozinska 1991; Koninckx 1992; Menczer 1993; de Bruijn 1993; 
Gaetje 1994; Vercellini 1995; Reimer 1997; Harlozinska 1997]. CA-125 and/or Carcino- 
Embryonal-Antigen (CEA) were the most frequently studied tumormarkers in ovarian cyst 
fluid [van Nagell 1975; Yamashita 1979; Hill 1981; Khoo 1982; Knight 1986; Tohya 1986; 
Fleuren 1987; Halila 1987; Harlozinska 1991, 1993, 1997; Koninckx 1992; de Bruijn 1993; 
Menczer 1993; Gaetje 1994; Vercellini 1995; Reimer 1997]. In several studies cyst fluid 
concentrations of CEA were elevated in mucinous tumors, however this was found in 
cystadenomas as well as in carcinomas [Tohya 1986; Halila 1987; Pinto 1990; de Bruijn
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1993; Gaetje 1994]. A gradient in CEA levels was noticed with the highest levels in the fluid 
from primary tumor, moderate in ascitic fluid, and the lowest values in peripheral blood 
[Khoo 1982]. Furthermore, it was found that ovarian cyst fluid CEA structurally appears to be 
similar to the CEA found in colon, but differs from CEA found in ascitic fluid, probably due 
to a loss of sialic acid from the CEA released into ascitic fluid [Yamashita 1979; Hill 1982; 
Tohya 1986]. In conclusion, elevated CEA cyst fluid levels seem to be associated with the 
mucinous subtype, rather than a marker for the differentiation between malignant and benign 
ovarian cysts.
Results of CA-125 cyst fluid levels are also conflicting. Higher concentrations were found in 
serous compared with mucinous cysts [Halila 1987]. However, in a study by Harlozinska 
comparable values were found for mucinous and serous cyst fluids [Harlozinska 1991]. 
Others describe higher levels in mucinous benign and malignant fluids [Pinto 1990]. Most 
authors report no significant differences between CA-125 levels in malignant and benign 
ovarian cysts. Based on these studies, it is concluded that cyst fluid determination of CA-125 
has no value in the differentiation between malignant or benign ovarian cysts [Halila 1987; 
Menczer 1993; de Bruijn 1993; Gaetje 1994; Vercellini 1995; Reimer 1997]. Other 
tumormarkers were described in a limited number of studies: CA 19-9 [Vercellini 1995], 
CA15-3 [Gaetje 1994], CA 195 [de Bruijn 1993], CA 72-4 [Reimer 1999], alpha-feto protein 
(aFP) [Pinto 1990], tissue polypeptide specific antigen (TPS) [Harlozinska 1993], tumor 
associated trypsin inhibitor (TATI) [de Bruijn 1993, Halila 1987], and cystadenocarcinoma 
specific antigen (CASA) [Reimer 1997]. Technical problems with laboratory equipment limit 
the use of these tumor markers, especially in dense fluids from endometriotic cysts and 
dermoid cysts [Vercellini 1995]. Although higher levels of TATI and CA 195 were found in 
mucinous tumors, these markers could not be used to distinguish accurately between 
malignant or benign cysts [de Bruijn 1993; Halila 1987]. This was also concluded for other 
tumormarkers CA 19-9, CA15-3, aFP, CASA, CA 72-4 [Pinto 1990; Gaetje 1994; Vercellini 
1995; Reimer 1997]. TPS is a marker, which assay measures soluble fragments of cytokeratin 
18, an acid cytokeratin protein of the cytoskeleton of epithelial cells. Increased levels of 
cytokeratin 18 are associated with malignant epithelial cells [Harlozinska 1997]. Significant 
differences in TPS cyst fluid levels between malignant and benign tumors were found, but 
this finding was never confirmed by others [Harlozinska 1997]. In conclusion, although some 
cyst fluid tumor markers may be able to differentiate mucinous from other types of tumors, 
there is no significant role in their differentiation between benign and malignant ovarian 
tumors.
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4. COMPONENTS RELATED TO TUMOR ANGIOGENESIS IN OVARIAN CYST 
FLUID
Figure 1 presents the most important components related to tumor angiogenesis and/or 
invasion that were determined in ovarian cyst fluid samples.
Angiogenesis is a complex process and an important factor in tumor growth and tumor 
spread. It involves the proliferation of new blood vessels from preexisting vessels. Moreover, 
the formation of metastases is angiogenesis-dependent since new blood vessels provide a 
gateway for tumor cells to enter the circulation and metastasize to distant sites. Metastatic 
tumor cells themselves require neovascularization if a metastasis is to grow to a clinically 
detectable size [Folkman 1992; Folkman 1995; Abulafia 2000]. Until now, several activators 
as well as inhibitors of angiogenesis have been described, and its number is far from 
complete. Their precise actions and, specifically, their interactions are only partially 
understood. It seems that the balance concept (netto effect of activators and inhibitors) plays 
an important role in tumor growth [Folkman 1992; Folkman 1995; Abulafia 2000]. 
Angiogenesis related molecules in ovarian cyst fluid were subject of a number of studies 
[Seppälä 1987; Punnonen 1991; Karasik 1994; Kanety 1996; Abu-Jawdeh 1996; Yamamoto 
1997; Ivarsson 1998; Sowter 1999; Hazelton 1999; Fasciani 2001]. These studies report on 
the determination of several activators of angiogenesis.
In literature, one of the most important growth factors in angiogenesis seems to be Vascular 
Endothelial Growth Factor (VEGF). This 34- to 46 kDa glycoprotein has been recognized as a 
stimulator of angiogenesis and vascular permeability in a variety of human malignancies 
including ovarian carcinoma. It also increases the production of plasminogen activators and 
their receptors by (tumoral) endothelial cells. VEGF was determined in a limited number of 
ovarian cyst fluid samples by Abu-Jawdeh et al. (1996) and Yamamoto et al. (1997), and in a 
larger series by Hazelton et al. (1999), and recently by Fasciani et al. (2001). Significantly 
higher VEGF cyst fluid levels in malignant and borderline tumors compared with benign 
tumors were found [Hazelton 1999, Fasciani 2001]. Furthermore, Fasciani et al. observed 
significantly higher levels in cystic endometriosis. It was concluded from these studies that 
high VEGF levels in malignant cyst fluids are consistent with the hypothesis that this growth 
factor plays an important role in ovarian carcinoma related angiogenesis and tumor 
progression [Hazelton 1999; Fasciani 2001]. Abu-Jawdeh et al. support a possible clinical role 
for VEGF in differential diagnosis of ovarian tumors [Abu-Jawdeh 1996].
Basic Fibroblast Growth Factor (bFGF) is another relevant activator of tumor angiogenesis 
[Crickard 1994]. Ovarian cyst fluid bFGF levels were determined by Hazelton et al. They
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found undetectable to very low bFGF levels and no differences between various histologic 
subtypes [Hazelton 1999]. However, they conclude that this does not preclude the possibility 
of involvement of this growth factor in ovarian cancer-related angiogenesis, since their results 
contradict with those of immunochemical studies of tissue extracts reporting the presence of 
bFGF in ovarian cancer. Hazelton et al. conclude that these differences may be explained by 
secretion of bFGF through non-conventional pathways and that its molecular properties 
explain the absence of accumulation in the cyst fluid. Interleukin-8 (IL-8) is a small (8 kDa) 
cytokine known to be expressed in the normal ovary, to be involved in periovulatory cellular 
interactions and to influence angiogenesis and proliferation of tumor cells. [Koch 1992]. 
Presence of IL-8 was studied in ovarian cyst fluid by Ivarsson et al. and Fasciani et al. 
[Ivarsson 1998; Fasciani 2001]. In cyst fluid samples from malignant tumors significantly 
higher IL-8 concentrations were found. Furthermore, Fasciani et al. detected significantly 
higher cyst fluid IL-8 concentrations in endometriosis cysts compared with follicular and 
serous cysts. These authors support a role for this cytokine in ovarian tumor biology 
Punnonen et al. determined Interleukine 1 (IL-1) and Tumor Necrosis Factor alpha (TNF- 
alpha) as stimulators of angiogenesis and important mediators of inflammation and 
immunological response in a small series of 14 ovarian cyst fluids. They found no differences 
in ovarian cyst fluid IL-1 and TNF-alpha concentrations between benign and malignant 
histologic diagnosis. They conclude that production of these cytokines is a non-specific 
indicator of an inflammatory rather than a specific response to a malignant process [Punnonen 
1991].
Insuline like growth factors (IGFs) comprise a group of polypeptide hormones with effects on 
cell proliferation. IGFs are bound to binding proteins (BP), of which six forms have been 
identified, coded IGFBP-1 through IGFBP-6. These IGFBPs not only act as carriers for IGFs, 
but also regulate the impact of IGF on cell proliferation by modulating its access to the IGF 
receptors. Therefore, it has been described that alterations in IGFBPs induced by the target 
cell can occur prior to changes in IGFs [Shimasaki 1991; LeRoith 1995]. Insulin Like Growth 
Factor I (IGF-1) and IGF binding protein 2 (IGFBP-2) in ovarian cyst fluid were determined 
[Karasik 1994; Kanety 1996]. These authors support a role for IGF-I in the proliferation of 
ovarian cancer. Furthermore, they conclude that increased local production by the tumor in 
vivo is responsible for the increased IGFBP-2 levels and that this supports an autocrine 
regulatory mechanism for the IGF-I proliferative effect on ovarian cancer [Karasik 1994; 
Kanety 1996]. This contradicts the results of Seppälä et al. who measured IGFBP cyst fluid 
concentrations and concluded that this is not a useful marker for ovarian tumors, although 
they did not document which specific IGFBP was measured [Seppälä 1987].
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Another angiogenesis growth factor that was determined in ovarian cyst fluid is Hepatocyte 
Growth Factor (HGF). This multifunctional growth factor induces proliferation, motility and 
morphogenesis of epithelial and endothelial cell types. Furthermore, it is one of the soluble 
factors affecting the motility of carcinoma cells. No significant differences between median 
HGF cyst fluid levels were found between different histological ovarian tumor types [Sowter
1999]. Untill now there are no studies presenting the results of components specifically 
involved in the inhibition of angiogenesis determined in ovarian cyst fluid.
In conclusion, results on the determination of ovarian cyst fluid components involved in 
angiogenesis are conflicting, but may play a role in further understanding angiogenesis- 
related processes in ovarian cysts. However, which (combination of) factors need to be 
determined remains unclear, as well as the possible role of their interactions.
Figure 1: Schematic overview o f  the most important factors involved in tumor angiogenesis 
and degradation o f  the extracellular matrix (as part o f  tumor invasion) that were determined 
in cyst flu id  from  ovarian tumors; + represents activation, - represents inhibition o f  
components/processes
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5. COMPONENTS IN OVARIAN CYST FLUID RELATED TO 
TUMOR INVASION
Tumor invasion involves three major steps: attachment, degradation, and migration. From 
their point of origin tumor cells attach to and degrade the basement membrane (BM) and 
extracellular matrix (ECM). Subsequently, continuous steps of attachment and degradation 
result in migration of the cells through the ECM resulting in invasive tumor growth. A limited 
number of studies reports on the results of molecules involved in invasion and determination 
of these analytes in ovarian cyst fluid [Saito 1990; Zhu 1993; Santala 1998; Darai 1998; 
Casslen 1994; Zhu 1994; Furuya 2000; Sundfeldt 2001].
Several specific cell-surface molecules involved in attachment have been described. These 
molecules function as cell-matrix and cell-cell attachment modulators and most of them 
present in two forms: a membrane-inserted form (detectable on the cell surface), and a soluble 
form (detectable in serum and biological fluids). These adhesion molecules include the 
integrins, cadherines, laminin-binding protein, the immunoglobulin superfamily, and CD 44 
[Stetler-Stevenson 1993]. Components that were determined in ovarian cyst fluid and known 
to be involved in attachment are soluble E-cadherins [Darai 1998; Sundfeldt 2001], and 
soluble forms of the intercellular adhesion molecule-1 (sICAM-1), and CD44std (sCD44std) 
[Darai 1998]. Sundfeldt et al. and Darai et al. found higher levels of soluble E-cadherin in 
cyst fluid aspirated from malignant and borderline tumors than in benign ovarian cysts. 
Higher concentrations in malignant cyst fluids compared to benign were also found for 
sICAM-1 and sCD44std [Darai 1998]. It was concluded that measurements of soluble E- 
cadherins in cyst fluid from patients presenting with complex ovarian masses may be 
beneficial in increasing the accuracy of preoperative diagnosis [Sundfeldt 2001]. Darai et al. 
support a role for these components determined in cyst fluid to differentiate between benign 
and borderline or malignant lesions, but they found no diagnostic value in determining 
concentrations of these molecules in serum.
Components involved in degradation, as a major step in ovarian cancer metastasis, were also 
subject of a number of studies. The process of degradation of the ECM can be accomplished 
by several proteolytic factors present in physiological as well as pathological conditions. 
Immunohistochemical studies have shown that tumor cells and/or stromal cells show protease 
expression. Proteolysis is influenced by stimulators as well as inhibitors and complexes 
between them. Molecules involved in invasion based on proteolysis are serine proteinases, 
matrix metalloproteinases, cysteine proteinases, aspartic proteinases, and their respective 
inhibitors (Figure 1). Two important serine proteinases are: urokinase- type plasminogen
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activator (uPA) and tissue-type plasminogen activator (tPA) [Dan0 1985; Andreasen 1997]. 
These are part of the plasminogen activation system which plays an important role in 
degradation of the ECM. The activity of these two serine proteinases is controlled by two 
serine proteinase inhibitors: plasminogen activator inhibitor type 1 (PAI-1) and type 2 (PAI-2) 
[Dan0 1985; Andreasen 1992]. Stimulators of proteolysis (serine proteinases: uPA and tPA) 
and inhibitors of proteolysis (serine proteinase inhibitors: PAI-1 and PAI-2) were determined 
in ovarian cyst fluid samples [Saito 1990; Casslén 1994], and their results are conflicting. 
Levels of tPA were found to be higher in ovarian cyst fluid from malignant compared to those 
from benign tumors by Saito et al. without specific histologic subclassification, but in a larger 
series by Casslén et al. no significant differences in tPA cyst fluid levels were found between 
malignant and benign cysts. Furthermore, Casslén et al. describe significantly higher cyst 
fluid levels of uPA, PAI-1 and PAI-2 in malignant tumors. They conclude that plasminogen 
activation system components determined in ovarian cyst fluid samples are a reflection of 
local production by malignant tumor tissue [Casslén 1994].
Another family of molecules mainly involved in the activation or inhibition of proteolysis, 
that were determined in ovarian cyst fluid are Matrix Metalloproteinases (MMPs) [Furuya
2000]. The group of MMPs are zinc endopeptidases which activation can occur through the 
uPA/ plasminogen cascade for plasmin generation [Murphy 1992]. MMPs are classified 
according to substrate specificity and include collagenases (MMP-1, -8, and -13), gelatinases 
(MMP-2, and -9), stromelysins (MMP-3, -10, and -11), and others [Furuya 2000]. In the 
study of Furuya et al. MMPs as well as tissue inhibitors of MMPs (TIMMPs) were 
determined in cyst fluid samples from mucinous neoplastic and functional cysts. Higher levels 
of MMP components were found in cyst fluid from malignant and borderline compared to 
benign tumors (MMP-9, TIMP-1, MMP-2). Furuya et al. conclude that their observations 
indicate the importance of analysing ovarian cyst fluid tumor associated matriolytic activity, 
and that these matriolytic enzymes, together with their inhibitors, play an important role in the 
growth of ovarian mucinous tumors [Furuya 2000].
In contrast with the intensive research during the last years that focused on proteolysis, the 
role of collagenases was the subject of only a few studies [Santala 1998]. Fibrillar collagens 
are essential components of the ECM of every tumor. Furthermore, extensive collagen 
synthesis is characteristic of the so-called desmoplastic reactions that are often observed 
surrounding the neoplastic epithelial cells of many tumors [Santala 1998]. Two major soft- 
tissue collagens are type I and III collagens. During the synthesis of the corresponding 
collagens, the amino-terminal and carboxy-terminal propeptides of type I (PINP and PICP, 
respectively) and type III (PIIINP) procollagens are removed. Some of these propeptides may
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remain on the collagen surface fibres and are released into body fluids during degradation of 
collagenous matrix. Most techniques however, measure the synthesis of the corresponding 
collagen molecules [Risteli 1988; Melkko 1996]. The synthesis and breakdown of fibrillar 
collagens in ovarian carcinoma was subject of some research [Zhu 1993; Zhu 1994; Santala 
1998]. In these studies, the procollagens PINP, PIIINP, PICP as indicators of synthesis of type
I and III collagen as well as ICTP (carboxy-terminal telopeptide of type I collagen) as 
indicator of type I collagen degradation were determined in ovarian cyst fluid samples. These 
authors found an enhanced synthesis of fibrillar collagens in case of malignant ovarian 
tumors, and a simultaneously enhanced breakdown of soft tissue and its collagenous network. 
This phenomenon might occur both in tumor tissue affecting the cyst fluid concentrations, as 
well as in the peritoneal cavity. Concentrations in cyst fluid from borderline tumors were 
predominantly in the same range as those from malignant tumors [Zhu 1993; Santala 1998]. 
The last major step in tumor invasion is cell migration that is not a uniform event but involves 
complex interactions between proteinases and adhesion molecules in order to facilitate 
migration of cells through the ECM [Friedl and Brocker 2000]. However, there is no simple 
concept on the exact function of different components in relation with tumor cell migration 
[Friedl and Bröcker 2000]. In conclusion, there seems to be a promising role for the 
determination of components that play a role in tumor invasion with the aim to differentiate 
between benign from malignant ovarian tumors. However, further research has to be 
performed to evaluate which factors seem to play the most significant role and to determine 
their clinical value.
DISCUSSION
The biochemical composition of cyst fluid derived from benign, borderline and malignant 
ovarian tumors has been subject of a number of studies in the past. Most of these cyst fluid 
studies focused on the determination of one component, and in some cases a combination of 
several metabolites was determined. The sample size of many of these studies was limited, 
mostly not exceeding 25 specimens. The majority of these studies aimed to investigate the 
possibility of using specific cyst fluid components for optimal differentiation between benign 
and malignant tumors. Very rarely, an attempt was made to investigate prognostic 
significance of ovarian cyst fluid markers.
Cytologic examination of ovarian cyst fluid provides little reliable information, with lack of 
diagnostic cells in many aspirates.
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Tumormarkers such as CA-125 and CEA may be helpful in the differentiation between serous 
(CA-125) or mucinous (CEA) tumors, but are not useful in the differentiation between 
benign or malignant cases.
Hormonal components (gonadotropins and steroids) were mostly used in the differentiation 
between functional and non-functional cysts while the results in the differentiation between 
malignant and benign tumors are conflicting.
Components involved in tumor angiogenesis and tumor invasion seem to be the subject of an 
increasing number of studies during the last years. Since a large number of activators and 
inhibitors are involved in angiogenesis as well as in invasion, and only a small number of 
them were determined in ovarian cyst fluid no firm conclusions can be drawn regarding these 
components. However, several authors indicate the importance of components involved in 
tumor angiogenesis and invasion in malignant ovarian tumors based on significantly higher 
cyst fluid levels that were determined compared to those found in benign cyst fluids. Due to 
lack of confirmation of many of these studies the role of these markers is not clear until now. 
Moreover, their prognostic significance was never investigated. In several of these studies 
cystic endometriosis as well as borderline malignancy seem to be special entities because 
significantly higher levels have been noted as compared to those found in benign cyst fluids 
for a number of components related to angiogenesis or invasion. The clinical behaviour of 
these subtypes has to be investigated in more detail, and determination of cyst fluid markers 
in cystic endometriosis and borderline cases may provide additional information. Thus, it is 
important not to include these histological subtypes in the benign or malignant group, but to 
consider them as separate entities.
Most studies on ovarian cyst fluid that were performed in the past focused on one or more 
metabolites. There is a need for a more overall evaluation of the ovarian cyst fluid 
compartment to determine in more detail the micro-environment of the cyst. New techniques, 
like in vitro proton nuclear magnetic resonance spectroscopy (1H-NMRS), may play a 
supportive role for this purpose. This technique may provide additional information with 
regard to the biochemical composition of ovarian cyst fluid since this technique provides an 
overall inventory of low molecular weight proton-containing metabolites present in the 
samples [Massuger 1998]. Differences in cyst fluid composition may ultimately lead to a non­
invasive discriminatory test of ovarian tumors by in vivo proton MRS.
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In conclusion, this review shows that ovarian cyst fluid samples provide valuable information, 
most probably reflecting biochemical processes in the epithelial cyst wall. Determination of 
the biochemical composition of ovarian cyst fluid may be helpful in understanding biological 
processes in ovarian tumors of different histological origin and may have prognostic 
significance. Thus, this biochemical “black-box” is too valuable to be neglected and lost 
during histopathologic examination and we propose that it can be included in the collection 
procedure of tissue sampling and ascitic fluid collection, especially because it can be easily 
obtained.
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ABSTRACT
Aim o f the study: To determine concentrations of LH, FSH, 17ß-estradiol and progesterone in 
ovarian cyst fluid and serum from patients with benign, borderline, and malignant ovarian 
tumors.
Materials and Methods: We prospectively collected ovarian cyst fluid and blood samples 
from one hundred and fifteen patients with an ovarian tumor. Seventy-four of the patients had 
benign ovarian tumors while 12 and 29 patients had borderline and malignant ovarian tumors, 
respectively.
Results: Significantly higher LH and FSH cyst fluid concentrations were found in case of 
malignancy compared to those observed in cyst fluid from patients with benign and borderline 
tumors. Within the malignant subset, LH and FSH concentrations correlated with increasing 
FIGO stage and degree of differentiation. Furthermore, both LH and FSH cyst fluid 
concentrations showed a strong correlation with serum concentrations in case of malignant 
tumors, especially in postmenopausal women, but not with benign tumors.
Conclusions: The highest gonadotropin concentrations were observed in cyst fluid from 
malignant ovarian tumors. The most probable explanation for this is an increased vascular 
permeability. Supportive evidence for such an increased vascular permeability is our previous 
finding of significantly higher VEGF concentrations in cyst fluid from ovarian malignancies. 
The possibility of ectopic production of LH and FSH by malignant ovarian tissue cannot 
completely be ruled out.
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INTRODUCTION
The concept that most ovarian cancers arise from the ovarian surface epithelium (OSE) was 
optioned by Sir Spencer Wells in 1872 [Ozols 1992; Dietl 1993]. Most epithelial ovarian 
tumors, benign as well as malignant, present as cystic structures with or without solid 
components [Dietl 1993]. Ovarian cysts contain variable amounts of fluid, most probably 
secreted by the OSE cells [Nicosia 1988]. The macroscopic characteristics of cyst fluid reflect 
the differentiation of the OSE into one of the celomic epithelium derivatives (serous, III 
mucinous, endometrioid) [Janovski 1973; Nicosia 1988; Nicosia 1991]. There are only few 
studies on the determination of various components in ovarian cyst fluid. A number of these 
studies involve measurement of gonadotropins or female sex steroid hormones [Geier 1981; 
Heinonen 1988; Gaetje 1994; Reimer 1997; Krämer 1998; Reimer 1999; Krämer 2001]. Most 
of these studies focussed on the differentiation between functional and neoplastic cysts.
Results of the studies that aimed to discriminate between benign and malignant tumors 
conflict. [Gaetje 1994; Krämer 1998; Reimer 1999; Krämer 2001].
The present study was designed to determine gonadotropin (LH, FSH) and female sex 
steroid hormone (17ß-estradiol, progesterone) concentrations in cyst fluid and serum from 
patients with benign, borderline or malignant ovarian tumors, and to assess the correlation of 
these hormone levels with tumor status and their relationship with known prognostic factors.
MATERIALS AND METHODS
Cyst flu id collection
One hundred and fifteen patients with an ovarian tumor planned for surgical removal were 
included in the cyst fluid collection procedure. Immediately after surgical removal, the tumor 
was transported to the pathology laboratory where aseptic fine needle aspiration was 
performed to collect cyst fluid. Next, the cooled fluid sample was transported to the 
Department of Chemical Endocrinology, and after centrifugation at 3000x g for 10 minutes, 
the supernatant was collected and immediately stored at -35 oC. From 61 of these patients 
blood was collected within 4 weeks before surgery, centrifuged at 2000x g for 15 minutes and 
the serum was stored at -35 oC until assayed. Histopathologic diagnoses were performed by a 
gynecologic pathologist according to WHO criteria.
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Immunoassays
Determination of LH and FSH cyst fluid and serum concentrations was performed by using 
the random access analyzer AxSym (Abbott Laboratories, Chicago, IL, USA), a fully 
automated analyzer system based on microparticle enzyme immunoassay (MEIA) technology. 
Cyst fluid and serum 17ß-estradiol and progesterone concentrations were measured with in­
house radioimmunoassay (RIA) procedures [Thomas et al. 1977]. Prior to RIA, the samples 
were extracted twice with di ethyl ether and the dried extracts subjected to Sephadex LH-20 
chromatography for isolation of the 17ß-estradiol and progesterone containing fractions. The 
minimum detectable concentrations of 17ß-estradiol and progesterone were 75 pmol/l and 1.3 
nmol/l, respectively. The precision in terms of within- and between-assay coefficients of 
variation for means of duplicate determinations for 17ß-estradiol were 4.3% and 7.9%, 
respectively, and 4.1% and 9.1% for progesterone.
Reference values for gonadotropins and sex steroids in blood in our laboratory were for 
postmenopausal patients: 12-75 IU/l for LH ; 37-140 IU/l for FSH; <200 pmol/l for 17ß- 
estradiol, and <1.3 nmol/l for progesterone.
Statistics
Results are given as median concentration and range (minimum-maximum). Assay results 
below the detection limits of the immunoassays for the different components in the clinical 
specimens were considered half of the detection limit. Significance of differences in 
concentrations of the various analytes between the histopathologic subgroups were tested 
using the Mann-Whitney-U test for independent samples (level of significance p<0.05). 
Correlations between cyst fluid and serum concentrations were calculated using the Spearman 
rank correlation coefficient.
RESULTS
Table 1 presents the histopathologic results of 115 ovarian tumors. Malignant (n=29), 
borderline (n=12), and benign (n=74) ovarian cysts were aspirated for the collection of fluid. 
Three malignant cysts with metastatic localization in the ovary of a primary tumor elsewhere 
(two breast, one colon) were excluded. In up to 30 cases only a subset of all components 
could be analysed due to the viscosity of the cyst fluids or too small sample volumes.
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Table 1: Histopathological diagnosis o f ovarian cyst (n=115)
MALIGNANT (n=29)
serous cystadenocarcinoma 
mucinous cystadenocarcinoma 
endometrioid carcinoma 
Undifferentiated cystadenocarcinoma 
metastatic*
10
8
6
2
3
BORDERLINE (n=12)
serous cystadenoma 
mucinous cystadenoma
2
10
III
BENIGN (n=74)
serous cystadenoma 
mucinous cystadenoma 
dermoid cyst 
functional cyst 
cystic endometriosis
18
21
11
11
13
n: number o f  tumors in each group 
* excluded from cyst fluid analysis
Cyst flu id gonadotropin and steroid concentrations according to histopathologic subgroups 
Figure 1 depicts the median (minimum and maximum) cyst fluid concentrations of LH, FSH, 
17ß-estradiol, and progesterone, for the three major histopathologic subgroups. The LH and 
FSH cyst fluid concentrations were low in both borderline and benign cysts, whereas the 
concentrations in cyst fluid from malignant tumors were both significantly higher (p<0.01) 
(Figure 1A,1B).
Median 17ß-estradiol concentrations were highest in the malignant group (Figure 1C). In cyst 
fluid from borderline tumors 17ß-estradiol was very low. Median progesterone cyst fluid 
concentrations were in the same range for all three histopathologic subtypes (Figure 1D). No 
significant differences were found in 17ß-estradiol or progesterone cyst fluid concentrations 
between the benign, borderline and malignant subgroups.
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Figure 1: LH (A), FSH (B), 17ß-estradiol (C), and progesterone (D) concentrations in cyst 
flu id from ovarian tumors o f different histopathologic origin
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As shown in Table 1, the benign histopathologic subgroup (n=74) was subdivided in serous 
cystadenomas, mucinous cystadenomas, dermoid cysts, functional cysts and cystic 
endometriosis. Gonadotropin concentrations were in the same range for the different benign 
subgroups (data not shown). This was also the case concerning the median concentrations of 
17ß-estradiol and progesterone in benign cyst fluid specimens. Higher (though not 
significant) median sex steroid concentrations were found in functional cysts compared to the 
other benign subgroups (data not shown).
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Correlation between cyst fluid and serum gonadotropin concentrations 
LH and FSH cyst fluid concentrations in benign and malignant histopathologic subgroups 
were correlated with the corresponding serum concentrations (Figure 2). A strong positive 
correlation was found for cyst fluid LH and FSH and their respective serum concentrations in 
patients with malignant tumors (correlation coefficient 0.79 and 0.78, respectively). However,
LH and FSH cyst fluid concentrations from patients with benign tumors showed a weak 
positive correlation with the corresponding increasing LH and FSH serum concentrations 
(correlation coefficient 0.21 and 0.41, respectively).
Gonadotropin and sex steroid cyst flu id and serum concentrations according to menopausal 
status
All available samples were subdivided according to menopausal status of the patients (Table 
2). Within the pre-or postmenopausal subset the serum gonadotropin and steroid 
concentrations of the respective histopathologic subgroups were in the same range and not 
significantly different from each other. Also, the observed serum concentrations were in 
accordance with the serum reference values.
In the case of premenopausal patients Table 2 indicates that the median LH and FSH cyst 
fluid concentrations tended to be highest in malignant compared to borderline and benign 
tumors, although differences for none of these components reached level of significance.
The borderline cysts from postmenopausal patients were excluded due to the low number of 
specimens available. Postmenopausal patients showed significantly higher LH and FSH 
concentrations (p<0.01) in cyst fluid from malignant compared to benign tumors. Also, ten­
fold higher median cyst fluid 17ß-estradiol concentrations, but similar median progesterone 
concentrations were found in malignant compared to benign tumors.
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Figure 2: LH (top) and FSH (bottom) cyst fluid and serum concentrations from malignant and benign 
ovarian tumors
Clinicopathologic characteristics
Table 3 presents gonadotropin and female sex steroid hormone cyst fluid concentrations 
related to tumor stage, histopathologic subgroup, and tumor differentiation grade. The median 
LH and FSH cyst fluid concentrations were significantly higher in FIGO stages II,III,IV, 
malignant serous and histologic grade 2,3 as compared to stage 1, malignant mucinous and 
grade 1, respectively (p<0.05). The median 17ß-estradiol was higher, and that of progesterone 
lower in stage II,III,IV, malignant serous and grade 2,3 as compared to those of stage 1, 
malignant mucinous and grade 1, respectively, but these differences were not statistically 
significant (Table 3).
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Table 2: Cyst fluid and serum concentrations o f gonadotropins and steroids in ovarian tumors 
according topre-postmenopausal status (n=112)
CYST FLUID SERUM
malignant
premenopausal
median
range
(N)
postmenopausal
median
range
(N)
LH
IU/l
FSH
IU/l
E2
pmol/l
PROG
nmol/l
1.7 8.5
0.15-9.7 2.1-23 
(8) (8)
8.1 (A) 30.5 (B)
0.54-18 3-68
(12) (12)
670 16.6
<100-1200000 <1.3-150
(9)
355
100-3800
(14)
(8)
8
1.9-84
(14)
LH FSH E2 PROG 
IU/l IU/l pmol/l nmol/l
3.2 7.5 
<0.2-19 0.9-19
(7)
33.8
3.7-44
(11)
(8)
52.1
26.8-95
(13)
365 3.2 
170-570 <1.3-23 
(8) (8)
93 <1.3 
39-270 <1.3-3.4 
(13) (13)
III
borderline
premenopausal
median
range
(N)
0.81 1.9 39.5 3.1 5.4 4.2
0.13-2.2 0.64-16.8 <10-170 <1.3-3.9 1.6-16 1.4-9
(6) (6) (4) (3) (3) (4)
245 <1.3 
61-1700 <1.3-1.4 
(4) (3)
postmenopausal
median
range
(N)
15
<10-130
(3)
35
8.4-68
(3)
12.7
9.8-42
(4)
37
18.4-69
(4)
162.5 2.9 
73-250 2.4-6.4 
(4) (4)
benign
premenopausal
median
range
(N)
0.47 1.18 250 9.7
<0.2-2.6 0.14-16 <10->100000 <1.3-29C 
(38) (40) (47) (45)
5 5.1 
<0.2-45 <0.2-67 
(15) (15)
300 1.5
56-740 <1.3-42 
(15) (15)
postmenopausal
median
range
(N)
0.93 (A) 6.8 (B) 
0.15-4.6 0.15-31.1 
(13) (13)
33
<10-1400
(11)
9
<1.3-77
(11)
35.2 70.4 
14-49 38-108 
(9) (10)
98 <1.3
57-300 <1.3-3.3 
(11) (11)
Footnotes.A, B; statistically significant difference (p<0.01) was found in postmenopausal patients 
between malignant and benign LH cyst fluid concentration and malignant and benign FSH cyst fluid  
concentration
Serum reference values fo r postmenopausal patients in our laboratory were: 12-75 IU/l fo r LH; 37­
140 IU/l fo r FSH; <200 pmol/l for 17ß-estradiol, and <1.3 nmol/l fo r progesterone.
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Table 3: Gonadotropin and steroid cyst fluid concentrations related to histopathologic characteristics 
in malignant ovarian tumors (n=26)
LH FSH 17ß-estradiol Progesterone 
(IU/l) (IU/l)_______ (pmol/l)________ (nmol/l)
FIGO stage 
I
median
range
(N)
2.2
(0.2-10)
(11)
9.7
(2.1-34)
(11)
315
(50-120000)
(14)
29
(0.6-84)
(13)
II-III-IV
median
range
(N)
8.3 (A) 
(0.1-18) 
(9)
28 (B)
(6.7-68)
(9)
560
(130-21000)
(9)
3.4
(1.9-150)
(9)
Histology
serous
median
range
(N)
8.3 (C) 
(6.1-18) 
(8)
39 (D)
(9.2-68)
(8)
430
(130-21000)
(9)
6.1
(1.9-150)
(9)
mucinous
median
range
(N)
0.64
(0.15-1.3)
(6)
5.45
(2.1-13.2)
(6)
150
(<100-120000)
(7)
31
(3-44)
(6)
Grade
1
median
range
(N)
0.85 
(0.2-1.3) 
(4)
3.6 
(2.1-7.4) 
(4)
205
(50-120000)
(6)
29
(4.2-84)
(5)
2-3
median
range
(N)
8.1 (E) 
(0.1-18) 
(16)
23.5 (F) 
(6.7-68) 
(16)
420
(100-21000)
(17)
3.9
(0.6-150)
(17)
Footnotes: A,B; significantly higher (p<0.05) cyst fluid concentrations were found in FIGO stage II, 
III, IV  compared to FIGO stage I  for LH and FSH, C,D; significantly higher (p<0.05) cyst fluid  
concentrations were found in malignant serous compared to malignant mucinous tumors for LH and 
FSH, E,F; significantly higher (p<0.05) cyst fluid concentrations were found in histologic grade 2-3 
compared to grade 1 tumors for LH and FSH.
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DISCUSSION
The present study aimed to determine gonadotropins (LH, FSH) and female sex steroid 
hormones (17ß-estradiol, progesterone) in cyst fluid from ovarian tumors and to explore the 
differences between histopathologic subgroups and their clinical value.
We observed significantly higher median LH and FSH cyst fluid concentrations in malignant 
compared to borderline and benign tumors. Concentrations in cyst fluid from borderline 
tumors were very low and similar to those from benign cysts. Higher FSH levels in malignant III 
cysts were also found by Reimer et al. (1999). However, in their study LH levels were found 
to be equal for benign and malignant cases. The inclusion in their study of four borderline 
tumors in the malignant group (n=7) is a possible explanation for this difference in 
observation. Krämer et al. describe higher cyst fluid LH and FSH concentrations in the serous 
malignant than serous benign subtype [Krämer 1998]. In that study mucinous cyst fluids were 
excluded due to viscosity of the samples. Although we experienced similar problems with 
mucinous fluids, we were able to determine gonadotropin and steroid levels in both benign as 
well as malignant mucinous tumors. In benign tumors no differences were found for 
gonadotropin levels between both subtypes. However, significantly higher LH and FSH 
concentrations were found in cyst fluids from malignant serous compared to malignant 
mucinous tumors. To our opinion it seems unlikely that assay problems form the basis of this 
difference, as the difference was not noticed between the benign mucinous and serous cysts.
The overrepresentation of higher tumor stages (in which higher gonadotropin concentrations 
were found) in the serous subgroup ( 2 FIGO stage I and 8 FIGO stage II,III,IV serous, 
compared to 7 FIGO stage I and 1 FIGO stage II,III,IV mucinous) probably is a better 
explanation for this finding.
Higher LH and FSH cyst fluid concentrations in malignant tumors might be resulting from 
local production of LH and FSH by the tumor tissue, although there are no studies describing 
LH or FSH production by tumor tissue epithelium. Differences in gonadotropin cyst fluid 
concentrations between malignant and benign tumors may also be the result of differences in 
vascular permeability. Due to increased angiogenesis with more permeable vessels in case of 
malignancy, higher serum LH and FSH concentrations (especially in postmenopausal women) 
may passively diffuse from the serum into the cyst fluid compartment. This hypothesis is in 
line with the strong positive correlation in malignant tumors for LH and FSH cyst fluid 
concentrations and their respective serum concentrations.
The indication of differences in vascular permeability between malignant and benign ovarian 
cysts is supported by significantly higher Vascular Endothelial Growth Factor (VEGF) levels
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that were found in cyst fluid from malignant tumors compared with benign tumors [Boss et al. 
2001]. VEGF acts not only as an activator of angiogenesis, but also leads to increased 
vascular permeability.
Our study did not observe significant differences in 17ß-estradiol and progesterone cyst fluid 
concentrations between the histopathologic subgroups, although 17ß-estradiol cyst fluid 
concentrations from postmenopausal patients with malignant tumors tended to be higher than 
those from patients with benign tumors. These results are in line with those from Gaetje et al. 
who determined 17ß-estradiol and progesterone in cyst fluid from ovarian tumors [Gaetje 
1994]. However, it contradicts with the results of the study by Reimer et al. who reported 
significantly lower 17ß-estradiol levels in cyst fluid from malignant tumors compared to 
those found in non-malignant cysts [Reimer 1999]. Ivarsson et al. describe production of 17ß- 
estradiol and progesterone by normal ovarian surface epithelium cells in vitro from pre- as 
well as postmenopausal patients. It is reasonable to assume that the finding of endogenous 
production of steroids by ovarian surface epithelium is a normal feature of epithelial cells that 
is still present during malignant transformation, rather than a tumor specific property. Results 
from the present study indicate only limited potential prognostic value (in terms of correlation 
with FIGO stage or histologic grade) for cyst fluid gonadotropins or steroids in malignant 
tumors. Although significantly higher median cyst fluid LH and FSH concentrations were 
found in higher tumor stages and high grade tumors, the results were too scattered to draw 
conclusions for individual patients.
Progesterone levels tended to be higher in fluid from prognostically more favorable tumors 
(lower stage and better histologic grade). Other studies describe a more favorable prognosis 
for tumors positive for the progesterone receptor compared to those that did not express this 
receptor [Slotman 1989, Münstedt 2000]. However, the relationship between tumors that are 
positive for the progesterone receptor and their cyst fluid progesterone levels remains unclear 
as well as their impact on prognosis, and might be subject of future studies.
In conclusion, higher gonadotropin concentrations were found in cyst fluid from malignant 
tumors compared to those from borderline and benign tumors. The correlation of cyst fluid 
and serum gonadotropins in malignant tumors might be explained by increased vascular 
permeability. Future studies have to determine whether the differences in ovarian cyst fluid 
gonadotropin concentrations might be of clinical interest. The therapeutical use of LHRH 
agonists in the treatment of ovarian cancer has been suggested [Emons 1996, Hofstra 1999]. 
Further exploration of the efficacy of such a treatment has to be performed to find out whether 
cyst fluid gonadotropin levels might be of additional value in determining which proportion 
of the patients may benefit from such a treatment.
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ABSTRACT
Purpose: The purpose of the present study was to determine the gluthathione S-transferases 
(GST) P1-1 and A1-1 levels in cyst fluid from malignant, borderline, and benign ovarian 
tumors. The clinical relevance of these enzymes in cyst fluid was investigated, including the 
possible relation with resistance to chemotherapy.
Methods: A total of 90 ovarian cysts were punctured for cyst fluid collection. GSTP1-1 and 
GSTA1-1 concentrations were determined by ELISA in cyst fluid from 23 malignant, 9 
borderline, and 51 benign primary ovarian tumors, and levels were correlated with 
histopathological data.
Results: Significantly higher GSTP1-1 concentrations were found in cyst fluid from 
malignant (median:477 ng/ml), compared with benign (median:52 ng/ml) ovarian cysts 
(p<0.0001), as well as in fluid from borderline (median: 366 ng/ml) compared with benign 
cysts (p<0.0001). No significant differences were found in cyst fluid GSTA1-1 concentrations 
between the histologic subgroups. In cyst fluid from malignant tumors higher GSTP1-1 and 
lower GSTA1-1 concentrations were found in patients with prognostic worse factors: FIGO 
II-III-IV, grade 2-3, residual tumor >2cm, presence of ascites, patients with recurrent disease, 
and survival, but differences were not significant. In the subgroup of patients that received 
cisplatin based chemotherapy (n=14) significantly higher GSTP1-1 (p=0.01) concentrations 
were found in patients with recurrence compared with patients without recurrence. 
Considering only FIGO stage I patients, a differentiation could be made between patients with 
or without recurrence based on cyst fluid GSTP1-1 concentrations.
Conclusions: Determination of gluthathione S-transferases P 1-1 in cyst fluid samples from 
ovarian tumors can be of additional value in the differentiation between histologic subgroups. 
In case of possible low malignant potential cysts where sampling of the most representative 
tissue can be an issue, determination of GSTP1-1 concentrations in cyst fluid may optimise 
histopathological classification. Cyst fluid GSTP 1-1 seems to be a good marker for 
aggressiveness of the ovarian tumor, and it may predict reponse to chemotherapy.
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INTRODUCTION
Neoplastic ovarian pathology, benign as well as malignant transformation, consists of many 
types and subtypes. The most common tumors are of epithelial origin. Malignant epithelial 
ovarian tumors are the fourth most common malignancy in women, and have the highest 
incidence in gynecologic malignancy [1]. Therapy of first choice for malignant ovarian 
tumors consists of cytoreductive surgery followed by systemic chemotherapy in case of 
advanced disease. Despite this regimen the percentage of long survivors >5years is low (15­
20%) [2].
Glutathione (GSH) and GSH-related enzymes are involved in the metabolism and 
detoxification of cytotoxic and carcinogenic compounds [3,4]. Glutathione S-transferases 
(GSTs) are cytosolic enzymes that play an essential role in the elimination of potentially toxic 
compounds by catalyzing the addition of GSH. In this way carcinogens, but also drugs such 
as anticancer drugs can be eliminated. The group of GSTs consists of four main isoenzyme 
classes: Alpha, Mu, Pi, and Theta. These four classes are each divided into one or more 
isoforms [4]. The role of GSTs in relation with reproduction [3], hypertensive disorders in 
pregnancy [5,6] or oncological disease [4,7,8] has been reviewed previously.
The expression of GST in ovarian carcinoma tissue and serum samples was subject of several 
studies, however has not as yet been fully established and results are conflicting [9-14]. Most 
studies agree on higher GST Pi (GSTP1-1) levels in malignant ovarian tissue as compared to 
benign. Some authors suggest prognostic significance of GSTP1-1 tissue levels [9,11,12], 
whereas others indicate no relation between tissue levels of GSTs and clinicopathologic or 
prognostic parameters [13,14]. Furthermore, GSTs are thought to play a role in the 
multifactorial process of resistance of tumor cells to chemotherapy [9,12,15-18].
The majority of ovarian tumors, benign as well as malignant, are of epithelial origin and 
consist of solid and cystic components [19]. These cysts can be single or multiple and are 
filled with fluid. The metabolic composition of cyst fluid may provide a better representation 
of overall tumor biology than random tissue samples since it is not always clear where to take 
the most representative samples due to tumor heterogeneity. To our knowledge, determination 
of gluthathione S-transferase levels in cyst fluid from ovarian tumors has never been 
performed.
The aim of the present study was to determine the concentrations of glutathione S-transferases 
P1-1 and A1-1 in cyst fluids from malignant, borderline, and benign ovarian tumors, and to 
investigate the relation with clinicopathologic characteristics and resistance to chemotherapy.
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METHODS
Patients and cyst flu id collection
Ninety patients with an ovarian cyst planned for surgical removal were recruted for this study 
and cyst fluid was collected in the period January 1998 until December 1999. Immediately 
after surgical removal, the ovarian tumor was transported to the Pathology Department for 
cyst fluid collection by aseptic fine needle aspiration. After cooled transport to the laboratory 
the cyst fluid samples were centrifuged at 3000 x g for ten minutes and the supernatant was 
stored at -350C in small portions until use. Determination of the levels of glutathione S- 
transferases was performed without prior knowledge of the histological or clinical outcome. 
Histopathology was performed by an experienced gynecologic pathologist. Clinicopathologic 
characteristics were retrieved from patients medical records. Two cyst fluid samples were 
obtained after primary chemotherapy (one malignant, one borderline) and are presented 
separately. Two fluid samples were obtained from cysts were primary location was elsewhere 
and not ovarian, and three samples could not be measured due to high viscosity of the fluid 
(one borderline malignancy, one mucinous cystadenoma, one dermoid). These 5 samples were 
excluded from further analysis.
ELISA procedures
ELISAs for glutathione S-transferase P 1-1 and A 1-1 were performed as described previously 
[20,21]. Polystyrene microtiter plates (Greiner, Alphen a/d Rijn, The Netherlands) were used. 
All incubations were performed at room temperature in 100 |iL/well, unless stated otherwise. 
In between incubations, plates were washed 5 times with > 200^L/well phosphate-buffered 
saline (140 mmol/L NaCL, 6.4 mmol/L Na2HPO4, and 1.3 mmol/L NaH2PO4, pH ~7.4; PBS) 
supplemented with 0.5 mL/L Tween 20 (PBS-T). Plates were coated overnight at 4o C with 10 
mg/L purified anti-GSTP1-1 or GSTA1-1 monoclonal antibody in PBS and blocked with 
200^g/L well PBS-T supplemented with 1% (w/v) bovine serum albumin (PBS-T-BSA) 
during 1 hour. Standards (0.4-100 |ig/L GSTP1-1; 0.04-20^g/L GSTA1-1) diluted in PBS-T 
supplemented with 10 mmol/L EDTA and 10% (v/v) heat-treated normal human plasma 
(PBS-T-EDTA-NHP) and cyst fluid samples diluted with an equal volume of PBS-T-EDTA- 
NHP were then added to the wells. Plates were incubated overnight, washed, incubated with 
rabbit anti-GSTP1-1 and GSTA1-1 antiserum diluted (1/1000 and 1/4000, respectively) in 
PBS-T supplemented with 10% (v/v) heated normal human plasma for 3 hours, washed and 
subsequently incubated for 2 hours with peroxidase-labeled swine anti-rabbit (Dakopatts, 
Glostrup, Denmark) diluted 1/2000 in PBS-T-BSA. After a final wash, plates were incubated
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with 3.75 |imol/L o-phenylenediamine, 1 mmol H2O2 in 24 mmol/L sodium citrate, 51 
mmol/L Na2HPO4, pH 5.0 for 15 minutes. The reaction was stopped by adding 100 |iL 
2mol/L H2SO4 and absorbance was read at 492 nm with a background subtraction at 620 nm. 
All standards and samples were measured in duplicate. A four-parameter weighted logistic 
regression model was used to calculate standard curves and unknowns.
The detection limit of the assays for GSTP1-1 and GSTA1-1, corresponding to 3 standard 
deviations above the mean signal of 5 zero standards was 0.4 and 0.04 ng/ml, respectively.
Clinicopathologic characteristics
From the medical records of 23 patients with malignant histopathologic diagnosis, the 
following clinicopathologic characteristics were retrieved: stage according to the International 
Federation of Gynecology and Obstetrics (FIGO), histopathologic grade, residual tumor after 
surgery, presence of ascites, tumor recurrence, disease free survival (DFS), and overall 
survival (OS). Residual tumor was divided into two groups; <2 cm or >2cm. Histopathologic 
grade was defined as grade 1 (well differentiated), grade 2 (moderately differentiated), or 
grade 3 (poorly differentiated). Tumor recurrence was defined as evidence of disease within 
the follow-up interval between date of surgery and closure of the follow-up period. Serum 
CA-125 concentrations (U/ml) after 3 courses of chemotherapy or, if  not determined at that 
time, after 6 courses were recorded.
Statistics
Significance of the differences in concentrations were tested by using the Mann-Whitney U- 
test for two groups of independent samples (level of significance p<0.05). Differences 
between more than two groups were tested by Kruskal Wallis analysis.
GSTP1-1 and GSTA1-1 concentrations are given as median, 25th and 75th percentiles, unless 
stated otherwise.
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RESULTS
The histopathologic diagnosis of ovarian tumors whose corresponding cyst fluids were used 
for assay of GSTP1-1 and GSTA1-1 concentrations, are listed in Table 1. The median 
GSTP1-1 and GSTA1-1 concentrations as found in the histologic subgroups are presented in 
Figures 1 and 2, respectively. The data comprised 23 malignant, 9 borderline, and 51 benign 
cysts.
Median GSTP1-1 concentrations in cyst fluid from malignant, borderline, and benign ovarian 
tumors were 477 ng/ml, 366 ng/ml, and 52 ng/ml, respectively. Significantly higher median 
GSTP1-1 concentrations were found in cyst fluids from malignant compared with benign, and 
in cyst fluid from borderline compared with benign cysts (Figure 1).
Median GSTA1-1 concentrations in cyst fluid from malignant, borderline, and benign ovarian 
tumors were 9 ng/ml, 6 ng/ml, and 2 ng/ml, respectively. No significant differences in cyst 
fluid GSTA1-1 concentrations were found between the histologic subgroups (Figure 2).
Table 1: Histopathological diagnosis o f ovarian tumors (n=83)
n
Malignant
serous cystadenocarcinoma 
mucinous cystadenocarcinoma 
endometrioid carcinoma 
undifferentiated cystadenocarcinoma
9
8
4
2
Total 23
Borderline
serous cystadenoma 
mucinous cystadenoma
1
8
Total 9
Benign
serous cystadenoma 
mucinous cystadenoma 
dermoid cyst 
functional cyst
13
18
4
16
Total 51
n: number o f tumors in each group
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Figure 1: Ovarian cyst fluid GSTP1-1 levels in malignant, borderline and benign ovarian cysts 
(n=83)
Median values are illustrated as horizontal bars. * statistical significance compared 
to benign subgroups
IV
Figure 2: Ovarian cyst fluid GSTA1-1 levels in malignant, borderline and benign ovarian cysts 
(n=83)
Median values are illustrated as horizontal bars. No significant differences were 
found between histopathologic subgroups
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Correlation with clinicopathologic characteristics
Clinicopathologic characteristics from 23 patients with a malignant ovarian cyst and their 
corresponding median, 25th-75th percentiles GSTP1-1 and GSTA1-1 concentrations are listed 
in Table 2. Higher median GSTP1-1 levels were found in FIGO stages II-III-IV, histologic 
grade 2-3, residual tumor >2cm, presence of ascites, patients with recurrent disease, DFS<14 
months, and OS<24 months as compared with stage I, grade 1, residual tumor < 2cm, absence 
of ascites, patients without recurrence during follow-up, DFS>14 months, and OS>24 months, 
respectively. However, the differences did not reach significance. In contrast, higher median 
GSTA1-1 levels were found in FIGO stage I, patients with residual tumor < 2 cm, ascites 
without malignant cells, patients without recurrent disease, and DFS >14 months as compared 
with stage II-III-IV, residual >2cm, presence of ascites, patients with recurrence, and DFS 
<14 months, respectively. However, differences did not reach significance. Significantly 
higher GSTA1-1 concentrations were found in histologic grade 1 compared with grade 2-3 
(p<0.05).
Response to chemotherapy
Cyst fluid GSTP1-1 and GSTA1-1 concentrations of the excluded two patients that received 
primary chemotherapy before surgery were 2542 ng/ml and 25 ng/ml (malignant) and 2 ng/ml 
and 4 ng/ml (borderline), respectively. Adjuvant cisplatin/cyclophosphamide based 
chemotherapy was given in 14 patients (6 stage I, 8 stage III-IV). Table 3 presents 
clinicopathological characteristics, GSTP1-1 and GSTA1-1 cyst fluid concentrations as well 
as the presence or absence of recurrent disease during follow-up. Median cyst fluid GSTP1-1 
levels in 10 patients with recurrence was 820 ng/ml and was significantly higher (p=0.01) 
than the median level of 96 ng/ml which was measured in the 4 patients without recurrence 
(Table 3). No significant differences were found between these groups for GSTA1-1, 
although median GSTA1-1 level was higher in patients without versus patients with recurrent 
disease (3 ng/ml versus 1 ng/ml, respectively). Considering only stage I patients revealed 2 
patients with recurrence with GSTP1-1 levels of 404 and 902 ng/ml, respectively and 4 
patients without recurrence with GSTP1-1 levels of 12, 64, 128, and 136 ng/ml, respectively 
(Table 3). GSTP1-1 and GSTA1-1 levels were compared with CA-125 concentrations after 3 
courses of chemotherapy in 11 patients. Median CA-125 after 3 courses of chemotherapy in 9 
patients with recurrence was 15 U/ml. In the two patients without recurrence these 
concentrations were 2 and 11 U/ml, respectively. The highest CA-125 after 3 courses of 
chemotherapy was found in the one patient with the highest GSTP1-1 and GSTA1-1
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concentrations of 32695 ng/ml and 12900 ng/ml, respectively. This patient developed 
recurrent disease within 3 months after surgery and died within 4 months.
Table 2: GSTP1-1 and GSTA1-1 cyst fluid concentrations in clinicopathologic subgroups o f patients 
with malignant ovarian tumors (n=23).
GSTP 1-1 GSTA 1-1
FIGO Stage
n
median
(ng/ml)
(25th-75th
percentile)
(ng/ml)
median
(ng/ml)
(25th-75th
percentile)
(ng/ml)
I 13 419 (128-907) 17 (2-35)
II-IV 10 967 (448-1747) 1 (1-22)
Grading
1 6 474 (64-1297) 34 (17-118)
2 5 1196 (419-1332) 1 (1-22)
3 12 535 (147-1553) 2 (0.5-15)
Residual tumor
<2cm 18 474 (136-1297) 15 (2-35)
>2cm 5 738 (158-1332) 1 (0.02-1)
Ascites
no 10 445 (136-1297) 27 (4-118)
yes 13 622 (158-1332) 2 (1-17)
Recurrent disease
no 10 304 (64-1297) 15 (2-35)
yes 13 738 (419-1332) 2 (1-22)
Disease free survival
>14 months 11 472 (64-1297) 21 (9-118)
<14 months 12 680 (147-1539) 1 (1-13)
Overall survival
>24 months 11 477 (158-1297) 9 (1-21)
<24 months 12 605 (132-1317) 18 (0.5-191)
All patients 23 477 (136-1302) 9 (1-35)
n: number o f patients in each category
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Table 3: GSTP1-1 and GSTA1-1 cyst fluid concentrations and clinicopathologic 
characteristics in patients with malignant ovarian tumors, treated with cisplatin-based 
chemotherapy after primary surgery.
patient
no.
Age FIGO Grade recurrence c GSTP 1-1 
(ng/ml)
GSTA 1-1 
(ng/ml)
CA-125 a
(U/ml)
1 74 IA 3 yes 902 21 8.4
2 65 IA 3 no 136 4 nd
3 66 IC 3 no 12 0.02 nd
4 49 IC 1 no 64 14 11b
5 44 IC 3 no 128 2 2
6 57 IC 3 yes 404 1 3.3
7 52 IIIB 3 yes 622 2 19
8 31 IIIC 3 yes 32695 12900 285
9 51 IIIC 2 yes 1747 22 15
10 59 IIIC 2 yes 1196 1 17
11 52 IIIC 3 yes 738 0.02 22 b
12 56 IIIC 3 yes 25963 987 7.6
13 63 IIIC 2 yes 59 1 nd
14 57 IV 3 yes 158 1 6.5
nd not determined, a after 3 courses o f chemotherapy, b after 6 courses o f  
chemotherapy
c GSTP1-1 was significantly higher (p=0.01) in patients with than without 
recurrence
DISCUSSION
Studies in the past investigating the role of glutathione-S transferase isoenzymes in ovarian 
tumors were performed on tumor tissue samples, and immunohistochemistry results are 
qualitative and conflicting. Tumors are heterogeneous and most likely tumor biology is not 
optimally reflected by one tissue biopsy. Murphy et al. suggested homogenisation of several 
tumor specimens to overcome this problem [22]. Analysis of cyst fluid probably provides an 
even better overall representation of cellular processes of the tumor. Cyst fluid can be easily 
aspirated after surgery without the risk of spill, no tissue homogenization is required, and the 
problem of sampling in a heterogeneous tumor is avoided. Until now, no study on the levels 
of glutathione-S transferases in cyst fluid of ovarian tumors was performed.
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The aim of the present study was to perform a quantitative assessment of GSTP1-1 and 
GSTA1-1 in a large number of ovarian cyst fluid samples from malignant, borderline and 
benign tumors. We found significant differences in GSTP1-1 cyst fluid concentrations 
between histopathologic subgroups. The highest levels were present in cyst fluid from 
malignant ovarian cysts. This was in line with several results from ovarian tissue studies 
[16,18]. However, this seems to contradict with results from Djuric et al. who described lower 
GST activity in malignant compared with normal or benign ovarian tissues [10]. In the Djuric 
study however, overall GST enzyme activity was determined and no estimation of the main 
isoenzyme levels was made, whereas the “normal” ovarian tissues were taken from patients 
with cervical or endometrial cancer in which high GST expression was described [23,24]. 
This may explain the high GST activity found by Djuric et al. in their group of normal ovarian 
tissue. The significantly higher median GSTP1-1 concentrations in the present study as found 
in cyst fluid of tumors of low malignant potential (borderline malignany) compared to benign 
cysts may reflect histopathological changes specific for this subgroup and emphasizes the 
relevance of including borderline malignancy as a separate entity. It would be worthwhile to 
analyse other prognostic factors that have been described in borderline malignancy, such as 
micro-invasive growth, in relation with the GSTP1-1 cyst fluid concentration in a larger series 
of patients with extensive follow-up.
Although differences were not significant, the higher median ovarian cyst fluid GSTP1-1 
concentrations that we found in the malignant subgroups with worse prognostic factors, 
suggest that GSTP1-1 cyst fluid level is a possible measure of aggressiveness of the 
corresponding ovarian tumor. However, this difference in prognosis can also be the result of 
the already mentioned chemoresistance. A significant correlation between positive GSTP1-1 
staining and shorter patient survival was also found by Green et al. [9], Hirazono et al. [12], 
Hamada et al. [15].
In contrast to GSTP1-1, cyst fluid GSTA1-1 concentrations were higher in the subgroups with 
more favourable characteristics. GSTA1-1 seems to have the capability of suppressing tumor 
aggressiveness. In this study no correlation was found for disease free survival or overall 
survival with neither GSTA1-1 nor GSTP1-1 cyst fluid concentrations.
Several authors reported a correlation between high tissue GSTP1-1 expression and resistance 
to chemotherapy [9,15,17]. However, it was suggested that the role of GSTP1-1 in the 
development of anticancer drug resistance is restricted to serous subtypes of 
cystadenocarcinoma of the ovary [16]. Other authors could not confirm the possible 
association between GST expression and response to chemotherapy [14,25-27]. Conflicting 
data in the literature can be explained by differences in tissue sampling methods, the
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relatively small number of examined patients and a large variation in clinicopathologic 
characteristics. Furthermore, resistance to chemotherapy is a multifactorial process with a 
number of potentially important determinants.
Our results support the prognostic value for GSTP1-1 cyst fluid concentrations in the 
prediction of response to chemotherapy. We found a relation between higher cyst fluid 
GSTP1-1 concentrations and tumor recurrence after chemotherapy. This indicates that higher 
GSTP1-1 cyst fluid levels reflect increased detoxification of anticancer drugs.
In summary, quantification of gluthathione S-transferase P1-1 levels in cyst fluid samples 
from ovarian tumors can be of additional value in the differentiation between histologic 
subgroups. Ovarian cyst fluid GSTP1-1 levels seem to be a good marker for aggressiveness of 
ovarian tumors, and may predict response to chemotherapy.
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ABSTRACT
Purpose: The purpose of the current study was to determine vascular endothelial growth 
factor (VEGF) concentrations in cyst fluid from malignant, borderline and benign ovarian 
tumors, and to correlate these data with preoperative serum VEGF concentrations and 
clinicopathologic characteristics.
Methods: One hundred seven ovarian cysts were removed and punctured for cyst fluid 
collection. Histologic diagnosis revealed 25 malignant, 12 borderline, and 70 benign ovarian 
tumors. The VEGF concentrations of all the cyst fluid specimens as well as in 37 
preoperatively collected serum samples were determined by making use of a sandwich type 
double determinant enzyme linked immunoadsorbent assay (ELISA) based on a combination 
of four polyclonal antibodies.
Results: Statistically significant higher VEGF concentrations were found in cyst fluid from 
malignant (median: 21.5 |ig/L) compared with borderline (median: 3.2 |ig/L; p=0.01), or 
benign tumors (median: 1.3 |ig/L; p<0.0001). Preoperative serum VEGF concentrations were 
significantly higher in patients with malignant (median: 0.63 |ig/L, range: 0.016-17.7 |ig/L) 
compared with non-malignant tumors (median: 0.28 |ig/L, range: 0.016-0.89 |ig/L; p=0.008). 
A significant correlation of preoperative serum VEGF was found with VEGF cyst fluid 
concentrations (r:0.38, p=0.02). Significantly higher VEGF cyst fluid concentrations were 
found in serous malignant (median: 31.9 |ig/L) compared with mucinous malignant tumors 
(median: 4.7 |ig/L, p=0.004). Not significant, though higher median VEGF cyst fluid 
concentrations were found in advanced FIGO stage II, III and IV, histologic grade 2 and 3, 
patients with residual tumor greater than 2 cm, with malignant cells in ascites or peritoneal 
washings, or with recurrent disease, as compared to FIGO stage I, histologic grade 1, patients 
with less than or equal to 2 cm residual tumor, without malignant cells in ascites/peritoneal 
washings, or without recurrent disease, respectively.
Conclusions: It has become clear from the increased study sample that ovarian tumors of 
different histologic etiology vary in VEGF cyst fluid concentrations, with the highest VEGF 
cyst fluid concentrations in malignant tumors. The prognostic significance of VEGF cyst fluid 
concentrations in advanced FIGO stage seems to be of limited value, but may be important in 
the selection of high-risk FIGO I, and borderline types. Data from this study indicate a 
possible role for VEGF as a serum tumormarker.
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INTRODUCTION
Angiogenesis is an important factor in tumor growth. It involves the process of proliferation 
of new capillaries from preexisting vessels, resulting in the formation of new blood vessels 
[1,2]. Several promotors of this process have been reported; the most important ones appear to 
be vascular endothelial growth factor (VEGF), and other factors structurally related to VEGF, 
such as acidic and basic fibroblast growth factors, or platelet derived growth factor [1-3]. 
Human cells express four different molecular isoforms of VEGF, comprising 121, 165, 189, 
and 206 aminoacids [4,5]. The isoforms of VEGF are supposed to have several other effects 
besides the induction of capillary tube formation, such as a mitogenic effect on endothelial 
cells, and induction of an increased vascular permeability [2,4]. VEGF is expressed in a 
variety of human malignancies and has been implicated as a regulator of angiogenesis in 
ovarian carcinoma [6]. Neoplastic ovarian pathology including both benign and malignant 
transformations consists of many types and subtypes, having solid and cystic components. 
Malignant epithelial ovarian tumors have the highest incidence of lethal gynecologic 
malignancy. Research focuses on early diagnosis, prognostic evaluation, and treatment [7,8]. 
In ovarian carcinoma, the presence of VEGF was mostly studied in tissue specimens [6,9-16] 
or in serum [11,17]. High VEGF expression was shown in lower as well as advanced 
International Federation of Gynecology and Obstetrics (FIGO) stages. Identification of high­
risk patients based on VEGF tissue levels [9,18] and serum concentrations [11,17] already has 
been suggested. Only a few studies with a limited number of observations on VEGF 
concentrations in cyst fluid from ovarian tumors are available [8,11,12]. The current study 
aims to extend these reports substantially by testing the presence of VEGF in 107 cyst fluid 
samples from ovarian tumors of different histologic origin including borderline malignancy. 
Furthermore, we evaluated VEGF concentrations of preoperatively collected serum specimens 
and correlated the results with the histologic diagnosis and the VEGF cyst fluid 
concentrations.
MATERIALS AND METHODS
Cyst flu id collection procedure
Patients with a cystic ovarian tumor planned for surgical removal were included in the cyst 
fluid sample collection procedure, starting January 1998. Immediately after surgical removal, 
the ovarian tumor was transported to the pathology laboratory. Histopathology was performed
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by an experienced gynecologic pathologist. Aseptic fine needle aspiration was performed to 
collect the ovarian cyst fluid specimen. Next, the cyst fluid was centrifuged at 3000x g for 10 
minutes, the supernatant was collected and immediately stored at -35 oC until further analysis 
was performed. One hundred seven samples were used in this study and stored at the 
laboratory of the Department of Chemical Endocrinology. Determination of VEGF was 
performed by a skilled technician without knowledge of the histologic outcome.
Laboratory assays 
VEGF assay
The analyte concentrations of the VEGF were measured in the same experimental setup as 
was described extensively by Grebenschikov et al. [19] for components of the plasminogen 
activator sytem. This assay is based on a combination of four polyclonal antibodies (raised in 
four different animal species including duck, chicken, rabbit and goat) which were used in a 
sandwich assay format. The composition of the buffers was as follows: coating buffer, 15 
mmol/L Na2CO3 and 35 mmol/L NaHCO3, pH 9.6. phosphate buffered saline (PBS), 14
mmol/L NaCl, 2.7 mmol/L KCl, 1.5 mmol/L KH2PO4 and 8.1 mmol/L Na2HPO4, pH 7.4. 
Blocking buffer, 2% Bovine Serum Albumin (BSA) in PBS. Washing buffer, 0.1% Tween-20 
in PBS. Dilution buffer, 1% BSA in washing buffer. Color buffer, 76 mmol/L NaH2PO4. 
H2O and 35 mmol/L citric acid, pH 5.0. Substrate solution contained 4 mg orthophenylene 
diamine (OPD) and 10 |il 30% H2O2 in 11 ml color buffer. All incubation steps were
separated by washing steps (4 times, 300 |il of washing buffer per well). The coating antibody 
(Ab) was diluted in the coating buffer, whereas catching, capture and detecting Abs as well as 
standards, unknowns and reference samples were diluted in the dilution buffer (100 |il per 
well). The procedure started with treating the microtiter plates with coating antibody (duck 
anti-chicken immunoglobulin (Ig)Y, overnight at 4 °C), after which the plates were blocked 
with blocking buffer (2 hours at 37 °C). The next step was the incubation with catching 
antibody (chicken anti-VEGF, 2 hours at 37 °C). The incubation with the unknowns, reference 
samples and the 7 standards (range 0-2 |ig/L) took place overnight at 4 °C. The incubation 
with capture antibody (rabbit anti-VEGF) as well as the subsequent incubation with detecting 
antibody (horseradish peroxidase-labeled goat anti-rabbit) was performed for 2 hours at 
ambient temperature. The incubation with substrate solution was performed in darkness for 30 
minutes at ambient temperature. Color reaction was stopped by the addition of 1M H2S04
(100^l per well) and the optical density was measured at 492 nm within 30 minutes. Before 
the ELISA was used, the sample specimens were diluted to 16x.
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The VEGF assay detects distinct molecular forms of VEGF are measured. There is no cross­
reactivity with Platelet Derived Growth Factor AB (PDGF AB), Insulin-like Growth Factor 
type 1 (IGF-1), human Growth Factor (hGH), Placental Growth Factor (PlGF), Nerve Growth 
Factor (NGF), Tumor Necrosis Factor alpha (TNF-a) or Transforming Growth Factor (TGF).
The analytical lower dectection limit of the assay is 0.023 |ig/L, whereas the functional 
sensitivity for VEGF amount to 0.032 |ig/L. The precision of the assay regarding within-run 
coefficient of variation (CV, n=10) and between-run CV as determined in 6 consecutive assay 
runs, for mean of duplicate determinations are 8.7% and 13.4%, respectively.
Protein assay
The protein concentrations of the cyst fluid samples were determined using the Pierce® 
(bicinchoninic acid) method using BSA fraction V as a standard [20]. Sample specimens and 
standard doses were both measured in duplicate.
CA-125 assay V
Serum concentrations were determined by the automated AxSYM microparticle enzyme 
immunoassay (Abbott Laboratories, Chicago, Illinois, USA). Assays were performed 
according to the manufacturers instructions, and given in units per milliliter (U/ml).
Clinicopathologic characteristics
From the medical records of 25 patients with a malignant ovarian cyst, we retrieved the 
following data: FIGO stage, histopathology, grading, residual tumor after surgery, malignant 
cells in ascites or peritoneal washings, the preoperative serum CA-125 concentration, tumor 
recurrence, disease free survival (DFS), and overall survival (OS). Tumor stage was recorded 
according to criteria of the International Federation of Gynecology and Obstetrics (FIGO).
Residual tumor was divided into two groups; less than or equal to 2 cm or greated than 2 cm 
residual tumor. Cytologic examination of ascites or, if  absent, peritoneal washing was noted 
as positive in the presence of malignant cells. Tumor recurrence was defined as evidence of 
disease within the follow-up interval between date of surgery and closure of the follow-up 
period.
Statistical analysis
Because of skewness of the test results, VEGF concentrations are given in median, 25th and 
75th percentiles. The VEGF detection limit was set at 0.032 |ig/L. Determinations less than 
the lower limit of detection were considered half this concentration (0.016 |ig/L). Differences
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in VEGF levels between the different histologic subgroups were tested using the Mann 
Whitney £/-test for independent samples (level of significance p<0.05). Differences between 
VEGF concentrations and clinicopathologic characteristics were tested also by using the 
Mann Whitney £/-test (level of significance p<0.05). For this purpose we used the median 
preoperative serum CA-125 level and disease free survival. Correlations between VEGF 
concentrations in serum and cyst fluid were determined using the Spearman rank correlation 
coefficient.
RESULTS
Table 1 presents the histologic diagnosis of 107 patients with ovarian tumors. This 
data comprised 25 malignant, 12 borderline and 70 benign tumors. Cyst fluid concentrations 
of VEGF of these groups are shown in figure 1. Data are given as median concentrations, and 
25th-75th percentiles. Median VEGF concentrations in cyst fluid from malignant, borderline 
and benign ovarian tumors were 21.5 |ig/L, 3.2 |ig/L, and 1.3 |ig/L, respectively. Statistically 
significantly higher VEGF concentrations were found in cyst fluid from malignant compared 
with borderline (p=0.01) and benign tumors (p<0.0001).
Subdividing the benign tumors into different histologic subtypes revealed median cyst 
fluid concentrations of 1.14 |ig/L in benign cystadenoma, 0.4 |ig/L in dermoid cyst, 0.016 
|ig/L and 12.4 |ig/L in case of functional cyst and cystic endometriosis, respectively (figure 
2).
Results of total protein measurements indicate significantly higher total protein 
concentrations in cyst fluid from malignant tumors (median: 68 mg/ml) compared with 
borderline (median: 33 mg/ml; p=0.0002) or with benign tumors (median: 35 mg/ml; 
p=0.0001). After correction for protein concentrations, VEGF levels in ng/mg protein, were 
still significantly higher in cyst fluid from malignant compared with benign tumors (p=0.002), 
but differences with borderline tumors were not significant (p=0.1).
VEGF serum concentrations
Preoperative serum VEGF concentrations were determined in a subset of patients, with 17 
patients with malignant and 20 with non-malignant ovarian cysts. For the entire patient subset 
the median serum VEGF concentrations amounted 0.37 |ig/L, with 25th and 75th percentile of
0.17 and 0.63 |ig/L, respectively. Serum VEGF level was significantly higher in patients with 
malignant (median: 0.63 |ig/L, range: 0.016-17.7 |ig/L) compared with non-malignant tumors
76
(median: 0.28 |ig/L, range: 0.016-0.89 |ig/L; p=0.008). For the total subset a significant 
correlation was found between VEGF concentrations in cyst fluid and serum specimens 
(rs=0.38; p=0.02).
Table 1: Histopathologic result o f ovarian cystic tumors (n=107)
_______________________________  N
Malignant
Serous cystadenocarcinoma 
mucinous cystadenocarcinoma 
endometrioid carcinoma 
undifferentiated cystadenocarcinoma
Total
Borderline
Serous cystadenoma 
mucinous cystadenoma 
Serous/mucinous cystadenoma
Total
Benign
Serous cystadenoma 
mucinous cystadenoma 
dermoid cyst 
functional cyst 
cystic endometriosis 
Total
Total___________________________
n: number o f tumors in each group
Differentiation between malignant and non-malignant tumors
Figure 3 depicts a Receiver Operating Characteristic (ROC) curve for malignant and non- 
malignant subclasses based on VEGF cyst fluid (figure 3 a) as well as serum concentrations 
(figure 3b). The area under the curve (AUC) amounted 0.80 and 0.75, respectively.
Correlation VEGF with clinicopathologic characteristics
Table 2 shows the characteristics from 25 patients with malignant ovarian cyst, and 
correlation with VEGF cyst fluid concentrations. Subdivision of malignant cyst in serous and 
mucinous cystadenocarcinoma revealed significantly higher median VEGF cyst fluid 
concentrations in serous tumors (p=0.004). Not significant though higher median VEGF cyst 
fluid concentrations were found in patients with advanced FIGO stage II, III and IV, with 
histologic grade 2 and 3, with residual tumor greater than 2 cm, with malignant cells in ascites 
or peritoneal washings, and with recurrent disease, as compared with FIGO stage I, histologic 
grade 1, patients with residual tumor less than or equal to 2 cm, without malignant cells in 
ascites/peritoneal washings, or without recurrent disease, respectively.
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Figure 3: Receiver operating characteristic curve for malignant and non-malignant ovarian 
tumors based on vascular endothelial growth factor (VEGF) cyst flu id (top) and preoperative 
serum (bottom) concentrations. ROC: receiver operating characteristic ; AUC: area under 
the curve
No correlations of VEGF cyst fluid concentrations were found with pre-operative CA- 
125 concentrations, disease free survival or overall survival.
The difference in median concentrations between patients with or without tumor recurrence, 
was mainly determined by differences in patients with FIGO stage I. Median VEGF cyst fluid 
concentrations in these patients were 32.7 |ig/L, whereas these amounted 6.5 |ig/L in 11 
patients without recurrence.
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ROC VEGF serum; AUC= 0.75
—
Cyst fluid VEGF fog/L)
Characteristic N median (range) P-value
All patients 25 21.5 (0.016-57.6)
FIGO Stage 
I 14 1 3.4 (0.016-56.8)
p=0.09A
II 2 48.2 (38.7-57.6)
III 7 30.2 (0.3-50.8)
IV 2 22.5 (15.0-30.0)
Histology
Serous 11 31.9 (0.9-57.6)
p=0.004B
Mucinous 8 4.7 (0.016-30.5)
Other 6 25.8 (15.0-42.4)
Grading
1 7 6.7 (0.016-38.7)
p=0.1 C
2 4 28.3 (15.8-50.8)
3 14 25.8 (0.3-57.6)
Residual tumor 
<2cm 20 19.3 (0.016-57.6)
p=0.5 D
>2cm 5 30.0 (15-37.8)
Malignant cells ascites 
Positive 16 28.3 (0.016-57.6)
p=0.5
Negative 9 15.8 (0.5-56.8)
Pre-operative CA-125E 
<120 U/ml 13 21.5 (6.7-38.7)
p=0.7
>120 U/ml 11 21.9 (6.2-31.4)
Tumor recurrence 
Yes 9 30.0 (0.3-56.8)
p=0.2
No 16 16.4 (0.016-57.6)
Disease free survival 
<13 months 14 22.9 (0.3-56.8)
p=0.7
>13 months 11 21.5 (0.016-57.6)
Overall survival 
<16 months 13 21.5 (0.3-56.8)
p=0.7
>16 months 12 21.9 (0.016-57.6)
Age (years) 25 57 (31-80)
Median observation time 
all patients 25 16 (2-128)
patients alive 20 15 (3-128)
Table 2: Median (25th-75th percentile) VEGF cyst fluid concentration from malignant ovarian tumors 
(n=25) and clinicopathologic characteristics
A: FIGO stage I  vs II,III,IV; B.serous vs mucinous; C:histologic grade 1 vs 2 and 3; D: none/<2cm vs 
>2cm residual tumor; E: not determined in one patient
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DISCUSSION
The current study reports on VEGF concentrations in a series of 107 cyst fluid samples from 
ovarian tumors, and relates these data with clinicopathologic characteristics. Significantly 
higher VEGF concentrations in cyst fluid from malignant compared with that of benign 
ovarian tumors are found. This is in accordance with several studies that, however, comprise 
only a few samples [8,11,12].
In the current study significantly higher protein concentrations in cyst fluid from 
malignant compared with borderline and benign tumors were observed. A similar observation 
was earlier described by Hazelton et al. [8]. Furthermore, this is in accordance with a study 
performed by Massuger et al. that describes increased levels of protein breakdown products in 
fluid from malignant cysts [21]. These authors proposed that rapid cellular turnover in 
malignant cysts leads to increased proteolysis. After correction for total protein concentration, 
the VEGF concentrations in cyst fluid from malignant tumors in the current study were still 
significantly higher compared with benign tumors. This finding is in agreement with the V 
suggestion of Hazelton et al. that the increase of total protein concentration cannot account for 
the increased VEGF cyst fluid concentrations in malignant tumors [8].
Ovarian cysts that are histologically classified as borderline, revealed VEGF cyst fluid 
concentrations in between those of malignant and benign cysts. This may suggest that VEGF- 
related processes are present more explicitly in this low-malignant subgroup than in benign 
tumors, but not comparable to those of malignant tumors. Micro-invasive growth in 
borderline tumors is noted to be an adverse factor in prognosis and appears to represent 
transitional stages in ovarian carcinogenesis [22]. In the current study only 1 of 12 borderline 
malignancies showed micro-invasive growth, which coincided with the highest VEGF cyst 
fluid concentration determined within that group amounting to 10-fold the median 
concentration. This indeed may indicate that VEGF plays a role in identifying “high risk“ 
borderline tumors as speculated previously [8,23].
Cyst fluid from cystic endometriosis contains higher VEGF concentrations compared 
with other benign subgroups. Hazelton et al. [8] included this subtype in the functional cyst 
group and found more than a 10-fold increased VEGF concentration in cystic endometriosis 
compared with the median concentrations in functional cysts. In our view, endometriotic cysts 
should not be included in the functional cyst group because ectopic endometrial glands and 
stroma are within the ovary causing a continuous breakdown of components of blood and 
stromal tissue. The high VEGF levels in this type of cyst might reflect extensive formation of 
blood vessels for resorption of blood.
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The role of VEGF as a prognostic factor in malignant ovarian tumors as yet has not 
been fully established. Paley et al. observed that patients with early stage disease and high 
VEGF tissue expression had poorer prognosis and needed further evaluation [9]. Yamamoto 
et al. concluded that the prognostic significance of VEGF is related to its correlation with 
FIGO and is not an independent prognostic factor in tissue samples [11]. Mattern et al. found 
no significant difference in recurrence free interval or overall survival between FIGO stage 
III/IV tumors with low and high VEGF tissue expression [16].
In our series of malignant tumors we compared VEGF cyst fluid levels with 
clinicopathologic characteristics. The current study indicates a trend towards higher median 
VEGF cyst fluid concentrations in patients with FIGO stage II-III-IV, histologic grade 2-3, 
residual tumor greater than 2 cm, malignant cells in ascites or peritoneal washings, and in 
patients with tumor recurrence as compared to lower or absence of these conditions. We 
compared VEGF cyst fluid levels in FIGO stage I (n=14) patients and FIGO stage II,III,IV 
(n=11) as one group because of the low numbers in stage II and IV. This may explain the lack 
of significance, and therefore these findings have to be explored in more detail after increase 
of the number of cyst fluids from advanced stage tumors. The higher median VEGF cyst fluid 
concentrations that were found in patients with FIGO stage I tumors with recurrent disease 
indicate a possible role for VEGF in cyst fluid in the detection of high-risk low stage patients. 
The significantly higher VEGF concentrations in cyst fluid from serous compared with 
mucinous malignant tumors (p=0.004) can possibly be explained by the overrepresentation of 
high stage tumors in this group. The results suggest a limited role for cyst fluid VEGF as a 
prognostic indicator in advanced stages. However, few advanced stage malignancies were 
included and follow-up for several of these cases was limited. In a laboratory animal model of 
epithelial ovarian carcinoma inhibition of tumor growth and a survival advantage were 
reported by the administration of a VEGF neutralizing antiserum [24]. Thus, when anti- 
angiogenic therapy becomes clinically available VEGF cyst fluid studies may provide 
additional information with regard to therapeutic options, for instance in the treatment of 
high-risk borderline and low FIGO stage patients.
Very promising in the current study are the significantly higher pre-operative VEGF 
serum concentrations in patients with malignant compared with those with non-malignant 
tumors. Increase of VEGF production by malignant tumor cells could result in a more 
pronounced vascular leakage than in the case of non-malignant tumor growth, and 
consequently leakage of VEGF from a highly permeable neovascularized tumor region finally 
results in higher VEGF blood concentrations [11]. This raises the question whether VEGF can
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be used as a serum tumor marker for discriminating benign and borderline from malignant 
ovarian cystic tumors. However, further research is required to confirm this possibility.
Ovarian cyst fluid originates from a homogeneous compartment surrounded by an 
epithelial cyst wall. These specimens therefore might be superior to tissue specimens, which 
by nature are heterogeneous. Pathophysiologic changes in the cyst wall lead to alterations of 
the metabolic composition of cyst fluid, which can be related to cyst wall histology [21]. 
Pathophysiologic cyst wall changes thus could result in storage of metabolites in the cyst 
compartment but also could be directly diffused into the blood. Alternatively, it is also 
possible that metabolites produced by the cyst wall are stored in the cyst fluid compartment 
and diffusion to blood subsequently results in increased blood concentrations of these 
metabolites. Thus, determination of VEGF concentrations in ovarian cyst fluid and in serum 
may provide information on the biology of the tumor. Obviously, serum determinations are 
favorable and are the basis for studies on its role as a serum tumormarker.
In conclusion, ovarian tumors of different histologic etiology significantly vary in VEGF cyst V 
fluid concentrations. The prognostic significance of VEGF cyst fluid concentrations in 
advanced FIGO stage seems to be of limited value but may be important in the selection of 
high-risk FIGO I and borderline types. Data from this study indicate a possible role for VEGF 
as a new serum tumormarker.
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ABSTRACT
Background: The aim of this study was to analyze the concentrations of different components 
of the plasminogen activation system in cyst fluid from malignant, borderline, and benign 
ovarian tumors and to compare these results with clinicopathologic characteristics (FIGO 
staging, histologic grading, residual tumor, ascites, tumor recurrence and disease free 
survival).
Methods: One hundred and seven cyst fluid samples were enrolled from 25 malignant, 12 
borderline and 70 benign ovarian tumors. Determination of uPA, tPA, PAI-1, PAI-2, 
uPA:PAI-1 complex, and tPA:PAI-1 complex was performed by specific double determinant 
ELIS As based on the concept described previously by Grebenschikov et al. With these 
ELIS As both complexes of the activators (uPA, tPA) with their inhibitor (PAI-1) can be 
measured as a separate component.
Results: Significant differences were found in median cyst fluid concentrations of uPA, PAI-
1, uPA:PAI-1, and tPA:PAI-1 from malignant, borderline, and benign ovarian tumors, with 
the highest levels in malignant ovarian tumors. Cystic endometriosis seems to be a special 
entity within the benign subclass. To achieve better discrimination between malignant and 
benign cases we introduced a new malignancy index: ([uPA:PAI-1] + [tPA:PAI-1])x [PAI-1]. 
The area under a Receiver Operating Characteristic (ROC) curve amounted 0.80. 
Significantly higher concentrations were found in FIGO stages II-III-IV compared with stage 
I for uPA (p<0.05), tPA (p<0.05), uPA:PAI-1 (p<0.01), and tPA:PAI-1 (p<0.05).
Conclusions: Concentrations of plasminogen activation system markers in cyst fluid from 
ovarian tumors are related to histologic subtype. The most significant components are uPA, 
PAI-1, and the complexes uPA:PAI-1, tPA:PAI-1. The prognostic value of the components 
seems to be limited but might be important in detecting high risk borderline or low stage 
patients.
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INTRODUCTION
One of the processes involved in cancer metastasis is the degradation of components of the 
surrounding extracellular matrix (ECM). As a result invasion of cancer cells into the 
surrounding tissue is possible [1]. The plasminogen activation system comprises a set of 
proteolytic enzymes that play an important role in the ECM degradation process [1,2]. A 
central step in the plasminogen activation system is the conversion of the inactive pro-enzyme 
plasminogen into the enzymatically active plasmin [1,2]. Two different plasminogen-activator 
(PA) glycoproteins have been described: urokinase type (uPA) and tissue-type (tPA) [3]. The 
activity of these components is controlled by two serine protease inhibitors: plasminogen 
activator inhibitor type 1 (PAI-1) and type 2 (PAI-2) [4]. uPA is synthesized and secreted by 
tumor cells in an inactive form [2,5-7]. This so called pro-uPA binds to specific receptors on 
the tumor cell surface. After binding to the urokinase-type plasminogen activator receptor 
(uPAR) the active uPA is formed by proteolytic cleavage [1,2,5-7]. Active receptor bound 
uPA converts plasminogen into plasmin, leading to degradation of components of the ECM 
[8,9]. A soluble form of uPAR has been reported in ascites and plasma of ovarian cancer 
patients by Pedersen et al. [10].
Tissue levels of plasminogen activators and inhibitors have been recognized as 
prognostic parameters in breast, lung, and gastric cancer [11-15]. The role of the plasminogen 
activation system in ovarian tumors has been described by several authors [16-23]. These 
studies focused on the quantitation of the different components in tissue-, blood-, and ascitic 
fluid samples from patients with benign and malignant ovarian tumors. Only two studies on 
ovarian cyst fluid have been published [16,17] of which the results are conflicting. Saito et al. 
[16] determined total uPA and tPA in cyst fluid from 11 malignant and 8 benign ovarian 
tumors, without specification of histopathologic subgroups. Casslén et al. [17] determined 
different components of the plasminogen activation system in a series of 87 benign and 22 
malignant ovarian cyst fluid samples. Most Enzyme-Linked Immuno Sorbent Assays 
(ELISAs) available for components of the PA system cannot differentiate between single 
components and complexes from the same component. In the current study we used ELISAs 
recently described by Grebenschikov et al. [24,25] for the detection of total uPA, PAI-1, and 
tPA as well ELISAs for the complexes uPA:PAI-1 and tPA:PAI-1.
The aim of this study was to analyze different components of the plaminogen activation 
system based on this assay format in ovarian cyst fluid. Clinical relevance was studied by 
relating the concentrations of the different components to clinicopathologic characteristics.
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METHODS
Cyst flu id  collection
A total of 110 patients with an ovarian tumor planned for surgical removal were included in 
the cyst fluid collection procedure (median age: 45 years). Immediately after surgical removal 
the tumor was transported to the pathology laboratory where aseptic fine needle aspiration 
was performed to collect cyst fluid. Next, the cooled fluid sample was transported to the 
laboratory of the Department of Chemical Endocrinology, centrifuged at 3000x g for 10 
minutes, the supernatant collected and immediately stored at -35 oC until further analyses. 
Histopathological evaluation was performed by an experienced gynecologic pathologist, and 
revealed 28 malignant, 12 borderline, and 70 benign diagnosis. Three patients with 
histopathologic malignant diagnosis were excluded from the cyst fluid analysis as pathology 
revealed a primary tumor location other than the ovary. The assays for the different 
components of the plasminogen activation system were all performed by an experienced 
technician.
ELISAs for different components o f the plasminogen activation system
Determination of uPA, tPA, PAI-1, PAI-2, uPA:PAI-1 complex and tPA:PAI-1 complex was 
performed by specific double determinant ELISAs based on the concept described previously 
by Grebenschikov et al. [24,25]. This microtiter plate based assay format comprises a coating 
Ab (sheep anti-chicken IgY), a catching Ab (chicken anti-analyte), a tagging Ab, (rabbit anti­
analyte), and a detecting Ab (goat anti-rabbit IgG) labelled with horse radish peroxidase 
(HRP), and requires a sample volume of 25 ^l of the clinical specimen. Prior to the assay the 
specimens were diluted 50 times for tPA and tPA:PAI-1 complex, 100 times for uPA, PAI-1 
and uPA:PAI-1 complex, and 200 times for PAI-2. Results were expressed in ^g/L. The 
analytical and functional sensitivities of these assays were, respectively: uPA: 0.013 ^g/L and
0.027 |ig/L, tPA: 0.017 ^g/L and 0.026 ^g/L, PAI-1: 0.010 ^g/L and 0.019 ^g/L, PAI-2:
0.027 ^g/L and 0.032 ^g/L, uPA:PAI-1: 0.017 ^.g/L and 0.025 ^g/L, and tPA:PAI-1: 0.014 
^g/L and 0.25 ^g/L. Assay precision in terms of intra- and interassay coefficients of variation 
for means of duplicate determinations were: uPA: 4.0% and 9.2%, PAI-1: 2.0% and 12.2%, 
tPA: 3.3% and 10.7%, and PAI-2: 5.3% and 11.2%, respectively.
Clinicopathologic characteristics
From the medical records of 25 patients with malignant histopathologic diagnosis the 
following clinicopathologic characteristics were retrieved: Stage according to the
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International Federation of Gynecology and Obstetrics (FIGO) guidelines, histopathologic 
grade, residual tumor after surgery, presence of ascites, tumor recurrence and disease free 
survival (DFS). Residual tumor was divided into two groups: <2 cm or >2cm. Tumor 
recurrence was defined as evidence of disease within the follow-up interval between date of 
surgery and closure of the follow-up period.
Statistics
Results are given as median, and 25th-75th percentiles. Assay results below the detection 
limits of the ELISAs for the different components in the clinical specimens were considered 
half these concentrations. Significance of differences in concentrations of the various markers 
between the histopathologic subgroups were tested using the Mann-Whitney-U test for 
independent samples (level of significance p<0.05). For disease free survival we used the 
median in months as a cut off level. Malignancy indices for the differentiation between cyst 
fluid from malignant and benign tumors were presented in a Receiver Operating 
Characteristic (ROC) curve relating sensitivity with 1-specificity.
RESULTS
VI
Plasminogen activation system components in ovarian cyst fluid
Table 1 presents the histopathologic diagnosis of 110 patients with ovarian tumors. 28 
malignant, 12 borderline and 70 benign tumors divided into the different histopathological 
subgroups.
Figure 1 depicts the median, and 25th-75th percentile concentrations of uPA, tPA, PAI-1,
PAI-2, and the complexes uPA:PAI-1 and tPA:PAI-1 as determined in the 107 cyst fluid 
samples.
Table 2 shows the concentrations of these PA-system components of the malignant, 
borderline and benign groups, including the histopathological subgroups of the benign 
tumors.
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n
Malignant
serous cystadenocarcinoma 
mucinous cystadenocarcinoma 
endometrioid carcinoma 
undifferentiated cystadenocarcinoma 
ovarian tumor, primary location not ovary (#) 
Total
Borderline
serous cystadenoma 
mucinous cystadenoma 
serous/mucinous cystadenoma 
Total
11
8
4
2
3
28
2
9
1
12
Benign
serous cystadenoma 
mucinous cystadenoma 
benign cystic teratoma 
functional cyst 
cystic endometriosis 
Total
16
22
9
11
12
70
n: number o f tumors in each group 
(#) excluded from statistical analysis
Table 1: Histopathological diagnosis o f  110 patients with ovarian tumor
Significantly higher median concentrations (21.7 |ig/L versus 3.7 |ig/L; p<0.01) of uPA were 
found in cyst fluid from malignant compared with benign tumors, and from borderline 
compared with benign tumors (13.9 |ig/L versus 3.7 |ig/L; p<0.05). The highest uPA 
concentration in the borderline subgroup (n=12) was observed in the only tumor with micro­
invasive growth (143 |ig/L).
The median tPA cyst fluid concentrations of malignant and borderline tumors (11.9 |ig/L, 7.9 
|ig/L, respectively) were not significantly different from that of the benign tumors (7.3 |ig/L). 
The median cyst fluid PAI-1 concentrations of malignant tumors (246 |ig/L) and borderline 
tumors (57.1 |ig/L) were significantly higher as compared to the median of the benign tumors 
(37.0 |ig/L; p<0.0001 and p<0.01, respectively).
The median PAI-2 cyst fluid concentrations were 12.2 |ig/L, 11.5 |ig/L, and 3.5 |ig/L, in 
malignant, borderline, and benign tumors, respectively and did not differ significantly. 
Significantly higher median cyst fluid concentrations of uPA:PAI-1 complex were found in 
malignant (6.6 |ig/L) and borderline (4.2 |ig/L) tumors as compared to the median 
concentrations of benign tumors (1.0 |ig/L; p<0.0001, and p<0.05, respectively). The median 
cyst fluid concentration of tPA:PAI-1 complex from malignant tumors (8.9 |ig/L) was 
significantly higher than the median concentrations detected in the borderline (0.7 |ig/L; 
p<0.005) and benign tumors (2.0 |ig/l; p<0.001).
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VI
Figure 1: Cyst fluid levels of uPA (A), tPA (B), PAI-1 (C), PAI-2 (D), and the complexes uPA:PAI-1 (E), 
tPA:PAI-1 (F) in patients with malignant (n=25), borderline (n=12), and benign (n=70) ovarian tumors. Values 
are given in median , 25th and 75th percentiles in ¡J.g/1.
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Table 2: Plasminogen activation system components in ovarian tumor cyst fluid (n=107) subdivided into histopthological subgroups
Histology (N)
CL 
^
* 
J
g 
p
 
) 
A PAI-1
(Mg/L)
PAI-2
(Mg/L)
uPA:PAI-1
(Pg/L)
tPA:PAI-1
(Pg/L)
Malignant (25) 21.7 10.1-43.0 11.9 4.9-34.9 246 105-480 12.2 4.9-25.0 6.6 4.5-16.1 8.9 2.3-27.4
Borderline (12) 13.9 7.8-37.7 7.9 0.7-57.6 57.1 26.9-132 11.5 3.9-18.9 4.2 0.9-6.3 0.7 0.3-3.5
Benign
total group (70) 3.7 0.6-19.7 7.3 2.6-26.0 37.0 9.2-149 3.5 1.3-34.9 1.0 0.9-4.3 2.0 0.3-10.3
serous cystadenoma (16) 2.4 0.6-10.6 26.8 14.9-36.3 20.0 5.5-52.8 2.1 1.3-5.8 0.9 0.9-4.0 4.6 0.3-13.4
mucinous
cystadenoma
(22) 4.0 0.6-10.4 0.8 0.4-3.2 29.4 10.2-64.8 3.4 1.5-8.4 1.1 0.9-3.9 0.3 0.3-2.4
benign cystic 
teratoma
(9) 1.1 0.7-3.3 5.3 0.6-7.5 6.7 1.0-30.5 1.3 1.3-101 1.0 0.7-4.7 1.8 0.3-4.1
functional cyst (11) 1.5 0.6-3.0 7.1 5.6-26.6 33.0 5.8-271 1.3 1.0-3.4 0.9 0.6-3.5 10.7 0.3-14.3
cystic endometrioma (12) 155 a 99-212 20.9 b 10.9-25.1 247 c 158-601 199 d 146-267 4.2 0.9-9.8 2.3 0.3-8.5
Footnotes
Values are given in median and 25th - 75th percentiles
Statistical significance according to Mann-Whitney U-test for cystic endometriosis compared with other benign subgroups 
a; p<0.0001, b; p<0.05, c; p<0.0001, d; p<0.0001.
94
Cystic endometriosis
As shown in table 2, one benign histopathologic subgroup (cystic endometriosis, n=12) 
demonstrated remarkably higher median concentrations of uPA, PAI-1 and PAI-2 than those 
found with the other benign subgroups. However, concentrations of the complexes tPA:PAI-1 
and to a lesser extend of uPA:PAI-1 were in the same range for all benign subclasses. Median 
uPA and PAI-2 concentrations in cystic endometriosis were more than seven and fifteen fold 
higher respectively, than those found in cyst fluid from malignant tumors. tPA and PAI-1 
concentrations were in the same range in these groups.
Malignancy index
Based on the different plasminogen activator system components a malignancy index was 
determined for the differentiation between cyst fluid from malignant and that from benign 
ovarian tumors. This malignancy index is represented by ([uPA:PAI-1 complex] + [tPA:PAI- 
1 complex]) x [PAI-1]). Figure 2 depicts a Receiver Operating Characteristic (ROC)-curve for 
this malignancy index, with an area under the curve (AUC) of 0.80. By incorporating our 
results in the malignancy indices proposed by Pujade-Lauraine et al. [19] for tissue samples 
([uPA] x [PAI-1]) / [tPA] and Casslén et al. [17] for peritoneal fluid (log [tPA] + log [PAI- 
1]), AUCs of 0.76 and 0.78, respectively were found. VI
Area Under Curve = 0.80
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0,8
0,7
0,6
>
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--------
J
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1-Specificity
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Figure 2: Receiver Operating Characteristic (ROC)- curve for malignancy index based on levels o f  
components o f the plasminogen activation system in cyst fluid from maligant (n=25) and benign 
(n=70) ovarian tumors. Malignancy index is represented by ([uPA:PAI-1] + [tPA:PAI-1]) x [PAI-1]. 
Area under the curve (AUC) =0.80.
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Clinicopathologic characteristics
Table 3 shows the median cyst fluid concentrations of the different plasminogen activator 
components, and the correlations with clinicopathologic characteristics as found in the 25 
patients with malignant tumors. Significantly higher concentrations were found in FIGO 
stages II, III, IV compared with stage I in the case of uPA (p<0.05), tPA (p<0.05), uPA:PAI-1 
complex (p<0.05), and tPA:PAI-1 complex (p<0.05). When only FIGO stage I patients were 
considered, recurrence (n=3) was associated with higher median PAI-1 (670 |ig/L) levels than 
those of patients without recurrence (n=11; 105 |ig/L) (data not shown). In the subgroup of 
patients with compared to those without ascites significantly higher median tPA (26.2 vs 6.9 
|ig/L, p<0.05) and tPA:PAI-1 concentrations (19.2 vs 4.3 |ig/L, p<0.05) were found. None of 
the plasminogen activator system components showed significant correlation with disease free 
survival.
DISCUSSION
In the current study we report on concentrations of different components of the plasminogen 
activation system in a large number of cyst fluid samples from malignant, borderline and 
benign ovarian tumors. For this study we used in-house ELISAs described by Grebenschikov 
et al. [24,25]. This assay format allows to measure uPA, tPA, PAI-1 and PAI-2 antigen levels 
as well as the complexes of uPA or tPA with PAI-1 (uPA:PAI-1 and tPA:PAI-1). The only 
two studies on ovarian cyst fluid reported so far are those by Saito et al. [16] and Casslén et 
al. [17] which both describe total uPA or tPA in cyst fluid aspirated from malignant and 
benign ovarian tumors.
The current study reports significant differences (especially for uPA, PAI-1, and 
uPA:PAI-1, and tPA:PAI-1) in median cyst fluid concentrations from malignant, borderline 
and benign ovarian tumors. We found significantly higher median uPA concentrations in cyst 
fluid from malignant and borderline, compared with benign tumors. These findings are in line 
with results found by Casslén et al. [17]. Other authors describe higher uPA levels in ovarian 
tumor tissue extracts in case of malignancy [16-20] and it was suggested that the epithelial 
surface of the tumor produces uPA, as was first demonstrated for ovarian cancer cells in 1976 
by Âstedt and Holmberg [26]. It could be argued that local synthesis of uPA in malignant 
epithelial cells results in higher uPA concentrations in the cyst fluid of the tumors.
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Table 3: Correlations between plasminogen activation system components in malignant ovarian tumor
cyst fluid (n=25) and clinicopathological characteristics
uPA tPA PAI-1 PAI-2 uPA:PAI-1 tPA:PAI-1
N  fcg/L) p  fcg/L) p  fcg/L) p  fcg/L) p  fcg/L) p  fcg/L) p
All patients (25) 21.6 11.9 246 12.2 6.6 8.9
FIGO Stage
I
II,III,IV
(14)
(11)
17.4
43.0
0.03
8.2
26.2
0.05
169
290
0.5
11.6
12.2
0.8
5.1
15.4
0.01
4.6
24.0
0.03
Grading
,3
(7)
(18)
9.5
22.0
0.2
10.0
22.0
0.3
187
286
0.5
9.8
12.8
0.7
4.7
8.0
0.3
4.9
12.4
0.2
Residual tumor
<2cm
>2cm
(20)
(5)
21.7
16.6
0.7
11.8
20.6
0.9
188
296
0.1
12.8
3.0
0.5
6.6
13.4
0.9
5.8
12.4
0.1
Ascites
No
Yes
(13)
(12)
18.3
33.2
0.1
6.9
26.2
0.04
189
286
0.7
13.4
9.0
0.5
5.4
13.4
0.1
4.3
19.2
0.02
Tumor recurrence
No
Yes
Disease free Survival
(16)
(9)
20.2
22.2
0.6
10.6
20.8
0.2
168
296
0.07
11.6
12.2
0.8
6.6
13.4
0.4
5.3
14.4
0.2
>13 months 
<13 months
(11)
(14)
18.9
22.0
0.5
9.6
16.3
1
246
220
0.6
9.8
18.4
0.9
6.5
8.0
0.6
4.9
10.7
0.4
Concentrations (pg/L) given as median values: N= number o f patients
tPA concentrations in cyst fluid from malignant and benign tumors were found to be in the 
same range. This is in line with findings by Casslén et al. [17] and supports earlier 
suggestions by Âstedt and Holmberg [26] that tPA is not released by malignant ovarian tissue. 
We found significantly higher PAI-1 concentrations in ovarian cyst fluid from malignant 
compared with benign or with borderline tumors. This is in line with several other studies 
reporting higher PAI-1 levels in malignant ovarian tissue compared with benign tissue [17­
19]. Casslén et al. reported higher PAI-1 concentrations in cyst fluid than in peripheral blood 
or ascitic fluid both in the case of malignant and benign tumors [17]. This suggests that cyst 
fluid PAI-1 level is not the result of diffusion from blood but that PAI-1 is locally 
synthesized.
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In the current study it was observed that the median PAI-2 concentrations in cyst fluid did not 
differ between malignant, borderline or benign tumors. These data seem to contradict with 
the results of Casslén et al. who found significantly higher PAI-2 concentrations in cyst fluid 
from malignant compared with benign tumors [17]. A possible explanation for this difference 
however, might be the inclusion of cystic endometriosis in the current study. This subgroup 
revealed 10- to 60- fold higher PAI-2 concentrations as compared with other benign tumor 
types. PAI-2 is supposed to originate from cells other than tumor cells, for instance activated 
macrophages [27]. High PAI-2 concentrations in cyst fluid from patients with cystic 
endometriosis might be explained by a continuous breakdown of components of blood and 
stromal tissue resulting in an increased number of macrophages in this type of cyst. 
Interestingly, when the subgroup cystic endometriosis was considered separately, the median 
PAI-2 cyst fluid concentrations were also significantly higher in malignant than in benign 
tumors.
Although there were no differences in tPA levels between the malignant and benign cyst 
group, the levels of the complex of tPA with its inhibitor PAI-1 (tPA:PAI-1) were clearly 
different between these groups, underscoring the value of assaying the levels of different 
components and complexes individually in addition to measuring total levels of tPA and PAI- 
1 immunoreactivity. The difference in uPA:PAI-1 complex levels between malignant and 
benign groups reflect the value of the individual components uPA and PAI-1 in these groups. 
Cystic endometriosis seems to be a special entity within the benign ovarian tumors. PAI-1 
concentrations in these tumors were in the same range as found in malignant tumors, whereas 
the median uPA concentration in cyst fluid from cystic endometriosis was more than seven 
fold, and that from PAI-2 more than fifteen fold higher than the ones found in cyst fluid from 
malignant tumors. Interestingly, in contrast to these components of the PA system, the 
concentrations of tPA:PAI-1 complexes were not elevated in cystic endometriosis. The 
neoplastic potential of cystic endometriosis is still unclear, but such a property has already 
been suggested [28,29]. The high cyst fluid concentrations of uPA and PAI-1 in this 
subgroup, when compared to those in the malignant group may indicate its invasive growth 
potential.
Various combinations of different markers have been presented as a malignancy index to 
achieve a better discrimination between malignant and benign cases, or to investigate the 
possibility of its prognostic significance [19,22]. Pujade-Lauraine -Lauraine et al. [19] 
introduced a plasminogen-activation dependent malignancy index ([uPA] x [PAI-1] / [tPA]) 
that distinguished benign and malignant tumors better than uPA alone. Casslén et al. [22] 
described another malignancy index (log [tPA] + log [PAI-1]) based on levels in peritoneal
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fluid. Since the levels of the complexes differed between malignant and benign groups we 
introduced another index including these markers: ([uPA:PAI-1] + [tPA:PAI-1]) x [PAI-1]. 
The clinical relevance of components of the PA system was studied in relation with several 
prognostic factors: FIGO stage, grading, residual tumor, presence of ascites, tumor 
recurrence, and disease free survival. We observed significantly higher concentrations of 
several of these markers in advanced FIGO stages II,III,IV as compared to stage I, indicating 
increased activity of the PA system in case of disease progression in malignant tumors. This 
contradicts with the results of Van der Burg et al. [20] who found no significant association 
between uPA or PAI-1 tissue expression and FIGO stage. These authors concluded that uPA 
and PAI-1 are apparently related with the malignant progression, but that these components 
may be less important once metastases have formed [20]. Results regarding prediction of 
survival are conflicting. Kuhn et al. [18] found in a series of 45 FIGO stage III patients that 
high levels of uPA and PAI-1 measured in triton extracts of the tumors predict poor survival 
after radical surgery and platinum-based chemotherapy. This could not be confirmed in a 
series of 44 FIGO stage III patients examined by Van der Burg et al. [20]. These authors 
concluded that the predictive power for survival of uPA and PAI-1 in ovarian cancer may be 
present only in patients without residual tumor, or in patients not treated with chemotherapy 
[20].
A possible explanation for the differences of results between our study and the one performed 
by Van der Burg might be due to tissue sampling bias. We determined the markers in cyst 
fluid whereas Van der Burg report on tumor tissue extracts. Besides this, we agree with Van 
der Burg et al. that actions of the secreted proteins may differ from their cell-bound effects. 
Although the number of patients was limited, the median PAI-1 concentration was higher in 
stage I with recurrent disease than without. Furthermore, the highest cyst fluid uPA 
concentration was found in the specimen from the only borderline malignancy in which 
micro-invasive growth occurred. Micro-invasive growth has been described as a worse 
prognostic factor [30]. These findings suggest a possible role for the detection of high-risk 
low stage malignant or borderline patients, but have to be analyzed further.
We conclude that the plasminogen activation system markers in ovarian tumor cyst fluid may 
be of potential use in the differentiation between histopathologic subgroups. The most 
significant components of the system are uPA, PAI-1 and the complexes uPA:PAI-1 and 
tPA:PAI-1. The prognostic significance of the factors seems limited, but might be important 
in detecting high risk borderline or low stage patients. Determination of the complexes 
uPA:PAI-1 and tPA:PAI-1 as a separate marker has additive value for the differentiation 
between histologic groups, but does not contribute to determine prognosis.
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ABSTRACT
In many tumor types, the level of angiogenesis is correlated with the degree of malignancy of 
the tumor. As a consequence, tumor vascular density constitutes in many tumor types an 
important prognostic tool. Determining the levels of relevant (anti-) angiogenic factors in the 
circulation, or in tumor-associated fluids, may provide a reflection of the overall angiogenic 
activity of a tumor. To test this hypothesis, and to shed more light on the process of tumor 
angiogenesis in human ovarian carcinoma, we assessed the levels of plasminogen and 
angiostatin in cyst fluid derived from epithelial ovarian tumors. We tested samples from 
ovarian carcinoma (n=26), borderline tumors (n=10) and benign ovarian tumors (n=35). Fluid 
samples from functional ovarian follicles (n=10) were taken along for reference. Levels of 
VEGF and components of the plasminogen activator system (uPA and tPA) were previously 
assessed in the same cyst fluid samples by specific ELISA. The presence of plasminogen and 
of the anti-angiogenic compound angiostatin, a proteolytically generated fragment of 
plasminogen, was determined semi-quantitatively by Western blot analysis.
As described previously, a strong correlation was found between the degree of 
malignancy of the ovarian tumor, and cyst fluid VEGF levels. In the present study we found 
no correlation between VEGF and plasminogen activator levels, or VEGF and angiostatin 
levels. A clear correlation, however, was observed between plasminogen activator levels, and 
the presence of angiostatin. Angiostatin was present in every cyst fluid containing 
plasminogen, and with plasminogen activator levels exceeding 40 ng/ml. Conversely, 
however, angiostatin was also found in cyst fluid samples without detectable plasminogen 
activators, indicating that other proteases are involved in in vivo angiostatin generation as 
well.
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INTRODUCTION
Solid tumors are dependent on angiogenesis (the formation of new blood vessels) for their 
sustained growth, and for the formation of metastases [1,2]. Angiogenesis is considered to be 
the result of a net balance between the actions of pro- and anti-angiogenic factors [3-5]. Pro- 
angiogenic factors include growth factors such as vascular endothelial growth factor (VEGF), 
basic fibroblast growth factor (bFGF), interleukin-8 (IL-8), and platelet-derived growth factor 
(PDGF) [6,7], proteases (plasminogen activators and matrix metalloproteneases or MMPs) 
[8;9], integrin adhesion molecules (avß3, avß5) [10,11], and extracellular matrix components 
(collagens, laminins, proteoglycans). The discovery of angiostatin, a proteolytic fragment of 
plasminogen [12], and endostatin, a proteolytic fragment of collagen XVIII [13] has prompted 
studies on anti-angiogenic factors. Both angiostatin and endostatin have been shown to 
possess potent anti-angiogenic and, as a consequence, anti-tumor activity in several animal 
tumor models [14,15].
The vascular density of a tumor constitutes in many tumor types an important prognostic tool, 
with highly vascularized tumors having an impaired prognosis compared to less vascularized 
tumors [16,17]. The vascular density of a tumor in situ, however, is not easy to determine. 
Tumor biopsies provide only a very limited view of the often heterogeneous tumor 
vasculature [18], whereas the resolution of imaging techniques such as MRI is often 
insufficient. We hypothesized that assessing the levels of relevant (anti-) angiogenic factors in 
the blood or in other body fluids that are in close contact with the tumor, may provide 
information on the overall angiogenic behaviour of a tumor. Obviously, the choice of the 
(anti-) angiogenic factors that are monitored, and the body fluid(s) in which the measurements 
are performed, is of crucial importance. Several studies have reported on levels of (anti-) 
angiogenic factors in blood and other body fluids, and have related these findings to clinical 
parameters [19-23]. Little information, however, is available on possible interactions between 
levels of (anti-) angiogenic molecules in body fluids. This study presents our attempts to 
determine the effect of VEGF, plasminogen activators and angiostatin, on the angiogenic 
balance in cyst fluid derived from epithelial ovarian tumors. We theoretically assumed that 
the protein content of cyst fluid is a reflection of the overall expression profile of the 
surrounding tumor tissue. Measurement of specific proteins in cyst fluid may therefore 
represent the tumor as a whole, in contrast to techniques that only measure in a fraction of the 
tumor, that are sensitive to sampling bias because of variations induced by heterogeneous 
expression patterns throughout the tumor. Obviously, the contents of cyst fluids may also be
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influenced by exchange processes with blood or other body fluids, and the nature of the cyst- 
surrounding tissue, as malignant tissues tend to be more permeable than normal tissues. 
Finally, cyst fluid content is influenced by protein break down processes, and by the volume 
of the cyst fluid.
We chose to further analyze the expression of VEGF, urokinase and tissue-type-plasminogen 
activators (uPA and tPA), and angiostatin, since in vitro studies have demonstrated reciprocal 
effects of these factors on each other’s generation, and/or production levels (schematically 
summarized in figure 1). VEGF not only induces endothelial cell proliferation and vessel 
permeability [24,25], but also increases the production of plasminogen activators and their 
receptors by (tumoral) endothelial cells [26-28]. Both tPA and uPA are able to excise the 
angiostatin fragment from the plasminogen parent molecule in vitro [29,30]. Increased VEGF 
levels, therefore, may enhance plasminogen activator mediated angiostatin generation, 
thereby inducing a negative feedback loop on its pro-angiogenic activity.
We determined the levels of VEGF, plasminogen activators and angiostatin in cyst fluid 
samples from ovarian carcinoma, borderline and benign ovarian tumors, and from functional 
ovarian follicles. As described previously, VEGF [31] and uPA [32] levels in tumor cyst 
fluids were closely correlated with degree of malignancy of the tumor. Furthermore, our 
results demonstrate for the first time that plasminogen activators are involved in in vivo 
angiostatin formation. Future studies should include a correlation of levels of (anti-) 
angiogenic factors with tumor vascular densities, and with patient survival.
MATERIALS AND METHODS
Patients
Sixty-one patients with an epithelial ovarian tumor that were planned for surgical treatment 
were included in the cyst fluid collection procedure. After surgical removal, the tumor was 
immediately transported to the pathology laboratory where aseptic fine needle aspiration was 
performed to collect the cyst fluid samples. Subsequently, the cooled fluid sample was 
centrifuged at 3000x g for 10 minutes. The supernatant was collected and stored at -35 oC 
until further analyses. Histopathological evaluation was performed by an experienced 
gynecologic pathologist, and clinicopathologic characteristics were retrieved from the medical
108
records of the patients. For comparison we used fluid collected routinely from functional cysts 
during an IVF procedure from 10 patients.
Figure 1: Schematic overview o f (possible interactions between) angiogenic and anti-angiogenic 
factors in ovarian tumors. Tumor derived VEGF induces vessel proliferation (a) and increases vessel 
permeability (b). As a consequence, plasma protein levels (including plasminogen) in the tumor tissue 
are elevated, resulting in increased concentrations in the cyst fluid. VEGF also augments the 
production o f plasminogen activators (c), which will accumulate in the cyst fluid. The increase in 
plasminogen activator and plasminogen levels in the cyst fluid may lead to increased angiostatin 
formation (d).
ELISAs for VEGF and plasminogen activator components
Determination of uPA, tPA and VEGF concentration was performed by specific double 
determinant ELISAs as described previously [33,34].
Purification ofplasminogen and angiostatin from cyst samples.
50 pl of lysine-sepharose slurry prepared according to the manufacturer’s instructions 
(Pharmacia, Upsala, Sweden) was added to 200 pl of cyst fluid, and incubated overnight on a 
roller bank at 4 °C. Lysine-sepharose was washed twice with phosphate buffered saline, and 
bound material was eluted with 100 pl 0.2M s-amino-capronic acid.
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Western blot for plasminogen and angiostatin
SDS-PAGE and Western blot were performed essentially as described elsewhere [30]. 
Briefly, samples of 15 pl purified plasminogen/angiostatin plus 15 pl sample buffer were run 
on a 10% polyacrylamide gel. After electrophoresis, samples were electroblotted onto 
nitrocellulose membrane (Schleier & Schuell, Dassel, Germany). Blots were blocked for 60 
minutes in blocking solution (PBS / 0.05% Tween-20 / 2% block (Roche)), followed by 
overnight incubation with polyclonal rabbit-anti-human antibody, affinity purified against 
plasminogen kringle domains 1-3, diluted in blocking solution. After washing, blots were 
incubated for two hours with peroxidase-conjugated swine-anti-rabbit secondary antibody 
(Dako, Glostrup, Denmark). After washing, blots were developed by chemiluminescence 
according to the manufacturer’s protocol (Roche). Plasminogen content was assessed semi- 
quantitatively by visually scoring the intensity of the resulting bands as high, moderate, or 
low. Angiostatin content was assessed relative to plasminogen content by visually scoring the 
intensity of angiostatin bands as higher, equal or lower as the plasminogen band in the same 
lane.
RESULTS
VEGF and plasminogen in ovarian tumor cyst flu id  samples
We determined VEGF levels in cyst fluid derived from malignant, borderline and benign 
ovarian tumors by specific ELISA (figure 2). As reported previously [31], a clear correlation 
was observed between VEGF levels and histologic subtype of the tumor. Highest VEGF 
levels were found in ovarian carcinoma cyst fluid samples. Intermediate VEGF levels were 
observed in samples derived from borderline tumors and mucinous cystadenomas, whereas 
the lowest levels of VEGF -  comparable with those found in functional cyst fluid -  were 
found in serous cystadenomas. Interestingly, cyst fluid samples with absent or low VEGF 
levels were present in all tumor types, including borderline tumors and carcinomas. No 
correlation was observed between VEGF levels and FIGO stage or histologic grade of the 
tumors (data not shown).
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Figure 2: VEGF levels in cyst fluid derived from different types o f ovarian tumors, as determined by 
specific ELISA. Note increase in mean VEGF level with increasing malignancy. Benign (m): mucinous 
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VEGF induces an increase in vessel permeability. In theory, this may lead to increased levels 
of plasma proteins, including the angiostatin parent molecule plasminogen, in cyst fluids. To 
test this, cyst fluid plasminogen levels were assessed semi-quantitatively by Western blot 
analysis (examples are shown in figure 5), and scored as absent, minimal, moderate or high. 
In all tumor types more than half of the cyst fluid samples showed moderate or high amounts 
of plasminogen (figure 3). No obvious correlations between tumor type and plasminogen
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levels were observed. When the relative amount of plasminogen was plotted against VEGF 
levels a trend towards more VEGF in cyst fluid samples containing high amounts of 
plasminogen was observed (figure 4). The four different classes of plasminogen content, 
however, did not differ significantly from each other with regard to mean or median VEGF 
level. When plasminogen content was plotted against VEGF level for each tumor type 
separately, again no correlation between these two parameters could be established. 
Interestingly, the majority (70%) of cyst fluid samples with a high plasminogen content 
contained no or only very low amounts of VEGF.
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Figure 4. Relative plasminogen levels versus VEGF concentration in ovarian tumor cyst fluid.
Note tendency to increased VEGF levels in cyst fluids containing high plasminogen levels. Mean 
VEGF levels, however, did not differ statistically between groups o f cyst fluids with different 
plasminogen content.
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113
Plasminogen activators and VEGF in ovarian tumor cyst fluid samples 
uPA and tPA were measured by specific ELISA in ovarian tumor cyst fluid. Results were 
recently published [32]. Briefly, significant differences were found in median cyst fluid 
concentrations of uPA but not tPA from malignant, borderline, and benign ovarian tumors, 
with the highest levels in malignant ovarian tumors, lower levels in borderline tumors, and the 
lowest levels in benign tumors (data not shown).
VEGF treatment has been shown to induce an increase in in vitro plasminogen activator 
expression in several tumor cell lines. The effect of VEGF expression on plasminogen 
activator expression in vivo has, to our knowledge, not been reported. We analyzed the 
correlation between VEGF levels and tPA and uPA levels, in ovarian tumor cyst fluid 
samples. A very weak correlation (r2=0.19) was observed between VEGF and uPA levels 
when all samples were analyzed together, whereas no correlation was found between VEGF 
and tPA. When relating VEGF levels to plasminogen activator levels for each histologic 
tumor subtype separately, no additional or better correlations were found (data not shown).
Angiostatin in ovarian tumor cyst fluid samples
We employed a previously described Western blot technique to detect plasminogen and 
angiostatin in cyst fluid samples. This Western blot uses a polyclonal rabbit-anti human 
plasminogen antibody, which has been affinity purified against the first three globular kringle 
domains of plasminogen. Angiostatin consists of the first three or four kringle domains of 
plasminogen. Consequently, both the parent plasminogen molecule as well as the 3- and 4- 
kringle form of angiostatin were detected in this assay, at 92, 38 and 50 kDa, respectively. In 
figure 5 the results of 24 samples (selected at random from our panel of cyst fluid samples) 
are depicted. Whereas in some samples neither plasminogen nor angiostatin was present 
(samples 7, 9, 12 and 42), others contained large amounts of both proteins (e.g. samples 3, 4, 
10 and 11). Some samples contained plasminogen but no (samples 38, 43) or only very low 
amounts (samples 37, 40) of angiostatin. Alternatively, angiostatin containing samples with 
no plasminogen present were never observed. The 50 kDa angiostatin species was most 
abundant, whereas only low amounts of the 38 kDa species were detectable, and in relatively 
few samples (samples 5, 45, 47). The 50 kDa angiostatin species most often presented itself as 
a doublet, with molecular weights differing about 4 kDa. Whether these bands represent 
different glycosylation forms of the same proteolytic fragment, or proteolytic fragments of 
different sizes, is unknown. Interestingly, high molecular weight (>100 kDa) molecules were 
frequently observed in angiostatin containing cyst fluid samples.
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Angiostatin in relation to tumor subtype, VEGF and plasminogen activators.
First, we investigated the possible correlation between the presence of angiostatin and the 
histologic tumor subtype. As the presence of angiostatin is dependent on the presence of its 
parent molecule plasminogen, we determined the angiostatin content of a sample semi- 
quantitatively not solely based on the intensity of the angiostatin band(s) in the Western blot, 
but rather in comparison to the intensity of the plasminogen band in the same sample. Thus, 
we divided our samples in four categories; 1) neither plasminogen nor angiostatin present, 2) 
more angiostatin than plasminogen present, 3) approximately equal amounts of both proteins 
present, and 4) more plasminogen than angiostatin present (figure 6). The proportion of 
angiostatin containing samples was roughly equal in each cyst fluid group (ranging from 70 to 
95% angiostatin-positive samples). However, a tendency to a higher relative angiostatin 
content was observed in samples derived from ovarian carcinoma, borderline tumors and 
serous cystadenomas (angiostatin content higher than, or equal to, plasminogen content in 60­
70% of the samples, and plasminogen exceeding angiostatin levels in 10-30% of the samples), 
compared to the angiostatin content in fluids from mucinous cystadenomas and functional 
cysts (angiostatin higher than, or equal to, plasminogen in 20-30% of the samples, and 
plasminogen exceeding angiostatin levels in about 50% of the samples).
Several studies have described plasminogen activators to be involved in the conversion of 
plasminogen to angiostatin in vitro. As VEGF increases plasminogen activator expression in 
vitro, VEGF may indirectly increase angiostatin generation. Additionally, VEGF-induced 
elevation in blood vessel permeability may lead to an increase in the extravasation to, and 
accumulation of circulating angiostatin in, ovarian tumor cyst fluid. For this reason, we 
investigated the relation between VEGF levels and angiostatin levels in cyst fluids (figure 7). 
No significant differences were observed between VEGF levels in samples containing 
no/minimal amounts of angiostatin, and in samples with moderate/high amounts of 
angiostatin.
Finally, we investigated the correlation between absence/presence of angiostatin, and 
plasminogen activators levels in ovarian tumor cyst fluid samples (figure 8). Our data show 
that angiostatin was present in all samples with an uPA or tPA level exceeding 40 ng/ml 
(figure 8a and b). Numerous angiostatin-positive/plasminogen activator-negative samples, 
however, were observed as well. Therefore, mean uPA /tPA levels were not significantly 
different in samples with and without angiostatin (p=0.065 in both cases). When uPA and tPA 
levels were combined, however, a significant difference in total plasminogen activator level
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was observed between angiostatin-positive and -negative samples (figure 8c, p<0.002). When 
analyzing angiostatin content versus plasminogen activator level in cyst fluids from each 
histological tumor subgroup separately, no additional or more pronounced differences were 
observed (data not shown).
Figure 6. Angiostatin (ang) levels expressed relatively to plasminogen (plg) levels in ovarian tumor 
cyst fluid samples. Note higher relative angiostatin content in cyst fluid samples derived from  
carcinoma, borderline and serous cystadenomas as compared to mucinous cystadenomas and 
functional cysts.
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Figure 7. VEGF content o f  ovarian tumor cyst fluid samples with angiostatin present or no/minimal 
angiostatin present. Although there appears to be a tendency to increased VEGF levels in angiostatin 
containing ovarian carcinoma cyst fluid samples, mean VEGF levels were not statistically different in 
the two groups.
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DISCUSSION
Tumor angiogenesis is a prerequisite for tumor growth and metastasis formation. As a 
consequence, tumor vascular density is in many tumor types an important prognostic 
parameter. In vitro studies have identified and analyzed a large number of pro- and anti- 
angiogenic molecules, but the interplay between these factors, and, therefore, the regulation of 
(tumor) angiogenesis in vivo, is at present largely unknown. Several studies have reported a 
correlation between the presence of a certain anti-angiogenic factor in the circulation or in 
other body fluids, and prognosis, histological subtype of the tumor, or other biological 
parameters. Attempts to assess and correlate several factors together, however, have been 
scarce. Designing this type of studies highly depends on the choice of the combination of 
(anti-) angiogenic factors that can or should be determined, as well as the type of body fluid in 
which these analytes should be measured.
In this study we have investigated the possible relationships between levels of uPA, 
tPA, VEGF, plasminogen and angiostatin in ovarian tumor cyst fluid samples, and their 
relation to the histological subtype of the tumor. We have chosen ovarian tumor cyst fluid, as 
this fluid is constantly in close contact with the tumor. As a result, its contents may provide a 
good reflection of the protein expression pattern of a tumor. The choice of the (anti-) 
angiogenic mediators that we measured was inspired by findings reported in literature, that 
have described a stimulating effect of VEGF on tumoral plasminogen activator production, 
and involvement of plasminogen activators in the in vitro conversion of plasminogen to 
angiostatin. Furthermore, the permeability-inducing effect of VEGF on blood vessels could 
theoretically lead to increased levels of plasma proteins such as the angiostatin parent 
molecule plasminogen in the extravascular compartment, possibly followed by accumulation 
in the tumor cyst fluid.
Previous studies by our group have reported a correlation between VEGF [31], uPA [32] or 
gluthathione S-transferase P1-1 [35] levels on one hand, and the histological subtype of the 
tumor on the other. In the current study, however, we did not find a number of other 
correlations that could theoretically be expected. We found no correlation between VEGF and 
plasminogen levels. Although we did observe a tendency of higher plasminogen levels with 
increasing VEGF levels, numerous cyst fluid samples with a high plasminogen content 
contained no or only very low amounts of VEGF, indicating that plasminogen content is not 
solely dependent on VEGF levels. The nature of our substrate, tumor cyst fluid, may partly 
explain our data. We do not know whether our assumption is correct as to whether this fluid
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represents an accurate reflection of the protein expression level of the tumor. A high level of a 
certain angiogenic factor in ovarian tumor cyst fluid may reflect a moderate production level 
of this factor by the (majority of) the tumor cells, a very high production by a restricted 
number of tumor cells (representing an “angiogenic hot spot”) or, finally, an accumulation 
over time of a low production level. In addition, the protein content of a cyst also depends on 
reciprocal exchange processes with other body fluids such as blood and ascites, and on the 
nature of the surrounding tissue, as malignant tissues may be relatively permeable. Finally, we 
have only analyzed three of the possibly dozens of molecules that may ultimately determine 
the position of the angiogenic balance. Support for our hypothesis that measuring 
combinations of (anti-) angiogenic factors will ultimately lead to the development of better 
prognostic markers, however, was provided recently by Volm et al., [36], who showed that in 
a group of non-small cell lung cancer patients, patients with a VEGF-positive/angiostatin 
negative (pro-angiogenic) tumor displayed a worse prognosis compared to patients who 
presented with a VEGF-negative/angiostatin-positive (anti-angiogenic) tumor.
We did observe a clear correlation between the presence of angiostatin in the cyst fluid 
samples, and the presence of uPA and tPA. When one of these molecules was present at a 
level of 40 ng/ml or higher, this was always accompanied by the presence of angiostatin. 
Conversely, many angiostatin containing samples were uPA and tPA negative, indicating that 
other proteolytic enzymes are probably involved in angiostatin generation as well. In fact, a 
number of enzymes (elastase, MMPs, PSA, etc.) [37-39] have been described to be able to 
excise angiostatin from plasminogen in vitro. Our data are in accordance with a previous 
report in which we analyzed the angiostatin generating capacity of a large number of tumor 
cell lines [30]. In this study we found a strong correlation between uPA and tPA production 
and angiostatin generation, but we also observed angiostatin generation by a number of 
uPA/tPA negative cell lines. The data we present in this study provide for the first time 
evidence for the involvement of plasminogen activators in angiostatin formation in humans, 
in vivo.
It is not clear whether factors that are present in the cyst fluids are able to diffuse back into the 
tumor, and exert an effect on the tumor vasculature. An interesting option to study this would 
be to determine the vascular density of the tumors from which the cyst fluids that were used 
in this study were derived. Linking these data with (anti-) angiogenic factor levels, combined 
with patient follow-up data may eventually provide insight in the factors constituting the
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“angiogenic balance” in ovarian tumors, and which (combination of) factors should be 
measured to provide prognostically relevant information.
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GENERAL INTRODUCTION 1H-NUCLEAR MAGNETIC RESONANCE 
SPECTROSCOPY ON BODY FLUIDS
Analyses of body fluids provides information that reflects the biochemical status of a living 
organism [Nicholson et al., Bell et al., Lindon et al., Wevers et al.]. One of the methods used 
in biofluid analysis is 1H-Nuclear Magnetic Resonance (HNMR) spectroscopy, a technique 
that can detect different metabolites simultaneously.
The first description of the NMR phenomenon appeared in 1946 [Purcell, Bloch]. After the 
introduction of superconductive magnets (1965), the interest in NMR spectroscopy became 
more important. Its principle is based on the so called “quantum-characteristics” of 
elementary parts (protons, neutrons, electrons). One of these characteristics is called “spin”. 
This is the circle-movement of the elementary parts round their axis. Due to their nuclear 
spin, elementary parts have a magnetic moment. NMR spectroscopy is based on the fact that 
in an external magnetic field nuclei can undergo certain quantum changes. NMR spectroscopy 
can therefore, only be performed by using extremely strong homogeneous magnetic fields, for 
instance by using superconductive electromagnets. With NMR spectroscopy it is possible to 
examine a distribution of chemical species in a spatially homogenous sample. The most used 
nuclei in oncological NMR spectroscopy are 1H and 31P. 31P-NMR spectroscopy is mainly 
used for the determination of energy and lipid metabolism. 1H-NMR spectroscopy is able to 
detect different components like amino-acids, lactic acid, citric acid, creatinine, choline. The 
number and position of protons result in a specific “fingerprint” of a compound in the 1H- 
NMR spectrum.
Body fluid 1H-NMR spectroscopy provides an quantitative overview of the most 
important proton containing low molecular weight metabolites. Most of the 1H-NMR 
spectroscopy studies performed in the past have been “analytical” and focussed on the 
determination of metabolite concentrations in fluids or the detection of new metabolites 
[Nicholson]. Other studies were more dynamic in nature, for example with the purpose to 
study different inborn errors of metabolism [Moolenaar, Wevers]. Until now 1H-NMR 
spectroscopy has been used to determine metabolites, drugs and toxic agents in several 
different body fluids. The majority of samples studied in the past involved serum/plasma 
samples, but other studies focused on cerebrospinal fluid (CSF), urine, amniotic fluid, bile 
[Wevers, Lindon, Bell, Nicholson, Moolenaar].
Benefits of this technique are that it is potentially non-destructive to the samples and that it 
requires little sample pre-treatment. High concentrations of proteins and lipids result in peak 
overlap and chemical noise that can obscure the signals from other low molecular weight
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metabolites [Bell, Lindon, Nicholson, Wevers]. Based on the experiments with serum/plasma, 
urine and CSF databases containing the resonances of more than two hundred metabolites 
could be developed [Wevers, Nicholson, Lindon]. The position of metabolites in the spectra 
could be confirmed by using control samples that only contained one specific metabolite and 
by other techniques like 2D-COSY NMR [Wevers]. With 1H-NMR Spectroscopy on body 
fluids a number of unknown resonances will be experienced, that in some cases can be related 
to medication or dietary factors. They might also originate from normal metabolic pathways. 
All body fluids have their own specific physicochemical characteristics and thus 1H-NMR 
spectroscopy provides the opportunity to play an important role in further exploring the field 
of metabolic analyses of body fluids in analytical as well as more dynamic oriented studies.
Massuger et al. were the first to describe the results of 1H-NMR spectroscopy on cyst 
fluid aspirated from benign and malignant ovarian tumors. In that study a first attempt was 
made to demonstrate significant differences in metabolite concentration between malignant 
and benign ovarian cysts, and it was concluded that larger studies are promising and needed to 
explore in further detail the role of 1H-NMR spectroscopy in ovarian cyst fluid [Massuger].
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ABSTRACT
Background: Most ovarian tumors are cystic structures containing variable amounts of fluid. 
Several studies of ovarian cyst fluid focus on one specific metabolite using conventional 
assay systems. We examined the potential of 1H-Nuclear Magnetic Resonance spectroscopy 
in evaluation of the overall metabolic composition of cyst fluid from different ovarian tumors. 
Methods: Ovarian cyst fluid samples obtained from 40 patients with a primary ovarian tumor 
were examined. After deproteinization and pD standardization, we performed 1H-NMR 
spectroscopy on a 600 MHz instrument. With 1H-NMR spectroscopy we found detectable 
concentrations of 36 metabolites with high intersample variation.
Results:  A number of unassigned resonances as well as not expected metabolites were found. 
We introduce an overall inventory of the low molecular weight metabolites in ovarian cyst 
fluid with corresponding resonances. Significant differences in concentration (p<0.01) were 
found for several metabolites (including an unknown metabolite) between malignant and 
benign ovarian cysts. Furthermore, higher concentrations in malignant- and lower in benign 
fluids were found compared to normal serum values, indicating local cyst wall metabolic 
processes in case of malignant transformation.
Conclusions: We conclude that 1H-nuclear magnetic resonance spectroscopy can give an 
overview of low-molecular weight proton-containing metabolites present in ovarian cyst fluid 
samples. The metabolic composition of cyst fluid differs significantly between benign and 
malignant ovarian tumors. Furthermore, differences between benign subgroups possibly 
related to histopathological behavior can be detected. The presence of N-acetyl aspartic acid 
and 5-oxoproline exclusively in serous cystadenoma samples is remarkable. Future studies 
will concentrate on these findings and explore the possibilities of extrapolating information 
from the in vitro studies to in vivo practice in which metabolic differences between malignant 
and benign subtypes can be of great importance in a pre-operative phase.
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INTRODUCTION
Neoplastic ovarian pathology, benign as well as malignant transformation, consists of many 
types and subtypes. The most common tumors are of epithelial origin. Malignant epithelial 
ovarian tumors are the fourth most common malignancy in women, and the number one lethal 
gynecologic malignancy (1). The group of benign ovarian tumors is a diverse group of 
tumors. The most common histologic types are serous and mucinous cystadenomas (1,2). In 
most ovarian neoplasma cyst formation is present. Cysts consist of variable amounts of fluid 
(2). In clinical practice the preoperative discrimination between malignant and benign ovarian 
tumors is important, and several techniques have been described for this purpose. 
Visualization of ovarian tumors is possible with ultrasonography but prediction of malignancy 
is not accurate (3). Other tools, such as CT examination and MR imaging, can also not 
differentiate accurately between benign and malignant tumors (4,5). Studies on the metabolic 
composition of cyst fluid for this discrimination mostly focus on one metabolite or one group 
of metabolites by using conventional assay systems. The presence of tumor markers (CA-125, 
CA 15.9, CEA, CASA, CA 72-4) and their role in the differential diagnosis of ovarian tumors 
has been studied extensively. There is compelling evidence that cyst fluid tumor marker levels 
cannot distinguish adequately between the different histologic types (6,7). Other metabolites 
that have been described are steroid hormones (8), Neopterin (9), and mitogens like Insulin­
like growth factors (10). Levels of these metabolites can be higher in malignant cyst fluids, 
but are not sensitive enough as pre-operative marker. Furthermore, determination of these 
markers in a pre-operative phase requires cyst puncture, which involves the risks of an 
invasive interference as well as the spread of malignant cells. We, as well as others, have 
demonstrated that in vitro *H-NMR spectroscopy on plasma, cerebrospinal fluid (CSF), urine, 
and amniotic fluid can provide valuable biochemical information on the composition of low 
molecular mass metabolites (11-14). A pilot study with in vitro proton NMR spectroscopy 
performed by Massuger et al, the first of this kind on ovarian cyst fluid samples, described 
significant differences in metabolic composition of cyst fluid from benign and malignant 
ovarian cysts (11).
The aim of the current study was to provide a full inventarization of NMR spectra from cyst 
fluid samples of ovarian subtypes based on a careful morphological cyst subclassification. 
The paper provides the basis for further pathophysiological and diagnostic studies on ovarian 
cysts.
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EXPERIMENTAL
Cyst fluid samples
A total of 40 cyst fluid samples were obtained by aseptic fine needle aspiration during 
laparoscopic operation, or ex vivo by aseptic aspiration of cysts from the removed cystic 
ovaries. A sample volume between 10-40 ml could be obtained. Within 30-60 minutes after 
cooled transport, all samples were centrifuged at 3000 G for 5 minutes for cell separation and 
immediately stored at -35oC. Sample processing involved deproteinization, freeze drying and 
redissolution in D2O adjusted to pD 2.5+ 0.10, and was performed essentially as described 
before (12,13). A limitation of this procedure is the loss of volatile components (e.g. ethanol, 
acetone). As some compunds, like methylmalonic acid and hippuric acid, contain exchangable 
protons their resonances in D2O may differ from those in H2O, but both compounds still have 
a characteristic signal in the spectrum. The deproteinization procedure involved centrifugation 
of the cyst fluid samples (3000 g for 2 hours) over a filter (Microsep no. OD010C45, 
membrane type omega, with a molecular mass cut-off of 10 kDa; Filtron, Northborough,
MA). Before use, the filters were cleaned by passing 6 mL of 0.05 mol/l NaOH and 6 ml of 
distilled water. The cleaning procedure was performed to remove the glycerol.
As a result of this procedure, resonances of a number of amino acids (isoleucine, leucine, 
lysine and valine) were resolved more clearly and the broad protein resonances were absent in 
the ultrafiltrate (11).
An experienced independent gynecologic pathologist performed the histolopathological 
classification of the cysts. This resulted in 12 malignant and 28 benign tumors. The benign 
subgroups endometrioma (n=3), and benign cystic teratoma (dermoid) (n=2) were not taken 
into the statistical result analysis, due to the small number of samples.
1H-NMR measurements
Single pulse 1H-NMR spectra (600 MHz) were obtained on a Bruker AMX-600 (Bruker 
Analytische Messtechnik, Karlsruhe, Germany) spectrometer at 298 K. A 600 radio 
frequency pulse (6 ps) and a 12 s repetition time were used. For each spectrum 128 scans 
were recorded, and 32K data points per scan were sampled. The sweep width was 6667 Hz. 
The residual H2O resonance was presaturated during the relaxation delay (12 s). Sample 
volume in the spectrometer was standardized at 500 pL. For evaluation of the NMR spectrum 
we used one dimensional WINNMR software (version 960901), and AMIX software (version 
2.0), (Bruker, Analytische Messtechnik, Germany). The free induction decays (FIDs) were 
zero filled to 65 536 datapoints, which provided sufficient data points for each resonance.
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Subsequently, the spectra were Fourier transformed. Chemical shifts were calibrated with 
respect to the chemical shift position of the trimethylsilyl 2,2,3,3-tetradeuteropropionic acid 
(TSP) resonance. The line widt of all resonances was about 1.0 Hz. Phase and baseline were 
corrected manually, and resonances were fitted to a Lorentzian lineshape model function in 
the frequency domain. The concentrations of the metabolites were calculated by comparing 
the metabolic fit integrals with the fit integral of TSP, corrected for the number of protons 
corresponding to the resonances.
1H-1H  correlation spectroscopy (COSY)
COSY spectra (16) were recorded at 500 MHz for confirmation of assignments in the cyst 
fluid samples. In F2, 4K datapoints were used, and the spectral width was 6002 Hz. The 
number of increments was 256, and 16 FIDs per increment were used. The water resonance 
was presaturated during the relaxation delay of 1.8 s. Prior to Fourier transformation a sine 
function was applied in both time domains.
Quantification
For quantification, the integrals of the fits derived from the metabolites were compared with 
those of TSP. For the interpretation of the chemical shifts, we used the experience from 
earlier studies on serum, cerebrospinal fluid, and urine samples and experiments with model 
compounds. Nicholson et al, described low molecular weight peak overlap (“spectral 
crowding”), resulting in quantification problems for different body fluids (14). This 
phenomenon was also visible in the ovarian cyst fluids. Metabolites that were difficult to 
quantitate in the ovarian cyst fluid samples due to spectral crowding were leucine and glycine. 
Consequently, no quantitative data are given for these compounds in this study. The 
isoleucine concentration was calculated using the 1.02 ppm doublet resonance. For glucose 
quantification we used the 5.22 ppm doublet resonance caused by the aC1 proton. Glucose 
occurs in a  and ß isoforms in a 36:64 ratio (17). This equilibrium is pH dependent and thus 
can differ from this theoretically described ratio. With the described methods in this study we 
found a:ß-ratio of 39:61.
Statistical Analysis
For statistical analysis, we used the Mann-Whitney U- test for comparison of two groups in 
independent samples. Probability values of <1% were regarded as significant results (p<0.01).
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RESULTS
Assignments 1H-NMR spectra
Histopathologic characteristics are presented in Table 1. A total of 12 malignant and 28 
benign ovarian cysts were included. Figure 1 shows a representative spectrum of one of the 
malignant ovarian cyst fluids (serous cystadenocarcinoma). In the overall view of the 
spectrum, high intensities are visible of isoleucine, leucine, valine, 3-hydroxy-butyric acid, 
threonine, lactic acid, alanine, methionine, glutamine, and glucose. More details of the 
spectrum are shown in the lower part of figure 1.
Table 1: Histopathological diagnosis of 40 patients 
with a cystic primary tumor of the ovary.
Malignant Cysts n=12
Serous cystadenocarcinoma n=7
Mucinous cystadenocarcinoma n=1
Granulosa thecacell tumor n=1
Endometrioid cystadenocarcinoma n=2
Clear cell adenocarcinoma n=1
Benign Cvsts n=23
Mucinous cystadenoma n=7
Serous cystadenoma n=11
Pre-ovulatory follicle n=5
Endometrioma n=3
n=2
Benign cystic teratoma (dermoid)
Thirty-six compounds could be identified in the 40 cyst fluid samples (Table 2). The table 
summarizes the resonances with a signal to noise ratio >3, even when they only occurred in 
one cyst fluid sample. For the assignment of resonances we compared the model compound 
spectra. As a standardized pH was used there is only minimal intersample variability in the 
chemical shift of a resonance. To help assignment, in some cases COSY spectra of the cyst 
fluid samples were used and compared with the spectra of model compounds. Most of the 36 
detected compounds have earlier been observed in urine, CSF or plasma samples, as indicated 
in table2 (12,13). A number of metabolites were observed in all or almost all (>80%) cyst 
fluid samples. These metabolites were leucine, isoleucine, valine, 3-hydroxybutyric acid, 
threonine, lactic acid, alanine, lysine, citric acid, creatine, creatinine, betaine, tyrosine,
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phenylalanine, formic acid, and histidine. Although detected in other body fluids such as 
serum or CSF, a number of unexpected metabolites were found in the cyst fluid samples. In 
88% of the samples we found choline with a concentration range between 8-1427 ^mol/L. 5- 
Oxoproline was present in three samples with a concentration range between 30-734 ^mol/L. 
Figure 2 shows a spectrum of one of the cyst fluid samples containing 5-oxoproline. The 
COSY convincingly confirms the presence of this compound (figure 2).
N-acetylaspartic acid (NAA) was detected in five samples ranging in concentration between 5 
and 187 umol/L (figure 2). Using GC-MS it was independently confirmed that this actually 
was NAA.
Unassigned resonances
Some resonances (U1-U16 in Table 2) could not be assigned. Eight of these unknowns 
occurred only in <10% of the samples: (U2(1.24d), U4(1.58s), U6(1.99s), U7(2.04s), 
U11(2.81s), U14(4.20dd), U15(5.42d), U16(8.47s)). Eight others, however, were present 
more frequently: U1(1.17t), U3(1.56s), U5(1.79s), U8(2.22s), U9(2.25s), U10(2.77s), 
U12(3.11s), and U13 (3.14s). These were found in 15-63% of the samples. Table 2 illustrates 
that 10 of the 16 unknowns were also observed in our earlier studies on plasma and/or CSF: 
U1, U3, U4, U6, U7, U8, U12, U13, U15 and U16. The unknowns U2, U5, U9, U10, U11 and 
U14, were found in ovarian cyst fluid and have not been observed in proton NMR spectra of 
plasma or CSF (12,13). Also, they were not found in 300 urine samples of patients suspected 
of having an inborn error of metabolism.
Quantitative analysis o f metabolites in relation to histologic classification 
The concentration of metabolites showed a high intersample variation. For most metabolites, 
there is a factor 50-1000 between the lowest and the highest concentration found among 40 
samples. Table 3 shows that this high intersample variation to a large extent derives from the 
fact that the metabolic composition between cyst fluid samples from benign and malignant 
tumors differs. It shows concentration values of a number of compounds in cyst fluid from 
malignant ovarian tumors (n=12) compared with benign cystic epithelial tumors (n=23). 
Malignant cyst fluid samples showed significantly higher concentrations of various 
metabolites than benign cyst fluid samples (isoleucine, valine, threonine, lactic acid, lysine, 
methionine, glutamine and choline (table 3).
There was a trend towards lower glucose concentrations in malignant cyst fluid, but this was 
not statistically significant.
VIII
137
Figure 
1: 
1H-NM
R 
spectrum 
of 
m
alignant ovarian 
cyst fluid 
sample 
(serous 
cystadenocarcinom
a) 
with full spectrum 
view 
andfocus 
view
The resonances U9 (2.25 ppm singlet), and U10 (2.77 ppm singlet) that were observed in 28 
and 25% of the samples, respectively, seem to be rather specific for malignant 
cystadenocarcinomas. They were observed in nine of the 12 malignant cases. In comparison, 
U9 and U10 were only found in two of 28 benign cyst fluid samples. The area ratio for U9 
and U10 in the various samples where these resonances were present was variable. 
Furthermore, there was one sample where U10 occurred without U9 being present.
Serous cystadenoma
The metabolites 5-oxoproline and N-acetylaspartic (NAA) acid were only found in serous 
cystadenoma (27% and 45% respectively). In one sample they were both present. Neither 
metabolite was present in other benign or malignant subtypes. Figure 2 shows the NMR 
spectrum of one of these samples, illustrating the presence of 5-oxoproline.
Comparison between cyst fluid and serum
In table 3, concentrations of metabolites in malignant and benign cysts are presented as well 
as serum reference values for adults determined by conventional techniques (18,19). 
Interestingly, the median concentration for isoleucine, valine, threonine, alanine, lysine, 
methionine, and glutamine in malignant cyst fluid was higher than the serum upper reference 
range limit for adults. In contrast, the median concentration for isoleucine, valine, threonine, 
lysine, methionine, and glutamine in benign cyst fluids, was lower than the lower serum 
reference range limit for adults. Cyst fluid creatinine concentration was within the serum 
range limit, both for benign and malignant cysts. The median concentration of lactic acid was 
higher than the upper serum reference range limit, both for malignant and benign cyst fluid. 
The median glucose concentration was lower than the lower serum reference range limit for 
both benign and malignant cyst fluid. VIII
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Metabolite N (%) Chemical shift and multiplicity [proton (s) ] Body fluid
TSP(=Internal 0.00 s[Si-(CH3)3]
Standard)
2-Hydroxyisovaleric 2 (5) 0.89 d[CH3]; 0.98 d[CH3]; 2.06 m[CH]; 4.13 d[CH] CSF, P
acid
Isoleucine 40 (100) 0.94 t[CH3]; 1.02 d[CH3]; 1.28 m[CH2]; 1.47 m[CH2]; 2.00 m[CH]; 3.80
d[CH]
CSF, P
Leucine 40 (100) 0.95 t[CH3]; 0.97 d[CH3] CSF, P
Valine 37 (93) 1.00 d[CH3]; 1.04 d[CH3]; 2.29 m[CH]; 3.72 d[CH] CSF, P
2-oxoisovaleric acid 22 (55) 1.13 d[(CH3)2]; 3.02 m[CH] CSF, P
U-1 23 (58) 1.17 t[CH3] CSF, P
3- Hydroxybutyric acid 37 (93) 1.23 d[CH3]; 2.53 AB [CH2]; 4.23 m[CH] CSF, P
U-2 1 (3) 1.24 d -
Threonine 38 (95) 1.33 d[CH3]; 3.70 d[CH]; 4.29 m[CH] CSF, P
Lactic acid 40 (100) 1.41 d[CH3]; 4.36 q[CH] CSF, P
Alanine 39 (98) 1.51 d[CH3]; 3.87 q[CH] CSF, P
U-3 25 (63) 1.56 s CSF, P
U-4 4 (10) 1.58 s CSF, P
Lysine 35 (88) 1.47 m[CH2]; 1.72 m[CH2]; 1.92 m[CH2]; 3.01 t[CH2]; 3.77 t[CH] CSF, P
U-5 11 (28) 1.79 s -
U-6 1 (3) 1.99 s CSF
N-Acetylaspartic acid 5 (13) 2.03 s[O=C-CH3]; 2.95 AB; 4.72 m[CH] CSF
U-7 2 (5) 2.04 s CSF
Acetic acid 40 (100) 2.08 s[CH3] -
Methionine 25 (63) 2.13 s[CH3]; 2.18 m[CH2]; 2.67 t[CH2]; 3.99 t[CH] CSF, P
Glutamine 31 (78) 2.16 m[CH2]; 2.47 m[CH2]; 3.91 t[CH] CSF, P
5-Oxoproline 3 (8) 2.20 m[CH2]; 2.43 m[CH2];2.55 m[CH2] 4.36 dd[CH] P
U-8 6 (15) 2.22 s CSF
U-9 11 (28) 2.25 s -
Acetoacetic acid 15 (38) 2.31 s[CH3] CSF, P
Pyruvic acid 20 (50) 2.37 s[CH3] CSF, P
Succinic acid 31 (78) 2.67 s[CH2-CH2] CSF, P
Sarcosine 12 (30) 2.74 s[N-CH3]; 3.65 s[CH2] CSF, P
U-10 10 (25) 2.77 s -
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Metabolite N (%) Chemical shift and multiplicity [proton (s) ] Body fluid
U-11 3 (8) 2.81 s -
Citric acid 36 (90) 2.91 [CH2 -C-CH2 ] CSF, P
N,N-Dimethylglycine 13 (33) 2.93 s[N-(CHs)2] 3.80 s[CH2] P
Creatine 38 (95) 3.05 s[N-CHs]; 4.06 s[N-CH2 ] CSF, P
U-12 9 (23) 3.11 s P
Creatinine 37 (93) 3.13 s[N-CHs]; 4.29 s[N-CH2 ] CSF, P
U-13 21 (53) 3.14 s CSF, P
Choline 34 (85) 3.19 s[N-(CH3)3]; 3.50 m[N-CH2]; 4.05 m[CH2-OH] CSF, P
Glucose 28 (70) 3.23 dd[CH:ßC2]; 3.3-3.9(various);4.64d[CH:ßC1];5.22 d[CH:aC1] CSF, P
Carnitine 13 (33) 3.23 s CSF, P
Betaine 33 (83) 3.27 s[N-(CHs)3]; 3.94 s[CH2] CSF, P
myo-Inositol 8 (20) 3.26 t[CH:C-5]; 3.52 dd[CH:C-1/CH:C-3]; 3.61 t[CH:C-4/CH:C-6]; 4.05 t[CH:C-2] CSF
Glycine 16 (40) 3.72 s[CH2] CSF, P
Glycolic acid 14 (35) 4.18 s[CH2] CSF
U-14 3 (8) 4.20 dd -
Mannose 1 (3) 3.34-3.95 (various); 5.17 d[CH2 ] CSF
U-15 2 (5) 5.42 d (J-coupling=5.5 Hz) CSF
Tyrosine 33 (83) 3.15 m[CH2]; 4.07 m[CH]; 6.89 d[aromatic protons]; 7.19 d[aromatic protons] CSF, P
Phenylalanine 32 (80) 3.15 m[CH2]; 3.29 m[CH2]; 4.13 m[CH]; 7.30-7.44 m[aromatic protons] CSF, P
Xanthine 1 (3) 7.99 s -
Formic acid 35 (88) 8.25 s CSF, P
U-16 1 (3) 8.47 s P
Histidine 32 (80) 3.35 m[CH2]; 4.09 t[CH2] ; 8.68 d[ring proton]; 7.41 s[ring proton] CSF, P
Table 2 : 1H-NMR spectroscopy chemical shifts from ovarian cyst flu id  samples (n=40) (D2O; 600 Mhz; pD 2.50)
n=number o f cyst fluid samples; s=singlet; d=doublet; t=triplet; q=quartet; m=multiplet; AB=AB-system; U1,U2 etc. =unknown metabolite; 
CSF/P= detected in cerebrospinal fluid samples/ plasma samples.
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Figure 2: H-NMR spectrum and COSY o f benign serous cystadenoma cyst fluid sample 
showing 5-oxoproline crosspeaks (circles)
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M etabolite Quantification on M alignant3
N=12
(^mol/L)
Benign a
N=23
(^mol/L) P-value b
Normal Serum  
Range ac 
(^mol/L)
Isoleucine 1.02 d[CH3] 79 (45-1398) 10 (<10-136) 0.0012d 39-67
Valine 1.04 d[CH3] 395 (225-644) 113 (<10-586) 0.0012d 172-248
Threonine 1.33 d[CH3] 248 (169-541) 90 (<10-406) 0.0087d 93-197
Alanine 1.51 d[CH3] 586 (32-1352) 293 (<10-924) 0.0172 218-474
Lactic acid 1.41 d[CH3] 6536 (3426-22214) 2479 (631-11944) 0.0046d 500-1700
Lysine 1.67-1.78 m[CH2] 490 (372-966) 101 (<15-1149) 0.0026d 119-203
Methionine 2.13 s[CH3] 62 (<5-129) 7 (<5-90) 0.0039d 14-30
Glutamine 2.42-2.52 m[CH2] 828 (507-1352) 275 (<30-811) 0.0007d 340-696
Creatine 3.05 s[CH3] 66 (22-135) 63 (<5-113) 0.4762 -
Creatinine 3.13 s[CH3] 79 (45-113) 68 (<5-150) 0.4343 50-90
Choline 3.19 s[(CH3)3] 42 (19-113) 15 (<2-163) 0.0009d -
Glucose 5.22 d[CH] 260 (<30-5546) 1387 (<30-7628) 0.1925 4000-5000
Table 3: Concentration o f metabolites observed with H-NMR spectroscopy in malignant (n=12) and benign (n=23) ovarian cyst fluid  
a concentrations in ¡j.mol/L are given in median and range; b Mann-Whitney-U test for comparison between benign and malignant groups; c; according to 
references 18,19; d statistically significant difference (p<0.01).
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DISCUSSION
In this study, we present the qualitative and quantitative results of in vitro proton nuclear 
magnetic resonance spectroscopy on cyst fluid from ovarian tumors. A limited number of 
studies by Smith et al and Wallace et al describe ex vivo *H NMR spectroscopy on ovarian 
tissue samples (20,21). These studies on tissue samples, describe multiple disturbances of the 
MR spectra (immune cells, fat and vasculature) (21). In our spectroscopic fluid analysis these 
disturbing factors are not present. In the current study we observed in 40 fluid samples a total 
of 36 metabolites, and 16 unassigned resonances. These metabolites are involved in many 
different biochemical pathways. The NMR spectrum thus reflects the metabolic status of 
ovarian cysts, and may provide valuable information on the metabolism of the surrounding 
tumor cells. The concentration of the metabolites in the cyst fluid samples showed a high 
intersample variation (factor 50-1000). Interestingly, the morphological subtype of the cyst 
largely determined this variation. Compared to benign subtypes, we detected significantly 
higher concentrations of isoleucine, valine, threonine, lactic acid, lysine, methionine, 
glutamine, and choline in the malignant cyst fluids. Resonances of the metabolites with 
significantly higher concentration in malignancy, in our study, were in the same range of the 
chemical shift as presented in a study of Wallace et al (21). In this proton nuclear magnetic 
resonance spectroscopic study of ovarian tissue biopsies the regions 3.3, 3.2, 3.0, 2.8, 1.7 and 
1.5 ppm were presented as important classification regions for the purpose of discrimination 
between malignant and benign tissue samples. Future in vivo spectroscopy of ovarian tumors 
should specifically aim at these spectral regions of interest. The role in malignancy of some of 
these compounds has been discussed in the literature. Hagberg et al found higher serum 
concentrations of lactic acid in non-Hodgkin’s lymphoma, significantly correlating with 
spread of the disease, as well as histological grade of malignancy (22). The observation in 
malignant cysts of high lactic acid and alanine in combination with low glucose, compared to 
benign cysts, seems to indicate a preference for anaerobic metabolism or an impairment of 
aerobic pathways in this cyst type. A significantly higher concentration of choline was found 
in malignant cyst fluids. High choline concentrations were also found with 1H-NMR 
spectroscopy on tissue samples of prostate cancer by Cornel et al (23). Increased proliferation 
in malignancy resulting in increased membrane synthesis may form the basis of this high 
choline concentration (23). Methionine concentration in cyst fluid from malignant tumors also 
proved to be significantly higher than in benign cyst fluids. This may be related to a defective 
methionine cycle in ovarian cancer cells, as described by Corona et al (24). This group
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describes an ineffective remethylation of homocysteine to methionine in ovarian cancer cells. 
They found higher homocysteine levels in malignant ascitic/cyst fluid compared to serum 
levels referring to a possible excretion of these metabolites in these compartments. Singlets at 
2.25 ppm and 2.77 ppm seem to be specific for malignant ovarian cysts. The observation of a 
variable area ratio of U9 and U10 indicates that U9 and U10 do not derive from the same 
metabolite. Further studies, aimed at structural analysis of the metabolite(s) involved, are 
required to explain their possible role in malignant transformation of ovarian cysts. 
Furthermore, it seems worthwhile to investigate the presence of these resonances in blood and 
urine, as the compound from which they derive may be a potential new tumor marker.
We detected two unexpected metabolites (NAA and 5-oxoproline) in the same benign 
subgroup (serous cystadenoma). NAA was found in five samples. Normally, NAA is only 
found in neuronal cells. To our knowledge this compound has never been observed before in 
ovarian cyst fluid and needs further investigation. 5-Oxoproline was found in three serous 
cystadenomas. It is part of the y-glutamyl cycle in glutathione biosynthesis. Normally, 5- 
oxoproline is not detectable in blood plasma or urine. It does occur, however, in body fluids 
of patients with 5-oxoprolinuria, an inborn error of metabolism in glutathion biosynthesis. 
Glutathione and glutathione-related enzymes are involved in the metabolism and 
detoxification of cytotoxic and carcinogenic compounds as well as reactive oxygen species in 
the human ovary (25). As in other spectroscopic analysis, unassigned resonances were found. 
Some of the metabolites causing these resonances can also be detected in urine, blood plasma 
or cerebrospinal fluid (12,13). They may either derive from dietary sources or they are normal 
metabolic intermediates. Although most patients did not use any medication before operation, 
it cannot be fully excluded that they are caused by medication. Other unknowns have only 
been observed in cyst fluid samples. They were never observed in our studies on other body 
fluids. The metabolites causing these resonances may be specific for cyst metabolism. 
Identification of these unknowns seems important for our understanding of cyst formation and 
cyst metabolism. We conclude that proton nuclear magnetic resonance spectroscopy of 
ovarian cyst fluid can give valuable information about the presence of low-molecular weight 
metabolites and about cyst metabolism. More knowledge of the metabolic composition of cyst 
fluid may result in the possibility of developing a biochemical classification of ovarian cyst 
subtypes. Ultimately this may lead to the development of a non invasive in vivo technique to 
differentiate ovarian tumors. Furthermore, this paper forms the basis for further studies on 
pathophysiological mechanisms inducing ovarian cyst development. Findings from this study
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may also provide useful diagnostic tools for diagnosis and follow-up of patients with ovarian 
cysts.
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ABSTRACT
The aim of this case report is to evaluate the feasibility of in vivo proton magnetic resonance 
spectroscopy (1H-MRS) in the determination of ovarian cyst fluid components. Data were 
compared with in vitro proton nuclear magnetic resonance spectroscopy (1H-NMRS). This 
study is our first step to develop a model that may ultimately lead to a novel test for an 
accurate non-invasive differentiation of ovarian tumors.
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EXPERIM ENTAL
A 53 year old patient with an adnexal mass was included in this pilot study after informed 
consent was obtained. First, in vivo MR examinations were performed on a clinical MR 
system. After one week explorative laparotomy was performed and the tumor was removed. 
Subsequently, aseptic fine needle aspiration was performed for cyst fluid collection. After 
cooled transport to the laboratory, cyst fluid was centrifuged at 3000 g for 5 min for cell 
separation and stored at -70 oC for two weeks, until in vitro !H-NMRS analysis was 
performed. Histopathologic diagnosis was performed by a gynecologic pathologist and 
revealed cystadenocarcinoma.
MRS measurements 
In vivo 1H-MRS
The patient was positioned inside the magnet bore of a clinical 1.5 Tesla MR system 
(Magnetom Vision, Siemens, Erlangen, Germany). The body coil was used for radio 
frequency excitation. A linear polarized surface coil (0  19cm) for receiving was positioned as 
close as possible to the adnexal mass. MR images were made to select a voxel of interest of 
20 cc of exclusively ovarian cyst fluid for 1H-MRS (figure 1). MR spectra using a stimulated 
echo acquisition mode (STEAM) sequence [Frahm et al.] at an echo time (TE) of 20 ms with 
outer volume suppression was acquired. Subsequently, two MR spectra at a point-resolved 
spectroscopy (PRESS) sequence [Ordidge et al.] at TEs 135 and 270 ms, were aquired, to 
diminish possible contamination of lipid signals. The repetition time was 2500 ms. The 
number of averages was 256. The total examination time amounted 60 minutes.
In vitro 1H-NMRS
Single pulse 1H-NMR spectra (500 MHz) were obtained on a Bruker DMX-500. 
Measurements were performed essentially as described before [Wevers et al. 1995; Massuger 
et al. 1998; Boss et al. 2000]. We performed two separate analyses, the first after 
deproteinization over a filter (3000g for 2h, mass cut-off 10 kDa), without pH standardization. 
A second experiment involved adjustment to pH 2.5 + 0.10, in order to correlate chemical 
shift of the non pH standardized sample with our ovarian cyst fluid model compound data 
base [Boss et al 2000]. Chemical shifts were calibrated with respect to the chemical shift
VIII
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position of the trimethyl silyl 2,2,3,3-tetradeuteropropionic acid (TSP) resonance. Phase and 
baseline were corrected manually.
RESULTS
Figure 2a presents the in vitro 1H-NMR spectrum of the cyst fluid sample without pH 
standardization. High intensities were visible for leucine, isoleucine, valine, lactic acid, 
alanine, acetic acid, glutamine, methionine. These assignments were confirmed by comparing 
them with the spectrum of the pH standardized sample (spectrum not shown).
Figure 2b shows the in vivo *H-MR spectrum obtained with a STEAM sequence at TE 20 ms. 
Distinct signals of lactic acid (1.33 ppm) were obtained, which was inverted in the MR 
spectrum obtained at TE 135 ms. Also a resonance of acetic acid (2.03 ppm) was clearly 
visible, but could not be completely resolved from glutamine and methionine contributions. A 
third resonance complex at 0.9 ppm was obtained, most likely to be contributions of the 
valine, isoleucine, and leucine resonances. PRESS spectra obtained at TE 135 and 270ms 
showed the same resonances except for the glutamine and methionine signals.
Figure 1 : Sagittal MR image (1.5 Tesla) o f a 55-year old patient with an ovarian tumor. The 
voxel o f interest (20 cc) that was used for 1H-NMR spectroscopic analysis o f ovarian cyst 
flu id  is indicated
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Figure 2: In vitro 1H-NMR spectrum o f malignant ovarian cyst fluid sample (upper part), in vivo 1H- 
NMR spectrum (s20) o f the same patient (lower part)
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DISCUSSION
This pilot study shows that in vivo *H-MRS of ovarian cyst fluid is feasible. The obtained 
resonances correspond with results from in vitro 1H-NMRS on ovarian cyst fluid from the 
same patient. With in vivo *H-MRS resonances for lactic acid and acetic acid were clearly 
visible. Okada et al. (2001) performed single voxel 1H-MRS on benign and malignant tumors 
of the female pelvis. In line with our results they found lactic acid as the characteristically 
obtained signal. In our previous in vitro studies we detected significantly higher lactic acid 
concentrations in cyst fluid from malignant tumors, than those found in benign tumors. The in 
vivo *H-MRS cyst fluid lactic acid signal might be used as an index of differentiation among 
benign and malignant ovarian tumors. However, overlap in the cyst fluid concentration ranges 
was seen. Further research is needed to examine the possibilities of using non invasive in vivo 
1H-MRS in the discrimination between benign and malignant ovarian tumors based on 
differences in the contents of cyst fluid. Other components that showed significant differences 
between malignant and benign tumors with in vitro !H-NMRS have to be evaluated in further 
detail with in vivo MRS. Quantification of metabolites with in vivo spectra may be difficult 
since an internal standard is lacking. Since we found a large level of overlap in cyst fluid 
concentrations between benign and malignant tumors with our in vitro studies the highest in 
vivo accuracy probably will be achieved by using a combination of analytes.
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Summary and Conclusions
This thesis describes our studies on the composition of cyst fluid from ovarian tumors. Two 
important aspects in the management of patients with ovarian tumors are (1) the pre-treatment 
differential diagnosis and (2) the prognosis related to treatment protocol. The differential 
diagnosis of ovarian tumors has been explored extensively, applying serum for quantitative 
analysis of different tumor markers. Furthermore, several imaging techniques have been 
studied to optimise the differentiation between benign and malignant ovarian processes. From 
these studies it can be concluded that no single modality (or even a combination of these 
discriminatory tests) is able to confirm or exclude malignant disease in all patients with 
complete certainty.
The concentrations of analytes measured in serum are not only reflecting the activity of the 
ovarian tumor, but these may also be influenced by several other organ systems or conditions.
Thus, the direct measurement of such components in the tumor itself could be a better 
reflection of the actual tumor classification.
The majority of ovarian tumors present as (multi) cystic structures that are usually filled with 
fluid and surrounded by solid tissue derived from the ovarian surface epithelium. Once 
collected, this cyst fluid can be applied for biochemical analysis in order to assess the 
differential diagnosis and the prognostic value of the analytes measured. However, 
preoperative collection of cyst fluid may lead to tumor spill that should be avoided for 
obvious reasons. The development of techniques to non-invasively assess the biochemical 
composition of ovarian cyst fluid could overcome this problem. In this respect in vivo proton 
Magnetic Resonance Spectroscopy (1H-MRS) may provide a solution.
Once the patient has been surgically treated and the diagnosis has been pathologically 
established based on the tumor tissue, ovarian cyst fluid is available for specific 
measurements.
Analysis of the ovarian cyst fluid has several theoretical advantages above assessment of the IX 
tumor tissue. It is reasonable to assume that potential tumor associated analytes are distributed 
more homogeneously in ovarian cyst fluid than in the surrounding tissue. Up till now, several 
studies have evaluated the tissue content of a number of biochemical analytes. These studies 
aimed at finding whether the analytical results obtained in ovarian tumor tissue could provide 
information concerning the prognosis. The limitations of these studies may probably lie in the 
heterogeneity of the tumor. To circumvent these problems we have explored the ovarian cyst
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fluid that is in close contact with the tumor tissue itself. This fluid provides a practical source 
for the quantitative measurement of biochemical compounds, with the objective to study their 
correlation with tumor status and prognosis.
For this purpose, we prospectively collected a large series of ovarian cyst fluid samples that 
were aspirated immediately after removal of the ovarian tumors. Chapter 3 describes the 
results on gonadotropic and female sex steroid hormone determinations in cyst fluid and 
serum samples of patients with an ovarian tumor. Significantly higher LH and FSH fluid 
concentrations were found in case of malignancy compared to those observed in cyst fluid 
from patients with benign and borderline tumors. Furthermore, within the malignant subset, 
LH and FSH concentrations correlated with increasing FIGO stage and differentiation grade. 
Also, both FSH and LH cyst fluid concentrations correlated well with serum concentrations in 
case of malignant tumors, but not with benign tumors. This data suggests that the most 
probable explanation for higher gonadotropin concentrations in cyst fluid from malignant 
ovarian tumors is an increased vascular permeability. Supportive evidence for such an 
increased vascular permeability is our finding of significantly higher concentrations of 
Vascular Endothelial Growth Factor (VEGF) in cyst fluid from malignant compared to benign 
ovarian tumors. VEGF not only acts as an activator of angiogenesis but also results in 
increased vascular permeability. Finally, the possibility of ectopic production of LH and FSH 
by malignant ovarian tissue cannot completely be ruled out.
Glutathione-S-transferases (GST) are of importance in the detoxification of cytotoxic 
compounds. The role of GSTs in relation with resistance to chemotherapy in ovarian 
carcinoma tissue and serum samples has not been fully established. GSTs were never studied 
in cyst fluid from ovarian tumors. Chapter 4 describes the results on our determinations of 
GSTP1-1 and GSTA1-1 in ovarian cyst fluid with special emphasis on their prediction of the 
response to chemotherapy. Significant differences were found in GSTP1-1 cyst fluid 
concentrations between histopathologic subgroups, with the highest levels in malignant and 
borderline compared to benign tumors. For GSTA1-1 no significant differences were found. 
Clinically worse prognostic parameters (FIGO stage II-IV, differentiation grade 2 and 3, 
residual tumor > 2 cm, presence of ascites) were associated with higher GSTP1-1 and with 
lower GSTA1-1 cyst fluid concentrations. In line with these findings, worse clinical outcome 
(recurrent disease, disease free survival < 14 months and overall survival < 24 months) was 
also associated with higher GSTP1-1 and, except for overall survival, with lower GSTA1-1.
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Thus, cyst fluid GSTP1-1 appears to be a measure o f the aggressiveness o f the ovarian tumor 
whereas increased concentrations o f GSTA1-1 are reflecting a more favourable prognosis.
Angiogenesis (the formation o f new blood vessels) and invasion (which involves degradation 
o f the extracellular matrix; ECM) are two complex processes involved in growth and spread 
o f malignant tumors. Although more knowledge was gained the last years on the actions and 
interactions o f several components involved in these processes, clear insight in their role in 
the development o f ovarian tumors is lacking. VEGF has been recognized as an activator of 
angiogenesis and vascular permeability in a variety o f human malignancies including ovarian 
cancer. Our studies described in Chapter 5 revealed significantly higher VEGF cyst fluid 
concentrations in malignant compared with benign tumors. Interestingly, borderline tumors 
revealed VEGF cyst fluid concentrations in between those o f malignant and benign cysts.
Higher median VEGF cyst fluid concentrations in patients with FIGO stage I tumors with 
recurrent disease indicate a possible role for this analyte in the detection o f high-risk low  
stage patients.
Furthermore, significantly higher pre-operative VEGF serum concentrations were found in 
patients with malignant compared to those with non-malignant tumors. This raises the 
question whether VEGF can be used as a serum tumor marker for discrimination o f non- 
malignant from malignant ovarian cysts. Further research is required to confirm this possible 
application.
Components o f the plasminogen activation system that play a central role in degradation o f  
the ECM as part o f cancer spread were determined in ovarian cyst fluid (Chapter 6). 
Significantly higher median uPA and PAI-1 concentrations were found in cyst fluid from 
malignant- compared with benign tumors. Levels o f the complex o f tPA with its inhibitor 
PAI-1 (tPA:PAI-1) were clearly different between malignant and benign cysts, underscoring 
the value o f assaying the levels o f different components and complexes separately in addition 
to measuring levels o f total tPA and PAI-1 immunoreactivity. IX
Median PAI-1 concentration was higher in stage I tumors with recurrent disease than without, 
as was also found for VEGF cyst fluid levels. Furthermore, the highest cyst fluid uPA 
concentrations were found in the specimen from the only borderline malignancy in which 
micro-invasive growth was found. These findings suggest a possible role for the detection of 
high-risk low stage malignant or borderline tumors, but have to be analyzed in further detail.
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Angiogenesis is considered to be the net balance between the action o f pro- and anti- 
angiogenic factors. Chapter 7 presents our attempt to establish the relative contributions of 
VEGF, plasminogen activators and angiostatin to the angiogenic balance in ovarian cyst fluid. 
N o correlation between VEGF and plasminogen cyst fluid levels was found. Although we did 
observe a tendency o f higher plasminogen levels with increasing VEGF levels, numerous cyst 
fluid samples with a high plasminogen content contained no or only very low amounts of 
VEGF, indicating that plasminogen content is certainly not dependent on VEGF levels alone. 
A clear correlation, however, was observed between the presence o f angiostatin in the cyst 
fluid samples, and the presence o f either uPA or tPA. However, many angiostatin containing 
samples were uPA and tPA negative, indicating that other proteolytic enzymes are probably 
involved in angiostatin generation as well.
The data we present in this thesis provide, for the first time, evidence for the involvement o f  
plasminogen activators in angiostatin formation in humans, in vivo. Currently, we are 
determining the vascular density o f the tumors from which the cyst fluids used in this study 
were derived. Linking this data with (anti-) angiogenic factor levels, combined with patient 
follow-up data may eventually provide insight in the factors constituting the “angiogenic 
balance” in ovarian tumors, and also which (combination of) factors should be measured to 
provide relevant prognostic information.
We explored the feasibility o f using the relatively new technique o f proton nuclear 
magnetic resonance spectroscopy (1H-NMRS) in determining the overall metabolic 
composition o f ovarian cyst fluid (Chapter 8). In vitro *H-NMRS provides a reflection o f the 
low-molecular weight metabolites that are present. We developed a data base containing 36 
analytes that could be determined with in vitro 1H-NMRS. Significant differences in ovarian 
cyst fluid concentrations were found for several analytes between benign and malignant 
tumors. The chemical shift range from 1.00 to 3.20 ppm contained all the relevant 
components and can be considered as a special region o f interest in distinguishing benign 
from malignant tumors. As in other spectroscopic analyses, unassigned resonances were 
found. These may either derive from dietary sources or they are normal metabolic 
intermediates. Interestingly, singlets at 2.25 ppm and 2.77 ppm seem to be specific for cyst 
fluid from malignant tumors. Future studies aimed at structural analysis o f this metabolite or 
the detection in blood or urine samples has to reveal its possible role as a new tumor marker 
in more detail. With in vitro !H-NMRS unexpected metabolites were found in ovarian cyst 
fluid. For instance, N-acetyl aspartic acid (NAA) was detected, which is normally only
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present in neuronal cells. It was found in cyst fluid from serous cystadenoma. The explanation 
for this finding needs further investigation.
Based on the significant differences between benign and malignant cyst fluids with in vitro 
1H-NMRS, a first attempt was made to explore the feasibility of in vivo !H-MRS of ovarian 
cyst fluid. For this purpose a patient with an ovarian tumor was placed into the magnet bore of 
a clinical MR system. A number of metabolites were clearly visible in the in vivo spectra.
Although our first in vivo experiments are promising, it is not clear to what level our database 
of cyst fluid contents derived from the in vitro *H-NMRS studies can be incorporated in the in 
vivo studies. The quantification of metabolites with in vivo spectra may be difficult since an 
internal standard is lacking. Furthermore, with in vitro *H-NMRS the concentration ranges of 
all metabolites showed a large level of overlap between benign and malignant tumors. For a 
more accurate differentiation a subset of analytes with the highest sensitivity and specificity 
has to be determined. In vivo !H-MRS analysis of the contents of ovarian cyst fluid may 
ultimately lead to a novel non-invasive discriminatory test for ovarian tumors.
Our methods of cyst fluid analyses might have been influenced by a number of limitations or 
possible pitfalls. First, we had to exclude a small number of patients in which only solid 
tumor growth was found and thus no cyst fluid could be collected. The majority of these cases 
involved malignant tumors and these may represent a special entity within the malignant 
group. Furthermore, some tumors, benign as well as malignant, present as multicystic 
processes. It would be interesting to explore possible cyst fluid differences between several 
cysts in the same ovarian tumor. If so, these differences might reflect local tumor tissue 
differences. To study these differences in tumor micro-environment, inclusion of separately 
aspirated cyst fluids and their respective cyst wall epithelium is needed.
In conclusion, the composition of ovarian cyst fluid seems to be a reflection of multiple 
processes in the ovarian tumor. For several analytes we found a correlation with important 
clinicopathologic factors. IX
We support an additive role for the determination of components in ovarian cyst fluid, in 
exploring biological behaviour of different histopathologic subtypes, differential diagnosis, 
and prognosis. However, future research has to determine in further detail the clinical value of 
various analytes that can be determined.
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Samenvatting en Conclusies
Dit proefschrift beschrijft onze studies naar de samenstelling van cystevocht van 
ovariumtumoren. Twee belangrijke aspecten bij de behandeling van patiënten met 
ovariumtumoren zijn (1) de differentiële diagnose vóór behandeling en (2) de prognose in 
relatie tot behandelingsprotocol. De differentiële diagnose van ovariumtumoren is uitgebreid 
bestudeerd, gebruikmakend van serum voor kwantitatieve bepalingen van verschillende 
tumormarkers.
Bovendien zijn er verschillende beeldvormende technieken bestudeerd om de differentiatie 
tussen benigne en maligne ovariële processen te optimaliseren. Uit deze studies kan worden 
geconcludeerd dat geen enkele test (of zelfs een combinatie hiervan), in staat is om met 
volledige zekerheid maligniteit te bevestigen of uit te sluiten bij alle patiënten.
De concentratie van metabolieten, gemeten in serum, weerspiegelt niet alleen de activiteit van 
de ovariumtumor, maar deze kan ook beïnvloed worden door verschillende andere 
orgaansystemen of omstandigheden. Dus, het meten van zulke componenten direct in de 
tumor zelf zou een betere weerspiegeling kunnen zijn van de aard van de tumor.
Het merendeel van ovariumtumoren presenteert zich als een (multi) cysteuze structuur, die 
meestal gevuld is met vocht en omgeven door solide weefsel, afkomstig van het ovariële 
oppervlakte-epitheel. Wanneer eenmaal verzameld, kan dit cystevocht gebruikt worden voor 
biochemische analyse, met het doel de differentiële diagnose en prognostische waarde van de 
gemeten analyten te bepalen. Echter, een pre-operatieve verzameling van cystevocht kan 
leiden tot tumor spill die om vanzelfsprekende reden voorkomen dient te worden. De 
ontwikkeling van technieken die op een niet-invasieve wijze de biochemische samenstelling 
van cystevocht bepalen, zou dit probleem kunnen omzeilen. In dit kader zou in vivo proton 
Magnetische Resonantie Spectroscopie (1H-MRS) een oplossing kunnen bieden.
Nadat de patiënt chirurgisch behandeld is en de histopathologische diagnose van het tumor- 
weefsel is bepaald, is ovarieel cystevocht beschikbaar voor specifieke bepalingen. IX
De analyse van het cystevocht heeft verschillende theoretische voordelen boven bepalingen in 
het tumorweefsel. Het is redelijk te veronderstellen, dat potentiële tumor-gerelateerde stoffen 
in ovarieel cystevocht meer homogeen verdeeld zijn dan in het omringende weefsel. Tot op 
heden hebben verschillende studies de samenstelling van weefsel geëvalueerd op een aantal 
biochemische componenten. Deze studies waren met name gericht op de vraag of de 
analytische samenstelling van ovarium tumorweefsel informatie zou kunnen leveren met
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betrekking tot de prognose. De beperkingen van deze studies liggen in de heterogeniteit van 
de tumor. Om deze problemen te omzeilen hebben wij het ovariële cystevocht in kaart 
gebracht dat in nauwe relatie staat met het tumorweefsel zelf. Dit vocht levert een praktische 
bron voor kwantitatieve analyse van biochemische componenten, met het doel hun relatie te 
bestuderen met tumorstatus en -prognose.
Voor dit doel verzamelden we prospectief een grote serie monsters van ovarieel cystevocht 
die omiddellijk werden verkregen na verwijdering van de ovariumtumoren.
Hoofdstuk 3 beschrijft de resultaten van gonadotropinen en sex steroid hormoonbepalingen 
in cystevocht en serum monsters van patiënten met een ovariumtumor.
Significant hogere LH en FSH cystevochtconcentraties werden gevonden in maligne- in 
vergelijking met benigne- en borderlinetumoren.
Verder correleerden, binnen de maligne subgroup, LH en FSH concentraties met toenemend 
FIGO stadium en differentiatiegraad. Ook correleerden zowel LH als FSH cystevocht- 
concentraties met serumconcentraties in het geval van maligne tumoren, maar niet bij benigne 
tumoren. Deze data suggereren dat de meest waarschijnlijke verklaring voor hogere 
gonadotropinenconcentraties in cystevocht van maligne ovariumtumoren een toegenomen 
vasculaire permeabiliteit is. Ondersteunend bewijs voor zulk een toegenomen vasculaire 
permeabiliteit is onze bevinding van significant hogere concentraties van Vasculair 
Endotheliale Groei Factor (VEGF) in cystevocht van maligne- in vergelijking met benigne 
tumoren. VEGF heeft niet alleen een functie als activator van angiogenese, maar resulteert 
ook in toegenomen vasculaire permeabiliteit. Tot slot kan de mogelijkheid van ectopische LH 
en FSH productie door maligne ovariumweefsel niet helemaal uitgesloten worden.
Glutathione S-transferases (GST) zijn van belang bij de detoxificatie van cytotoxische stoffen. 
De rol van GSTs in weefsel en serum monsters in relatie tot chemotherapieresistentie bij 
ovariumcarcinoom is niet geheel duidelijk. GSTs werden niet eerder bestudeerd in cystevocht 
van ovariumtumoren. Hoofdstuk 4 beschrijft de resultaten van onze metingen van GSTP1-1 
en GSTA1-1 in ovarieel cystevocht met speciale nadruk op het voorspellen van de respons op 
chemotherapie. Significante verschillen werden gevonden in GSTP1-1 cystevocht­
concentraties tussen verschillende histopathologische subgroepen, met de hoogste waarden in 
maligne- en borderline- vergeleken met benigne tumoren. Voor GSTA1-1 werden geen 
significante verschillen gevonden. Klinisch prognostisch ongunstige factoren (FIGO stadium 
II-IV, differentiatiegraad 2 en 3, tumorresten groter dan 2 cm, aanwezigheid van ascites)
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waren geassocieerd met hogere GSTP1-1 en met lagere GSTA1-1 cystevochtconcentraties. In 
lijn met deze bevindingen, bleek slechte klinische uitkomst (recidief ziekte, ziekte vrij interval 
< 14 maanden en overall overleving < 24 maanden) ook geassocieerd met hogere GSTP1-1 
en, behalve voor overall overleving, met lagere GSTA1-1 concentraties.
Dus, cystevocht GSTP1-1 lijkt een maat voor de agressiviteit van de ovariumtumor, 
daarentegen weerspiegelen hogere GSTA1-1 concentraties een meer gunstige prognose.
Angiogenese (de formatie van nieuwe bloedvaten) en invasie (waarbij degradatie van de 
extra-cellulaire matrix; ECM) zijn twee complexe processen betrokken bij de groei en 
verspreiding van maligne tumoren. Hoewel de laatste jaren meer kennis is verkregen 
betreffende de acties en interacties van verschillende componenten betrokken bij deze 
processen, ontbreekt een duidelijk inzicht in hun rol bij de ontwikkeling van ovarium- 
tumoren. VEGF is bekend als een activator van angiogenese en vasculaire permeabiliteit bij 
een verscheidenheid aan humane tumoren waaronder ovariumcarcinoom.
De studies beschreven in Hoofdstuk 5 leverden significant hogere VEGF cystevocht- 
concentraties in maligne-, vergeleken met benigne tumoren. Een interessante bevinding was, 
dat VEGF cystevochtconcentraties van borderlinetumoren waarden opleverden tussen die van 
maligne- en benigne cysten. Hogere mediane VEGF cystevochtconcentraties bij patiënten met 
FIGO stadium I tumoren met recidief, indiceren een mogelijke rol voor deze component bij 
de opsporing van hoog risico patiënten met een laag stadium.
Tevens werden significant hogere pre-operatieve VEGF serumconcentraties gevonden bij 
patiënten met maligne- in vergelijking met niet maligne tumoren. Dit roept de vraag op of 
VEGF een rol zou kunnen hebben als serum tumor merkstof voor de discriminatie van niet­
maligne en maligne ovariële cysten. Verder onderzoek is noodzakelijk om deze mogelijke 
toepassing te bevestigen.
Componenten van het plasminogeen activator systeem dat een centrale rol speelt bij de 
degradatie van de ECM als onderdeel van metastasering van kanker werden bepaald in IX 
ovarieel cystevocht (Hoofdstuk 6). Significant hogere mediane uPA en PAI-1 concentraties 
werden gevonden in cystevocht van maligne- in vergelijking met benigne tumoren. Waarden 
van het complex van tPA met zijn inhibitor PAI-1 (tPA:PAI-1) waren duidelijk verschillend 
tussen maligne- en benigne cysten, het belang benadrukkend van het afzonderlijk meten van 
de concentraties van de verschillende componenten en complexen als aanvulling op de 
bepaling van de totale hoeveelheid tPA en PAI-1 immunoreactiviteit.
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Mediane PAI-1 concentratie was hoger in stadium I tumoren met recidief dan zonder, zoals 
ook werd gevonden voor VEGF cystevochtconcentraties. Verder werden de hoogste 
cystevocht uPA concentraties gevonden in het monster van de enige borderline maligniteit 
waarbij micro-invasieve groei werd gevonden. Deze bevindingen suggereren een mogelijke 
rol voor het opsporen van hoog risico laag stadium maligniteiten o f borderline tumoren, maar 
dienen in verder detail bestudeerd te worden.
Angiogenese wordt beschouwd als het netto evenwicht tussen de actie van pro- en anti- 
angiogene factoren. Hoofdstuk 7 beschrijft onze pogingen om de relatieve bijdragen te 
bepalen van VEGF, plasminogeen activatoren en angiostatine aan de angiogene balans in 
ovarieel cystevocht. Er werd geen correlatie gevonden tussen VEGF en plasminogeen 
cystevochtconcentraties. Ondanks dat we een tendens observeerden van hogere 
plasminogeen-waarden met toenemende VEGF concentraties, bleken meerdere cystevocht- 
monsters met een hoge plasminogeeninhoud geen o f slechts zeer lage hoeveelheden VEGF te 
bevatten, aangevend dat plasminogeen aanwezigheid zeker niet afhankelijk is van alleen 
VEGF waarden.
Er werd echter een duidelijke correlatie gevonden tussen de aanwezigheid van angiostatine in 
de cystevochtmonsters en de aanwezigheid van uPA of tPA. Echter, veel angiostatine 
bevattende monsters waren uPA en tPA negatief, aangevend dat mogelijk ook andere 
proteolytische enzymen betrokken zijn bij de angiostatineproduktie.
De data die beschreven worden in dit proefschrift geven, voor het eerst, bewijs voor de 
betrokkenheid van plasminogeen activatoren bij de formatie van humaan angiostatine, in 
vivo.
Momenteel worden vasculaire dichtheden van de tumoren bepaald waarvan de cystevochten 
gebruikt in deze studie werden verkregen. Door deze data te koppelen met waarden van (anti-) 
angiogene factoren, in combinatie met follow-up gegevens van patiënten, zou uiteindelijk 
mogelijk inzicht verkregen kunnen worden in de factoren die bijdragen aan de ” angiogene 
balans” in ovariumtumoren, en ook welke (combinatie van) factoren bepaald zouden moeten 
worden om relevante prognostische informatie te leveren.
We onderzochten de mogelijkheid om, gebruikmakend van de relatief nieuwe techniek van 
proton Nucleaire Magnetische Resonantie Spectroscopie (1H-NMRS), de overall metabole 
samenstelling van ovarieel cystevocht te bepalen (Hoofdstuk 8). In vitro !H-NMRS geeft een 
weergave van de laag moleculair gewicht metabolieten die aanwezig zijn. We ontwikkelden 
een data base met 36 metabolieten die aangetoond konden worden met in vitro !H-NMRS.
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Voor diverse metabolieten werden significante verschillen in ovariële cystevocht 
concentraties gevonden tussen benigne- en maligne tumoren. Het gebied van de chemical 
shift tussen 1.00 en 3.20 ppm bevatte alle relevante componenten en kan worden beschouwd 
als een speciaal aandachtsgebied voor het onderscheid tussen benigne- en maligne tumoren.
Net als in andere spectroscopische analyses, werden onbekende resonanties gevonden. Deze 
kunnen afkomstig zijn van dieetfactoren of zijn normale metabole intermediairen. Een 
interessante bevinding was, dat de singlets op 2.25 ppm en 2.77 ppm specifiek lijken voor 
cystevocht van maligne tumoren. Toekomstig onderzoek gericht op structurele analyse van 
deze metaboliet of de aanwezigheid in bloed of urinemonsters, zal zijn mogelijke rol als een 
nieuwe tumormerkstof duidelijker moeten maken. Met behulp van in vitro !H-NMRS werden 
onverwachte metabolieten gevonden in ovarieel cystevocht. Bijvoorbeeld, N- 
acetylaspartaanzuur (NAA) werd gevonden, dat normaal alleen aanwezig is in neuronale 
cellen. Het werd gevonden in cystevocht van sereus cystadenomen. De verklaring voor deze 
bevinding vereist nader onderzoek.
Gebaseerd op de significante verschillen tussen benigne- en maligne cystevochten met in vitro 
1H-NMRS, werd een eerste poging gedaan om de mogelijkheid van in vivo !H-MRS van 
ovarieel cystevocht te onderzoeken. Voor dit doel werd een patiënt met een ovariumtumor in 
de magneet van een klinisch MR systeem geplaatst. Een aantal metabolieten was duidelijk 
zichtbaar op de in vivo spectra. Ondanks dat de eerste in vivo experimenten hoopvol lijken, is 
het nog niet geheel duidelijk in welke mate onze database van cystevochtinhoud, verkregen 
uit de in vitro !H-NMRS studies, kan worden gebruikt voor de in vivo studies. Het 
kwantificeren van metabolieten met in vivo spectra kan moeilijk zijn aangezien een interne 
standaard ontbreekt. Verder bleek er een grote mate van overlap in de spreiding van 
concentraties met in vitro *H-NMRS tussen benigne- en maligne tumoren. Voor een meer 
betrouwbare differentiatie zal een panel van metabolieten met de hoogste sensitiviteit en 
specificiteit bepaald dienen te worden.
In vivo *H-NMRS analyse van de inhoud van ovarieel cystevocht zou uiteindelijk kunnen
leiden tot een nieuwe niet-invasieve test voor de discriminatie van ovariumtumoren. IX
Onze methoden van het bestuderen van cystevocht kunnen beïnvloed zijn door een aantal 
beperkingen of mogelijke valkuilen. Als eerste werd een klein aantal patiënten geëxcludeerd 
waarin alleen solide tumorgroei werd gevonden en dus geen cystevocht kon worden 
verzameld. Het merendeel van deze gevallen betrof maligne tumoren en deze zouden een 
speciale subgroep kunnen vertegenwoordigen binnen de maligne groep. Verder presenteren
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sommige tumoren, zowel benigne als maligne, zich als multicysteus proces. Het kan 
interessant zijn om eventuele verschillen in cystevocht tussen verschillende cysten van 
dezelfde tumor te bestuderen. Indien aanwezig, zouden deze verschillen locale tumorweefsel 
verschillen kunnen weergeven. Om deze variaties in de micro-omgeving van de tumor te 
bestuderen, dienen afzonderlijk verzamelde cystevochten en hun bijbehorende cystewand- 
epitheel geïncludeerd te worden.
Concluderend lijkt de samenstelling van ovarieel cystevocht een weerspiegeling van 
verschillende processen in de ovariumtumor. Voor diverse analyten vonden we een correlatie 
met belangrijke klinisch-pathologische factoren.
We steunen een aanvullende rol voor de bepaling van componenten in ovarieel cystevocht, bij 
de bestudering van biologisch gedrag van verschillende histopathologische subtypen, 
differentiële diagnose en prognose. Echter, toekomstig onderzoek zal in nader detail de 
klinische waarde moeten bepalen van verschillende analyten die gemeten kunnen worden.
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Ik realiseer me dat dit dankwoord begint met een open deur maar ik weet nu uit eigen ervaring 
dat een proefschrift niet tot stand komt zonder de hulp van velen. Het zal onmogelijk zijn om 
alle mensen die op enige wijze hun bijdrage geleverd hebben bij naam te noemen. Elke 
bijdrage, klein of groot, direct of indirect heb ik enorm gewaardeerd. Enkele personen wil ik 
graag in het bijzonder danken.
Promotor, Prof. dr. H Boonstra, beste Henk: direct na je overstap van Groningen naar 
Nijmegen heb ik op vele fronten je steun mogen ervaren. Naast de mogelijkheid tot 
wetenschappelijke ontplooiing heb ik de kans gekregen veel te leren, met name op het gebied 
van de oncologisch-chirurgische vaardigheden en het voeren van slecht-nieuws-gesprekken.
Promotor, Prof dr. JO Barentsz, beste Jelle: onze gezamenlijke wetenschappelijke 
inspanningen op het gebied van de snelle dynamische MRI bij cervixcarcinoom zijn 
uiteindelijk niet opgenomen in dit proefschrift. Desondanks hebben we vele uren gedacht,
MRI’s bekeken, gepresenteerd in binnen- en buitenland en gepubliceerd. Ik hoop nog lange 
tijd onderdeel te mogen uitmaken van deze onderzoekslijn.
Co-promotor, Dr. LFAG Massuger, beste Leon: jouw enthousiasme en wetenschappelijke 
honger zijn niet in dit dankwoord tot uiting te brengen, maar eenieder die jou kent zal je in 
deze woorden herkennen. Je was als geen ander in staat om op momenten van het onderzoek 
dat ik even dacht er iets van te snappen mij met die ene vraag of opmerking weer het 
tegendeel te doen laten geloven. Dit werkte zeer stimulerend en heeft zeker mijn 
wetenschappelijke interesses verder ontplooid. Ook in de kliniek ben je altijd in staat ervoor 
te zorgen dat iedereen er altijd “bovenop zit” . Ik hoop in de toekomst nog veel van je te 
mogen leren.
Co-promotor, Dr. CMG Thomas, beste Chris: onze samenwerking heeft in de loop van de tijd 
gelukkig steeds duidelijker vorm gekregen. Ik bewonder je geduld en vertrouwen dat je op 
hebt kunnen brengen om de zoveelste promovendus naar de eindstreep te begeleiden.
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Emeritus hoogleraar, Prof. dr. HWM Merkus, beste Hans: als redelijk onervaren AGNIO 
gynaecologie heb ik vanaf mijn intrede in het UMCN in 1997 zeer veel vertrouwen mogen 
ervaren tijdens mijn eerste onwennige academische maanden. Dank voor alle inspanningen 
mijn toekomst binnen de gynaecologie verder vorm te kunnen geven.
Laboratorium voor Kindergeneeskunde en Neurologie: Ron Wevers, Udo Engelke, Sytske 
Moolenaar en secretaresse Sandra Hoenderop; vele uren heb ik op jullie laboratorium door
177
mogen brengen. Dank voor het mij wegwijs maken in de wondere wereld van de 
spectroscopie en speciaal Udo dank voor alle nieuwe woorden die ik van je mocht leren als de 
apparatuur weer eens op tilt sloeg.
Laboratorium voor Chemische Endocrinologie; Fred Sweep, Anneke Geurts-Moespot, Tijn 
Seegers, Dorlinde van Tienoven, en vele andere medewerkers: dank voor de bergen werk die 
jullie voor dit proefschrift hebben geleverd en speciaal Fred bedankt voor de snelle en 
zorgvuldige correcties, je bent een onmisbare schakel geweest voor dit proefschrift. 
Laboratorium Maag-Darm en Leverziekten; Wilbert Peters en Hennie Roelofs: dank voor de 
prettige samenwerking met jullie laboratorium.
Afdeling pathologie UMCN en CWZ: dank voor de vriendelijke ontvangst die ik altijd mocht 
ervaren als ik met de zoveelste tumor aankwam op jacht naar vocht voordat jullie je werk 
konden doen.
OK personeel UMCN en CWZ: jullie interesse en aandacht voor het onderzoek heeft een 
grote rol gespeeld tijdens de monsterverzameling, dank daarvoor.
Collega arts-onderzoekers van toen en nu: Willianne, Maarten, Cathelijne, Marcel, Ruben, 
Ron, Rolf, Eva-Maria, Iris, Jesper, Marieke, Pascal, René, Wai Yee, Petra, Tanja, Ingeborg en 
duizendpoot Mark Flink: momenten van lief en leed op onderzoeksgebied en gelukkig ook 
daarbuiten hebben we gedeeld. Vaak waren we samen aan het werk, maar ook geweldige uren 
hebben we elkaar van het werk gehouden. Ik vind het nog steeds vreselijk jammer dat we niet 
met zijn allen de eindstreep van de opleiding zullen bereiken, maar geloof wel dat uiteindelijk 
iedereen voor zichzelf de juiste keuzes heeft gemaakt.
Collega arts-assistenten; de start van mijn opleidingsperiode in Nijmegen en nu het vervolg in 
Arnhem is mede door het gevoel van “samen de kar trekken”, collegialiteit en gezelligheid 
een geweldig begin geweest, laten we proberen dit zo vast te houden met zijn allen.
Stafleden gynaecologie UMCN: als AGNIO, arts-onderzoeker en AGIO hebben we elkaar de 
afgelopen jaren leren kennen en er is niet één moment geweest dat niet voor herhaling 
geschikt is. Dank voor de bijdragen aan de monsterverzameling en het goede 
opleidingsklimaat dat er al zo lang in Nijmegen aanwezig is.
Gynaecoloog Dr. Jan van Schaik: mede dankzij je hulp en die van de afdeling gynaecologie 
van het CWZ hebben we een grote monsterverzameling kunnen opbouwen, waarvoor veel 
dank.
Stafleden gynaecologie Rijnstate: vanaf nu ben ik dan ècht helemaal beschikbaar in de kliniek 
en beloof ik niet ineens lijfelijk of in gedachten weg te zijn op congres, voor overleg naar
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Nijmegen, of anderszins. Opleider Aad Huisman: mede door jouw enorme enthousiasme is 
het Rijnstate als opleidingskliniek voor mij nu al na driekwart jaar een top kliniek.
Gerda Theunissen: jouw rol binnen de kliniek is uniek, waar ben je nu niet bij betrokken?
Dank voor alle secretariële en andere soorten van ondersteuning.
Familie en vrienden: dank voor de support en het vertrouwen dat ik mijn hele leven al krijg 
van jullie, waar ik ook ben of wat ik ook doe. Ik hoop dan nu eindelijk wat meer en vaker af 
te kunnen spreken om te genieten van de andere dingen in het leven.
Mijn paranimfen Lily en Frank: al sinds onze vroege schooljaren delen we elkaars goede en 
slechte tijden en zijn jullie een onmisbare schakel in mijn leven. Dank voor jullie 
onvoorwaardelijke vriendschap.
Nane: de ontwikkeling van dit boekje heb je meegemaakt, helaas de afronding ervan niet 
meer. Waar je ook bent, weet dat ik nooit zal vergeten hoe snel en liefdevol je mij hebt 
opgenomen binnen jullie familie.
Mijn leukste en enige zus Monique: wat jij en je gezin voor mij betekenen moge duidelijk 
zijn. Ik hoop dat ik jou de komende periode net zo kan steunen bij jouw opleiding zoals jij en 
Gert-Jan dat vele jaren voor mij hebben gedaan.
Mijn “suikerkinderen” Nienke en Noud: jullie geboren zien worden was al een feest, jullie 
zien opgroeien een nog groter feest. Ik ben trots jullie oom te zijn. Nienke je hebt een 
prachtige voorkant gemaakt !
“Onze” twee andere kinderen: Irena en Zaklina: jullie namen mogen ook hier niet ontbreken.
Bedankt voor de vele dagen van gezelligheid waardoor ik de gewone dingen in het leven niet 
uit het oog verlies.
Moems: de weg naar dit boekje was lang, maar zonder jouw stimulerende opvoeding en de 
boodschap van ons gezinslied van vroeger tijden: ”keep on smiling” was het er nooit 
gekomen. Mijn waardering voor wat jij allemaal voor ons gedaan, maar vooral ook gelaten 
hebt, zal ik niet in woord kunnen uitdrukken maar zal ik nooit vergeten.
Esad: moja ljubavi, wat hebben we de afgelopen jaren nu niet allemaal meegemaakt, maar ik
ben blij dat ik het met jou heb beleefd. Het wordt tijd voor weer een nieuwe fase in ons leven IX
samen, niet meer in het teken staand van “het boekje”.
Erik
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